{
  "OPTISAGE": {
    "TITLE": "full title phase3 study compare gvhd prophylaxis anti thymocyte globulin thymoglobulin atlggrafalon elderly patient acute myeloid leukemia myelodysplatic syndrome receive allogeneic hematopoietic stem cell transplantation hla match unrelated donor follow reduced intensity condition regimen fludarabinetreosulfan",
    "JUSTIFICATION": "scientific justification allogeneic hematopoietic stem cell transplantation allo hsct remain curative therapy acute myeloid leukemia myelodysplastic syndrome mds patient require allohsct age transplant reduced intensity condition regimen optimal reduced intensity conditioning gvhd prophylaxis regimen allow good control disease prevent gvhd remain determine elderly patient phase3 trial compare conventional reduced intensity condition fludarabinebusulfan fludarabinetreosulfan demonstrate advantage flutreosulfan arm term event free survival therefore consider new standard reduced intensity condition regimen acute myeloid leukemia mds gvhd prevention crucial role posttransplant outcome potentially interfere graftversusleukemia effect immune reconstitution antithymocyte globulin recommend reduce risk acute chronic gvhd transplant perform match unrelated donor however optimal type anti thymocyte globulin approve brand anti thymocyte globulin thymoglobulin atlggrafalon display distinct characteristic optimal dose anti thymocyte globulin still unknown retrospective study patient transplant mainly reduced intensity conditioning match related unrelated donor haematological malignancy observe atlg associate reduction grade iiiv acute gvhd comparison anti thymocyte globulin without increase incidence relapse phase3 randomize study propose compare gvhd prevention anti thymocyte globulin versus atlg acute myeloid leukemia mds patient age transplant match unrelated donor follow fludarabinetreosulfan reduced intensity conditioning hypothesis atlg would better control gvhd population patient thus limit risk morbidity mortality procedure",
    "OBJECTIVE": "main objective primary endpoint main objective compare incidence grade iiiv acute gvhd posttransplantation mds acute myeloid leukemia patient transplant match unrelated donor follow reduced intensity conditioning fludarabinetreosulfan patient receive gvhd prophylaxis anti thymocyte globulin thymoglobulin versus atlggrafalon primary endpoint incidence grade iiiv acute gvhd accord magic classification appendix section posttransplantation secondary objective endpoint secondary objective evaluate effect gvhd prophylaxis engraftment graft failure evaluate effect gvhd prophylaxis incidence grade1 acute gvhd chronic gvhd evaluate effect gvhd prophylaxis incidence infection evaluate effect gvhd prophylaxis progression free survival evaluate effect gvhd prophylaxis relapse incidence evaluate effect gvhd prophylaxis nonrelapse mortality evaluate effect gvhd prophylaxis overall survival evaluate effect gvhd prophylaxis gvhd relapse free survival evaluate effect gvhd prophylaxis healthrelated quality life fact bmt evaluate effect gvhd prophylaxis chimerism evaluate effect gvhd prophylaxis immune reconstitution nk regulatory cell level peripheral blood evaluate effect gvhd prophylaxis hospitalisation first posttransplantation evaluate effect gvhd prophylaxis incidence severity vod identify prognostic factor associate primary endpoint prophylaxis arm search treatmentbycovariate interaction primary endpoint evaluate effect gvhd prophylaxis incidence late acute gvhd overlap syndrome chronic gvhd secondary endpoint hematopoietic recovery least 7consecutive neutrophils platelet immune reconstitution analyze nk regulatory cell gammaglobulin level peripheral blood posttransplantation chimerism grade1 acute gvhd incidence appendix section acute gvhd treatment first line treatment response steroid treatment course refractory acute gvhd chronic gvhd incidence date grading nih classification appendix section relapse incidence relapse define reappearance leukemic cell mds feature allohsct bonne marrow cytology cytogenetic analysis bone marrow aspiration extramedullary site prove biopsy progression free survival severe infection ctae grade34 fully describe incidences cmv ebv reactivations nonrelapse mortality overall survival gvhd relapse free survival define alive without disease relapse without develop acute grade iiiiv severe chronic gvhd healthrelated quality life assess use factbmtv4 questionnaire inclusion posttransplantation number hospitalization transplant hospitalization transplantation relate complication incidence severity vod lymphocyte count standard blood count conditioning late acute gvhd overlap syndrome chronic gvhd",
    "DESIGN": "design study phase3 multicenter randomize control openlabel trial compare gvdh prophylaxis anti thymocyte globulin versus atlg patient acute myeloid leukemia mds transplant match unrelated donor follow fludarabinetreosulfan reduced intensity conditioning ancillary study bio collection pbmc plasma dry pellet total blood cell perform base line patient per arm future biological study would perform find complementary funding collection organize via cryostem order good understand modulation immune response two anti thymocyte globulin brand plasma collection anti thymocyte globulin pk analysis atlg arm sample collect administration atlg days3 frozen center data analyze accord preconditioning lymphocyte count correlate posttransplant outcome gvhd relapse nrm able determine formula optimize atlg dose lymphocyte count future study plasma collection start include patient find complementary funding",
    "INCLUSION CRITERIA": "population study participant patients age present acute myeloid leukemia mds indication allogeneic stem cell transplantation inclusion criterion age patient unfit myeloblative conditioning acute myeloid leukemia require allogeneic stem cell transplantation intermediate highrisk acute myeloid leukemia complete cytologic response cr1 mds require allogeneic stem cell transplantation ipss ipssr ipssr risk feature rapide blast increase lifethreatening neutropenia thrombopenia high transfusion need without hla match related donor identify match hla unrelated donor usual criterion hsct ecog performans status severe uncontrolled infection cardiac leave ventricular ejection fraction lung dlco adequate organ function asat alat 3n total bilirubin 2n creatinine clearance except abnormality link hematological disease health insurance coverage sign write informed consent contraception method must prescribe duration research nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion carcinomas last except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity hiv htlv1 active hepatitis yellow fever vaccine others live virus vaccine within transplantation heart failure accord nyha ii left ventricular ejection fraction lung dlco preexisting acute hemorrhagic cystitis renal failure creatinine clearance pregnancy hcg positive breastfeeding patients debilitate medical psychiatric illness would preclude realization sct understanding protocol patient state medical aid patient legal protection protection court curatorship guardianship grafalon contraindication mention smpc grafalon thymoglobulin hypersensitivity rabbit protein excipients participation clinical trial medicinal product human use exclusion period end previous study contraindication mention smpc auxiliary medicinal product plan use trial cyclosporine mycophenolate mofetil fludarabine treosulfan",
    "INTERVENTION": "investigational medicinal product phase3 grafalon iv consecutive transplantation thymoglobuline iv transplantation transplantation modality conditionning regimen patient receive conditioning regimen fludarabine iv day6 treosulfan iv donor stem cell source hla match unrelated donor gcsfmobilized peripheral blood stem cell accept cd34 target dose body weight gvhd prophylaxis prophylaxis gvhd depend randomization arm atlggrafalon iv consecutive atlggrafalon anti thymocyte globulin thymoglobuline anti thymocyte globulin thymo two schedule administration antithymocyte globulin accept iv consecutive day3 iv follow iv addition patient receive cyclosporine csa mycophenolate mofetil mmf follow csa day1 progressive withdrawal start post sct agvhd accord practice center mmf arm",
    "STATISTICS": "statistical analysis hypothesis base reduction incidence posthsct grade iiiv acute gvhd anti thymocyte globulin arm atlg arm assume risk randomised patient would reach transplant incidence compete risk death without gvhd arm account compete risk twosided logrank test overall sample size subject control group treatment group achieve power significance level detect hazard ratio followup time total patient include interim analysis schedule perform"
  },
  "CAALLF01": {
    "TITLE": "name study caallf01 french protocol treatment acute lymphoblastic leukemia child adolescent",
    "JUSTIFICATION": "main background acute lymphoblastic leukemia curable disease child adolescent nevertheless numerous problem remain good result obtain intensive prolonged treatment include risk toxic death sequela secondary malignancy results still insufficient highrisk form particularly exhibit early resistance chemotherapy early bone marrow relapse less diagnosis still dismal prognosis render prevention mandatory acute lymphoblastic leukemia extremely heterogeneous disease term biology response treatment envisage targeted treatment future render key decipher heterogeneity two cooperative group fralle french center eortcclcg decide elaborate common protocol treatment childhood adolescent acute lymphoblastic leukemia childhood adolescent acute lymphoblastic leukemia france caallf01 two previous study group comparable result eventfree survival overall survival fralle pt eortc 1947pts still major question field acute lymphoblastic leukemia optimal use lasparaginase asnase know administer asnase result depletion asparagine circulating blood starve leukemic cell result death indeed use asnase varies protocol consider different brand dose administration modality rythm route intramuscular intravenous infusion three major form asnase currently available coli asparaginase kidrolase france erwinia asparaginase erwinase patient allergy pegylated form coli asparaginase oncaspar usa europe oncasparin usa oncaspar pegylated coli asparaginase pegaspargase manufacture initially enzon shire servier develop goal reduce immunogenicity native asnase addition oncaspar prolonged serum terminal halflife t1 dose less frequently native asnase achievement similar pd usa ccg1962 pivotal clinical trial support firstline use oncaspar children standard risk acute lymphoblastic leukemia randomize receive native pegylated coli asparaginase active pharmaceutical ingredient merck part induction delayed intensification di phase oncaspar administer intramuscularly dose iu induction phase two di phase native coli asparaginase merck elspar administer intramuscular dose iu three time weekly dos induction dos di phase children treat oncaspar rapid clearance lymphoblast bone marrow aspirate prolonged asparaginase activity treat native form first di phase26 native asparaginase patient hightiter antibody compare patient receive oncaspar high titer antibody associate low asparaginase activity native arm oncaspar arm rate infection hospitalization safety profile similar arm avramis et al oncaspar approve treatment acute lymphoblastic leukemia component multiagent chemotherapy usa since include firstline use since first line use transfer new oncaspar manufacture sigmatau pegaspargase asparaginase lonza shire oncasparin europe oncaspar currently available europe differ oncaspar market usa term asparaginase origin kyowahakko lonza although product pegylated sigmatau usa germany poland oncaspar kh kyowahakko register component antineoplastic combination therapy reinduction patient know hypersensitivity native lasparaginase secondline oncaspar kh use first line asparaginase preparation least three european acute lymphoblastic leukemia protocol uk mrc protocol acute lymphoblastic leukemia since uk bfmaieop protocol acute lymphoblastic leukemia since germany italy austria switzerland czech republic israel interfant protocol dedicate infant acute lymphoblastic leukemia since many country since january european commission grant marketing authorization use oncaspar combination therapy acute lymphoblastic leukaemia paediatric patient birth adult patient approval baxalta authorize market oncaspar member country european union eu well iceland liechtenstein norway authorization relate onacaspar incorporate active pharmaceutical ingredient manufacture lonza current status asparaginase preparation france january kidrolase register first line use erwinase available patient allergic native pegylated asparaginase maa france oncaspar oncaspar kh available named patient program atuon november oncaspar receive marketing authorization january different dose schedule use oncaspar induction therapy currently propose accord firstline acute lymphoblastic leukemia protocol iu one infusion cog dfci protocol us use oncaspar lonza iu one infusion st jude protocol us oncaspar lonza iu two infusion aieopbfm protocol europe oncaspar kh iu two infusion eortc protocol belgium oncaspar kh iu one infusion interfant protocol mainly europe oncaspar kh iu two infusion ukall protocol uk oncaspar kh iu two infusion dcog protocol nl oncaspar kh result protocol ukall interest eventfree survival overall survival vora et al lancet oncol obtain use low dosage per infusion oncaspar kh iu intramuscular repeat interval induction subgroup patient treat ukall cyk fong et al ash show dose provide adequate asparaginase activity iu sample study 1st second injection",
    "OBJECTIVE": "questions ask caallf01 protocol french protocol first europe use oncaspar lonza use usa since first approval another oncaspar manufacture merck active pharmaceutical ingredient randomized question best way administer pegaspargase cohort child adolescent standard medium risk acute lymphoblastic leukemia randomize receive induction either one infusion oncaspar lonza iu two infusion oncaspar lonza iu patients receive iu iu per dose consolidation delay intensification accord initial arm randomization non randomized question high high risk group non randomized intensification scheme asparaginase administration propose induction therapy infusion iu administer patient receive iu per dose consolidation delayed intensification primary objective child adolescent standard medium risk acute lymphoblastic leukemia study two primary objective assess superiority term pk fractionated scheme assess equivalence tolerance scheme induction high high risk group two primary objective define assess pk assess toxicity intensified scheme induction main endpoints adequate asparaginase activity iu induction toxicity incidence severe toxicity grade3 directly asparaginase relate central nervous system thrombosis pancreatitis anaphylaxia hyperbilirubinemia treatment anyway consolidation secondary endpoints linked study drug pharmacokinetics pharmacodynamics immunogenicity comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion include cid asparaginase activity asparagine level define timepoints cid incidence asparaginase antibody cid incidence silent inactivation arm induction consolidation intensification phase cid allergic reaction rate arm induction consolidation intensification phase cid percentage patient without switch erwinia asparaginase cid percentage patient receive intend dose asparaginase efficacy comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion efficacy include cid morphological complete remission rate assess whole population subgroup blineage acute lymphoblastic leukemia tcell acute lymphoblastic leukemia cid minimal residual disease end induction tp1 late timepoint tp2 tp3 subgroup patient assess ig tcrbased rqpcr evaluation make whole population within subgroup cid cumulative incidence relapse overall cid cumulative incidence bm relapse central nervous system relapse gonadal relapse combine relapse toxicity comparison arm undertake patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups cid adverse event ae relate asparaginase occur within first treatment anyway consolidation hyperglycemia induce diabetes coagulopathy allergy hyperlipidemia hypertriglyceridemia hypercholesterolemia non central nervous system thrombosis grade12 ae pancreatitis hyperbilirubinemia cid adverse event relate asparaginase occur induction anyway consolidation cid incidence acute lymphoblastic leukemia grade34 adverse event whatever imputability survival timepoints eventfree survival diseasefree survival overall survival classical outcome measure evaluation survival child acute lymphoblastic leukemia eventfree survival survival time free treatment failure relapse secondary malignancy treatment randomization randomize arm disease free survival eventfree survival responder measure time complete remission follow induction treatment failure define induction least blast minimal residual disease case available minimal residual disease blast criterion require 2other secondary objective cid evaluate incidence rare subgroup acute lymphoblastic leukemia prognostic value socalled bother subgroup bcrabl like include ebf1pdgfrb mef2dx znf384x tcf3hlf cid eventfree survival diseasefree survival overall survival rare patient suboptimal reponse therapy induction failure mrdtp1 ablclass fusion alls treat imatinib cid imatinib related adverse event immediate long term cf appendix rare patient suboptimal reponse therapy induction failure mrdtp1 ablclass fusion alls treat imatinib",
    "DESIGN": "study design french prospective multicentric cohort study child adolescent acute lymphoblastic leukemia stratify type acute lymphoblastic leukemia versus ii anticipate risk stratify group bcp acute lymphoblastic leukemia group tcell acute lymphoblastic leukemia randomized clinical trial perform population patient compose standard risk medium risk standard risk check eligibility criterion use two paralell arm randomization design patients allocate either receive one infusion oncaspar iu versus infusion iu induction therapy dose per infusion induction therapy dose per infusion attribute initial randomization randomized question ask high high risk group lineage patient receive infusion oncaspar iu induction iu infusion afterwards nevertheless patient submit evalauation term pk pd toxicity efficacy patient include caallf01 study induction treatment randomization take place first infusion pegaspargase patient belong standard risk medium risk standard risk group",
    "INCLUSION CRITERIA": "inclusion criterion cid children adolescent age yearsblineage lineage acute lymphoblastic leukemia cid written informed consent obtain treatment nb patient syndrome include randomize see detail protocol section",
    "EXCLUSION CRITERIA": "non inclusion criterion cid l3 burkitts leukemia lmb type protocol cid mixed phenotype acute leukemia criteria cid infant acute lymphoblastic leukemia age interfant protocol cid secondary leukemia cid patients previously treat chemotherapy steroid expose pt include stratify accord section known allergy pegylated product cid pregnancy women childbearing potential define acute lymphoblastic leukemia woman physiologically capable become pregnant must negative serum pregnancy inclusion reliable contraception exceptoral contraceptive contraception maintain throughout study treatment discontinuation cid known hiv positivity cid central nervous system thrombosis prophase exclusion criterion cid bcrabl acute lymphoblastic leukemia esphall protocol cid central nervous system thrombosis",
    "INTERVENTION": "investigational drug oncaspar pegaspargase supply sterile solution beginning trial replace powder solution injection package type1 singleuse vial contain international units native asparaginase per solution oncaspar store refrigeration 2c 8c product must shake frozen must protect light",
    "STATISTICS": "first interim analysis perform base acute lymphoblastic leukemia patient randomize january request dsmb study november"
  },
  "HAPLO-EMPTY": {
    "TITLE": "full title haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide patient acquired refractory aplastic anemia nationwide phase2 study",
    "JUSTIFICATION": "scientific justification outcomes patient severe aplastic anemia refractory firstline immunosuppressive therapy ist lack match unrelated donor remain poor recently use eltrombopag show blood count improvement patient however refractory patient respond eltrombopag secondline treatment therefore expose lifethreatening infection bleed past decade significant decrease infection related mortality patient severe aplastic anemia unresponsive initial ist clonal evolution include paroxysmal nocturnal hemoglobinuria myelodysplastic syndrome mds acute myeloid leukemia still occur longterm grim prognosis overall overall survival patient acquired refractory severe aplastic anemia eltrombopag hematopoietic stem cell transplantation use alternative donor source mismatch unrelated donor cord blood cbt haploidentical family donor may curative patient refractory severe aplastic anemia despite carry much high rate complication transplantation match relate unrelated donor recently group show cbt valuable curative option young adult refractory severe aplastic anemia however patient available cb cbt treatment related mortality high adult patient haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy preliminary result little number patient refractory severe aplastic anemia kings college london uk john hopkins baltimore usa seem promise retrospectively analyze data patient median age transplant europe behalf severe aplastic anemia work party european blood marrow transplantation group overall survival suggest approach might valid option particular poor clinical situation",
    "OBJECTIVE": "main objective primary endpoint main objective demonstrate benefit term overall survival rate historical rate patient acquired refractory idiopathic aplastic anemia use haplosct ptcy primary endpoint overall survival rate secondary objective endpoint secondary objective clinical biological outcome graft failure graft versus host disease progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment consecutive neutrophile consecutive platelet absolute number neutrophil platelet last platelet red blood cell transfusion incidence use growth factor poor hematopoietic reconstitution acute graft versus host disease incidence date maximum grading first line treatment response steroid treatment course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading relapse incidence progression free survival incidence cmv ebv infection severe infection ctae grade34 nonrelapse mortality incidence cardiac toxicity overall survival quality life questionnaire inclusion post transplantation chimerism immune reconstitution analyze nk regulatory cell level peripheral blood posttransplantation ferritin level",
    "DESIGN": "design study phase2 multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "population study participant patients age acquired refractory idiopathic aplastic anemia indication haploidentical allogeneic hematopoietic stem cell transplantation inclusion criterion patients aged suffering refractory acquire idiopathic aplastic anemia least one course immunosuppression antithymocyte globulin absence genoidentical donor match donor identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detect patient mfi antibody direct towards distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine mol health insurance coverage contraception method must prescribe duration research women men childbearing age must use contraceptive method within last dose cyclophosphamide respectively sign write informed consent parent patient age less nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis cancer last except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding receive attenuated vaccine within transplantation uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord nyha ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance urinary tract obstruction contraindication treatment use research debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship",
    "INTERVENTION": "transplant modality conditioning regimen fludarabine pretransplant cyclophosphamide total body irradiation gray day1 stem cell source bone marrow graft versus host disease prophylaxis rabbit atg dose cyclophosphamide tacrolimus residual microg mycophenolate mmf absence graft versus host disease mmf stop tacrolimus prevention ebv reactivation rituximab intravenously post hematopoietic stem cell transplantation infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine",
    "STATISTICS": "statistical analysis justification sample size hypothesize overall survival versus historical control twosided onesample logrank test calculate sample subject achieve power significance level detect proportion overall survival new group proportion overall survival historic control group terminal analysis realize observation required number event"
  },
  "KAPVEC": {
    "TITLE": "full title phase2 multicenter study talimogene laherparepvec classic endemic kaposi sarcoma",
    "JUSTIFICATION": "scientific justification kaposi sarcoma lymphangioproliferation associate human herpes virus hhv8 promote immunosuppression hivrelated kaposi sarcoma iatrogenic posttransplantation kaposi sarcoma treat immune restoration association local systemic therapy chemotherapy require conversely classic endemic kaposi sarcoma underlie relative immunosuppression directly target treatment poorly codify mostly base surgery radiotherapy localized kaposi sarcoma aggressive form visceral involvement treat chemotherapy interferon give best transient response may well tolerate elderly patient talimogene laherparepvec first oncolytic immunotherapy approve fda metastatic unresectable melanoma injectable nodal cutaneous lesion design induce tumor regression injected lesion direct lytic effect uninjected lesion induction systemic antitumor immunity merkel cell carcinoma another virusinduced tumor treatment pd1 pdl1 axis inhibitor prove efficacy thus provide proof principle immunotherapy could effective virusinduced tumor two case metastatic merkel cell carcinoma succesfully treat talimogene laherparepvec recently report suggest talimogene laherparepvec may also effective therapeutic option considering high immunogenicity viral epitope kaposi sarcoma tumor role immune evasion development kaposi sarcoma cutaneous manifestation patient easily inject classic endemic kaposi sarcoma good tumor model target talimogene laherparepvec",
    "OBJECTIVE": "main objective primary endpoint main objective assess whether talimogene laherparepvec clinically inactive partial complete response probability truly active partial complete response probability classic endemic kaposi sarcoma primary endpoint best overall response rate define occurrence complete response partial response injected lesion follow pga criterion pga record start treatment beginning specific therapy kaposi sarcoma occur secondary objective endpoint secondary objective safety profile talimogene laherparepvec classic endemic kaposi sarcoma parameter efficacy best response response rate duration response efficacy injected uninjected lesion quality life exploratory objectives characterize efficacy talimogene laherparepvec relate immunologic viral assessment tumor biopsy blood sample secondary endpoint adverse event follow ctcae v5 best overall response rate accord actg criterion response rate response rate lymphedema time response duration response response injected uninjected target lesion deaths cause kaposi sarcoma adapted dlqi score exploratory endpoint characterize immune tumor infiltrate immune cell quantification viral infiltrate tumor necrosis treatment hhv8 viral load blood tumor cell hhv8 sequence",
    "DESIGN": "design trial phase2 multicentre single arm open label trial scope trial kaposi sarcoma",
    "INCLUSION CRITERIA": "population trial subject adult patient inclusion criterion classic endemic histologically confirm kaposi sarcoma progressive require systemic therapy injectable measurable disease define least cutaneous lesion large diameter previously irradiated field least cutaneous lesion large diameter available repeat cutaneous biopsy previously irradiate field nb cutaneous lesion replace cluster small lesion edge edge distance big diameter cluster meet previous criterion willing provide tissue cutaneous biopsy least washout kaposi sarcoma specific therapy include topical treatment chemotherapy radiotherapy immunotherapy include interferon provide write informed consent prior performance study specific procedure age sign informed consent performance status ecog performance scale demonstrate adequate organ function haematological absolute neutrophil count platelets haemoglobin dl renal serum creatinine upper limit normal calculate creatinine clearance use mdrd formula subject creatinine level upper limit normal hepatic ast sgot alt sgpt 5xuln serum total bilirubin 5xuln direct bilirubin upper limit normal subject total bilirubin level 5xuln pt1 ptt tca female subject childbearing potential negative serum pregnancy within hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "exclusion criterion known history organ transplantation include allogeneic stemcell transplantation hiv hiv antibody detect selection symptomatic visceral involvement kaposi sarcoma include brain metastasis active autoimmune disease require systemic treatment require systemic treatment past use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type1 diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enrol evidence clinically significant immunosuppression following primary immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy include oral steroid dose prednisone equivalent within prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorder active herpetic skin lesion prior complication hsv infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral treatment antiherpetic drug eg acyclovir intermittent topical use previous treatment talimogene laherparepvec oncolytic virus prior radiotherapy field overlap injection sit prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within prior enrollment recover ctcae grade1 good adverse event due kaposi sarcoma therapy administer prior enrollment prior therapy tumor vaccine received live vaccine within prior enrolment currently treatment another investigational device drug study less since end treatment another investigational device drug study acute chronic active hepatitis hbs ag detect infection hcv rna detect inclusion active tb bacillus tuberculosis known additional malignancy currently progress require active treatment within last exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer sensitivity product component administer psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial last dose talimogene laherparepvec subjects unwilling minimize exposure blood body fluid individual high risk hsv1 induced complication immunosuppressed individual individual know hiv infection pregnant woman infant age talimogene laherparepvec treatment last dose talimogene laherparepvec pregnant breastfeeding expect conceive father child within projected duration trial female subject childbearing potential unwilling use acceptable method effective contraception study treatment last dose talimogene laherparepvec sexually active subject partner unwilling use male female latex condom avoid potential viral transmission sexual contact treatment within treatment talimogene laherparepvec addition male participant donate sperm last dose vulnerable subject prisoner incarcerate follow administrative court decision subject psychiatric disorder involuntary hospitalize subject legal protection measure subject express consent",
    "INTERVENTION": "investigational medicinal product talimogene laherparepvec dose pfu every injection route intralesional injection duration treatment cycle comparator treatment",
    "STATISTICS": "statistical analysis simons stage optimal design interim analysis plan patient"
  },
  "FIBRAPLO": {
    "TITLE": "full title haploidentical transplantation patient myelofibrosis phase2 prospective multicentric study",
    "JUSTIFICATION": "scientific justification curative treatment patient primary secondary myelofibrosis allogeneic hematopoietic stem cell hsct report intermediate high risk patient accord international prognostic score benefit hsct term survival kroger et al conduct france prospective trial test use ruxolitinib transplantation jakallo study nct01795677 outcome patient well patient transplant matched sibling donor unrelated donor confirm study kroger et al rondelli et al jakallo trial acute gvhd incidence high often hyperacute severe recently ebmt group report registry study familial haploidentical transplantation haplo patient myelofibrosis raj et al posttransplant cyclophosphamide use case oneyear overall survival diseasefree survival favorably compare outcome unrelated transplantation genova team also report impressive result haploidentical transplantation center bregante et al bregante et al report outcome cohort transplant main difference period frequent use haplo second period versus outcome much well second period overall survival versus author suggest improvement relate best outcome among haplo transplantation improvement outcome haplo attribute good gvhd prophylaxis especially use posttransplant cyclophosphamide given poor outcome unrelated transplantation especially hla mismatch unrelated setting encouraging result family haplo identical transplantation current study proposes test haploidentical transplantation myelofibrosis patient without match related donor",
    "OBJECTIVE": "main objective primary endpoint main objective diseasefree survival without rejection one haploidentical transplantation patient primary secondary myelofibrosis main criterion judgement disease rejection free survival hsct secondary objective endpoint assess incidence acute gvhd grade2 incidence acute gvhd grade3 engraftment incidence chronic gvhd nonrelapse mortality overall survival relapse progression incidence rejection incidence time neutrophil engraftment time platelet engraftment infection incidence cytokine profile transplantation day7 impact genetic alteration overall survival nonrelapse morality",
    "DESIGN": "design trial phase2 multicentric study scope trial goal show haploidentical hsct use thiotepa fludarabine combination treosulfan give acceptable result even good transplantation hla mismatch donor close match unrelated donor patient myelofibrosis",
    "INCLUSION CRITERIA": "population trial subject patients myelofibrosis contraindication transplant advanced disease international score could propose trial hlamatched donor inclusion criterion patients age primary myelofibrosis myelofibrosis secondary essential thrombocythemia polycythemia vera proven marrow biopsy myelofibrosis combine least following criterion constitutional symptom weight loss one fever without infection recurrent muscle bone join pain extreme fatigue anemia hemoglobin gr dl red blood cell transfusion requirement thrombocytopenia peripheral blast count least find time white blood cell count cytoreductive treatment karyotype 7q 17q 5q 12p inv 11q23 performance status accord ecog health insurance coverage sign write informed consent women agree take nomegestrol acetate contraception treatment treosulfan men agree conceive child treatment treosulfan",
    "EXCLUSION CRITERIA": "exclusion criterion myelofibrosis transform acute leukemia poor performance status ecog cardiac failure ef currently past even correct treatment renal failure creatininemia mol clearance respiratory function alter vital capacity force expired volume biological significant liver abnormality asat alat normal range bilirubin normal range hla match donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeed contraindications treosulfan hypersensitivity active substance active noncontrolled infectious disease fanconi anaemia dna breakage repair disorder administration live vaccine contraindications circumstance preclude use drug involve protocol especially thiotepa fludarabine",
    "INTERVENTION": "investigational medicinal product treosulfan investigational medicinal product use condition regimen haploidentical transplantation treosulfan receive euwide approval toxicity reduce conditioning therapy prior allogeneic haematopoietic stem cell transplantation june provide medac treosuflan conditioning regimen administer followed gr per iv route use combination standard association thiotepa fludarabine per therefore thiotepa fludarabine indissociable treosulfan also consider medicinal product comparator treatment na",
    "STATISTICS": "statistical analysis analysis base intenttotreat basis include patient whatever administer treatment study sensitivity analysis perform patient actually receive graft patient consent withdrawal positive report use data exclude baseline summary statistic namely percentages median interquartile range iqr perform right censor endpoint estimate use nonparametric method kaplan meier curve cumulative incidence curve consider case noninformative informative censoring base logrank test gray test respectively adjustment potential confounders use cox proportional hazard model model assumption check use test proportional hazard spline smoothing residual loglinearity assumption statistical analysis perform sas sas inc cary nc http www rproject org software package"
  },
  "SONIMEL": {
    "TITLE": "full title safety efficacy blood brain barrier open implantable device sonocloud combine nivolumab use alone association ipilimumab brain metastasis patient malignant melanoma",
    "JUSTIFICATION": "scientific justification anti pd1 monoclonal antibody nivolumab pembrolizumab alone association antictla4 ipilimumab establish indisputable treatment metastatic melanoma unprecedented overall survival indicate firstline treatment include patient braf mutation given high molecular weight penetration brain sanctuary uncertain relies disruption blood brain barrier occur occasionally sonocloud implantable device deliver low intensity pulse ultrasound along systemic injection ultrasound resonator sonocloud demonstrate safe efficient repetitively open blood brain barrier anticipate blood brain barrier opening could help increase brain penetration monoclonal antibody potentially boost immunity brain could translate control brain disease magnitude extracranial disease would also open avenue optimize treatment brain metastasis combination checkpoint inhibitor many cancer",
    "OBJECTIVE": "main objective primary endpoint one single objective one single endpoint main objective determination successful dose define dose high probability blood brain barrier open efficacy without toxicity directly relate ultrasound emission primary endpoint success define grade2 blood brain barrier opening disruption pulsed ultrasound use sonocloud system without toxicity relate device assess clinically use brain mri dlt evaluate first treatment nivolumab alone treatment nivolumab ipilimumab thus primary endpoint success define efficacy without toxicity first treatment nivolumab alone treatment nivolumab ipilimumab secondary objective endpoint secondary objective clinical efficacy nivolumab ipilimumab context blood brain barrier opening study population safety nivolumab alone combine ipilimumab context blood brain barrier open secondary endpoint best overall response rate objective response rate best intracranial overall response rate bicorr icorr best extracranial overall response rate becorr ecorr progression free survival intracranial progression free survival intracranial ipfs extracranial progression free survival extracranial epfs overall survival safety use ctcae version clinical activity assess use tep tdm scans extracranial lesion mri intracranial metastasis clinical objective response rate define rano immunotherapy rano recist version immunerelated response criteria progression free survival define time immunotherapy perfusion sonication disease progression accord recist version 1and rano immune relate response criteria death whichever first",
    "DESIGN": "design study patient treat maximum considering maximum would withdraw participate research budget patient consider",
    "INCLUSION CRITERIA": "population study participant advanced brain metastasis melanoma patient age inclusion criterion patients histologically confirm metastatic melanoma patients must recover side effect recent systemic local treatment metastatic melanoma grade1 least one measurable brain metastasis diameter previously treat surgery radiosurgery locate less skull patients may receive prior radiosurgery surgery brain metastasis receive prior local treatment must least 1new rano recist assessable brain metastasis braf status wild type mutate case previous treatment braf inhibitor mek inhibitor allow eastern cooperative oncology group performance status age hemoglobin dl platelets neutrophils creatinine clearance mn ast 3n alt 3n total bilirubin 5n alkaline phosphatase 3n inr prothrombin tca hepatocellular insufficiency unhealed wound head allergy poly isoprene signed informed consent patient health insurance coverage life expectancy",
    "EXCLUSION CRITERIA": "noninclusion criterion ocular melanoma symptomatic leptomeningeal involvement symptomatic hemorrhagic brain metastasis symptoms incoercible intracranial pressure patient receive corticosteroid patient present intermittent seizure enrol stable dose corticosteroid corticotherapy antiepileptic treatment since least enrolment indication urgent neurosurgery radiotherapy prior malignancy active within previous except locally curable cancer apparently cure stage untreated chronic lymphoid leukemia known hiv infection ongoing infectious disease significant background concurrent administration anticancer therapies administer study treatment cytotoxic investigational drug antictla4 target therapy halflives targeted therapy chemotherapy prior study prior whole brain radiotherapy pregnant lactate woman patient auto immune disease contraindications nivolumab alone association ipilimumab define spc http www vidal fr substances nivolumab serious uncontrolled medical disorder opinion investigator may increase risk associate study participation study drug administration impair ability patient receive protocol therapy interfere interpretation study result allergy iodine gadolinium lidocaine contraindications sonovue hypersensibility sulfur hexafluoride recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii iv define new york heart association concurrent treatment dobutamine severe pulmonary arterial hypertension uncontrolled systemic hypertension respiratory distress syndrome concurrent treatment cns benzodiazepin sedative hypnotic antihistaminic pro convulse drug butyrophenons phenothiazin conventional antipsychotic barbituric mao inhibitor anticholinergic drug accord investigator cause cerebral toxicity due blood brain barrier open concurrent anticoagulant antiplatelet therapy uncontrolled epilepsy mri contra indication claustrophobia intracorporal metallic material phlebitis active pulmonary embolism prisoners subject involuntarily incarcerate psychological familial sociological geographical condition potentially hamper compliance study protocol followup schedule condition discuss subject registration trial treatment drug authorize special condition stable dosage prior inclusion inhibitors acetylcholine esterase donepezil aricept galantamine rivastigmine memantine atypical antipsychotic eg quetiapine antidepressants mao inhibitor anticholinergic dose thyroid hormones exclusion criterion implantation sonocloud possible accord neurosurgeon patient morphological characteristic skin characteristic bone thickness neurosurgeon opinion prevent implantation device may impair ability patient receive treatment sonocloud would exclude",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis adaptive bayesian doseescalation model continual reassessment method crm use selected version crm modelbased design dose dlt relationship model cumulative function correspond oneparameter power model parameter sequentially estimate data via bayesian estimation setting mtd populationparameter refers 10th percentile dosetoxicity relationship total ultrasound dose level evaluate mpa minimum three patient include dose level october patient treat level 78mpa patient level 9mpa side effect toxicity observe good tolerance since crm design recommend new patient could treat high level 03mpa patient n5 receive 03mpa dose"
  },
  "DREPA-RIC": {
    "TITLE": "full title prospective multicenter trial compare allogeneic match related haematopoietic stem cell transplantation reduced intensity condition regimen standard care adolescent adult severe sickle cell disease",
    "JUSTIFICATION": "scientific justification although survival child sickle cell disease dramatically improve last decade us europe mortality remain high adult moreover many child adult develop chronic debilitating condition due organ damage allogeneic hematopoietic stem cell transplantation currently unique curative approach allow cure child transplant match relate donor myeloablative conditioning regimen date study address role hematopoietic stem cell transplantation sickle cell disease adult due risk graft versus host disease toxicity expect patient high risk organ damage development safe nonmyeloablative conditioning regimen allow stable mixed chimerism avoid graft versus host disease appear attractive option hematopoietic stem cell transplantation cure adult severe sickle cell disease four group previously report encouraging result total patient transplant match related mobilized peripheral blood cell non myeloablative conditioning regimen alemtuzumab low dose total body irradiation follow posttransplant sirolimus study demonstrate high sickle cell disease free survival rate death relate transplant graft failure graft versus host disease ninety two percent patient cure normalized hemoglobin level resolution hemolysis stable hemoglobin level identical proportion observe donor however outcome comparison patient transplant patient transplant lack design prospective multicenter trial target patient severe sickle cell disease compare nonmyeloablative transplant match related donor identify versus hematopoietic stem cell transplantation patient lack match related donor",
    "OBJECTIVE": "main objective primary endpoint main objective assess benefit hematopoietic stem cell transplantation event free survival calculate inclusion compare standard care primary endpoint event free survival event define death cause acute grade iiiv graft versus host disease accord magic consortium appendix moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography scan stroke define clinical event confirm mri cerebral cervical stenosis new territory evaluate mri mra apparition silent infarct increase least tricuspid regurgitation velocity confirm echocardiography perform delay least compare pre inclusion value patient trv inclusion hypothesize event free survival hematopoietic stem cell transplantation versus notransplant group secondary objective endpoint secondary objective compare group overall survival total require hospitalization first postinclusion acute complication sickle cell disease voc acs priapism stroke silent infarct cerebral cervical stenosis mra mri hemolytic index hematologic biochemical parameter organ function kidney eye heart lung liver bone grade iiiiv infectious complication need transfusion postinclusion alloimmunization rate iron overload chronic use oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost evaluate transplant group chimerism engraftment graft versus host disease patient free sirolimus posttransplant secondary end point death number require hospitalization exclusion first postinclusion clinical adverse event number voc acs require hospitalization number hospitalization intensive care unit number priapism number stroke changes biological parameter ldh aminotransferase gammagt alkaline phosphatase bilirubin pr aptt hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variant reticulocyte white blood cell platelet count estimate glomerular function rate microalbuminuria creatininuria ratio ferritin transferrin saturation level gonadic function spermogram men lh fsh oestrogen woman testosterone men number amenorrhea woman number parity eye function heart pulmonary hypertension auricular ventricular dilatation leave ventricular mass function transthoracic echocardiography lung function pulmonary function test walk test bone function new episode avascular osteonecrosis fracture central nervous system function mra mri liver heart magnetic resonance imaging iron overload evaluation patient ferritin microg inclusion number red blood cell pack transfuse postinclusion number delayed hemolytic transfusion reaction oral opioid consumption quality life questionnaire mos sf36 hospital anxiety depression scale questionnaire change weight severe infection ctae score grade34 gvhd incidence grading hematopoietic stem cell transplantation patient chimerism hematopoietic stem cell transplantation assess total blood population lymphocyte subset cost evaluate hospitalization inclusion",
    "DESIGN": "design study quasi experimental design phase3 prospective control multicenter cohort study group patient define genetic randomization eligibility criterion informed consent obtain hla typing perform identify potential hla match related donor define group group expose patient hla identical sibling identify patient receive hematopoietic stem cell transplantation group unexposed patient patient lack hla identical sibling receive best standard care transplant arm redcell exchange perform reduce hemoglobin level less precede transplant condition regimen consist 300cgy total body irradiation alemtuzumab iv total dose stem cell source gcsf mobilized peripheral blood stem cell cd34 target dose per body weight graft versus host disease prophylaxis consist sirolimus sirolimus taper stop post transplant transplant arm patient receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program initiation new drug prove improve sickle cell disease authorization use france",
    "INCLUSION CRITERIA": "population study participant adolescents young adult inclusion criterion patient sickle cell disease patient ss s0 aged least one non sickle cell disease sibling parental couple present least one following criterion voc require hospitalization last least severe acs within past define follow acs require red cell transfusion hospitalization intensive care unit acs pao2 60mmhg arterial blood pac02 50mmhg need liter mn reach sat02 voc require hospitalization last history recurrent acs three history ischemic stroke cerebral cervical arterial stenosis apparition silent infarct last pulmonary hypertension define mean pulmonary artery pressure mmhg rest determine right heart catherization osteonecrosis least joint include one diagnose past sickle nephropathy estimate glomerular filtration rate ckd epi formula 73m2 persistant microalbuminuria microalbuminuria creatininuria ratio mmol without cause nephropathy requiring treatment hydroxyurea chronic transfusion already treat hydroxyurea transfusion program inclusion patients already receive chronic transfusion voc acs respond hydroxyurea eligible provide beginning chronic transfusion least voc require hospitalization last least severe acs within past define follow acs require red cell transfusion hospitalization intensive care unit acs pac02 60mmhg arterial blood pac02 50mmhg need liter o2 mn reach sat02 voc require hospitalization last history recurrent acs three contraception study period sirolimus woman child bear potential signed inform consent amenable hla typing hematopoietic stem cell transplantation hlaidentical sibling available patients affiliate french health care insurance inclusion criterion donor age hb electrophoresis aa ac donor usual clinical biological eligibility criterion gcsf mobilization peripheral blood stem cell bone collection include legal viral serology assessment authorize transplant hla identical patient negative covid19 test time hematopoietic stem cell transplantation mobilization patient several potential donor several match sibling donor abo match donor choose priority",
    "EXCLUSION CRITERIA": "exclusion criterion patient performance status ecog scale pulmonary function fev1 et fvc theorical value post capillary severe precapillary pulmonary hypertension measured mean pulmonary artery pressure rest mmhg cardiac ejection fraction estimated glomerular fraction rate mn 73m2 conjugate bilirubin mole cirrhosis alat 4n severe uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin protein following excipients disodium edetate polysorbate potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injection positivity hiv pregnancy breastfeeding woman alloimmunization delayed hemolytic transfusion reaction preclude red cell transfusion previous solid organ transplant hematopoietic stem cell transplant uncontrolled hypertension history arterial dissection cervicocephalic artery history angina pectoris myocardial infarction",
    "INTERVENTION": "comparator arm patients receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program initiation new drug prove improve sickle cell disease authorization use france",
    "STATISTICS": "statistical analysis single efficacy analysis plan efs compare two group use logrank test effect hematopoietic stem cell transplantation assess hazard ratio use cox model primary endpoint event free survival calculate inclusion event define followed death cause acute grade iiiv graft versus host disease accord magic consortium appendix moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography scan stroke define clinical event confirm mri cerebral cervical stenosis new territory evaluate mri mra increase least tricuspid regurgitation velocity confirm echocardiography perform delay least compare pre inclusion value patient trv inclusion apparition silent infarct cerebral cervical stenosis new territory increase previous stenosis evaluate mri mra event free survival calculate inclusion also describe hematopoietic stem cell transplantation group overall survival define time date inclusion death due cause date last followup propensity score matching analysis also perform sensitivity analysis handle potential residual imbalance arm confounders sequential analysis tolerance data perform use bayesian method hypothesize event free survival hematopoietic stem cell transplantation versus notransplant group"
  },
  "PARADISE": {
    "TITLE": "full title prospective randomized control trial crohns disease exclusion diet versus corticosteroids adult pediatric patients active crohns disease",
    "JUSTIFICATION": "",
    "OBJECTIVE": "main objective primary endpoint main objective assess whether crohn disease exclusion diet superior corticosteroid term endoscopic response patient mildly moderately active luminal inflammatory crohn disease primary endpoint endoscopic response without corticosteroid far therapeutic intervention assess centralized pseudonymized blind double lecture panel panenteric pillcam crohns capsule endoscopic response define decrease least lewis score patient small bowel crohn disease decrease ses crohn disease least patient colonic crohn disease patient small bowel colonic crohn disease compare baseline value secondary objective endpoint compare arm trial steroidfree clinical remission harveybradshaw index response decrease least point harveybradshaw index steroidfree clinical remission crohn disease activity index response decrease least point crohn disease activity index need therapeutic intervention steroid immunosuppressant new biologic surgery decrease fecal calprotectin least steroid fecal calprotectin less less less creactive protein serum level median harveybradshaw index crohn disease activity index calprotectin creactive protein endoscopic remission define lewis score small bowel ses crohn disease colon without therapeutic intervention surgery biologics dietary intervention endoscopic response remission grade eliakim score segmental endoscopic response remission gut microbiota composition pcr pcr 18s fungi protist metabolomics shotgun metagenomics compliance corticosteroid treatment medication adherence report scale compliance crohn disease exclusion diet dietary habit questionnaires 72h food diary body weight arterial pressure fast serum glucose safety assess adverse event either severe suspect unexpected serious adverse reaction quality life assess short inflammatory bowel disease questionnaire work productivity activity assess work productivity index questionnaire",
    "DESIGN": "design study multicentre openlabel comparative randomize control single blind superiority",
    "INCLUSION CRITERIA": "population study participant patients active crohn disease inclusion criterion patients age mild moderate luminal active crohn disease define harveybradshaw index involve small bowel colon treat corticosteroid baseline patients either naive previously expose maximum two class biologics currently receive biologic therapy expose maximum two class biologic therapy include current one patent small bowel assess patency capsule active endoscopic lesion define lewis score small bowel ses crohn disease colon eligibility patient determine least one central reader informed consent participate study patient france israel age less parent inform consent participate study parent agreement require patient age netherlands affiliation social security health insurance",
    "EXCLUSION CRITERIA": "exclusion criterion inability follow crohn disease exclusion diet prior intolerance corticosteroid ongoing infection evolve virus disease live vaccine psychotic state control treatment arthritis uveitis main presenting symptom patients severe predominant rectal perianal disease heavy smoker cigarette per infliximab adalimumab vedolizumab ustekinumab rizankizumab upadacitinib methotrexate azathioprine initiate less inclusion trial change methotrexate azathioprine infliximab adalimumab vedolizumab upadactinib risankizumab ustekinumab dosage less inclusion severe pubertal delay tanner tanner height velocity zscore bone mineral density zscore hip lumbar spine know pregnant lactating woman patients already include biomedical research observational study registry cohort biobank persons deprive liberty judicial administrative decision person subject psychiatric care section person admit health social institution purpose research france present past history eat disorder include anorexia nervosa",
    "INTERVENTION": "comparator arm oral corticosteroid prednisolone budesonide",
    "STATISTICS": "statistical analysis base intenttotreat principle based available literature hypothesize patient reach primary endpoint crohn disease exclusion diet arm versus corticosteroid arm plan screen patient include patient randomize crohn disease exclusion diet corticosteroid"
  },
  "MARVEL": {
    "TITLE": "full title exploring venlafaxine pharmacokinetic variability phenotyping approach",
    "JUSTIFICATION": "scientific justification regarding direct cost social value depression decision antidepressant treatment prescription must optimize much possible development personalized medicine psychiatry may reduce treatment failure intolerance resistance hence burden cost affective disorder hope biomarkers find guide treatment selection might decisive interest able assess individual metabolism activity propose explore relationship activity drugmetabolizing enzyme transporters assess phenotypic approach efficacy antidepressant focus venlafaxine provide reasonable secondstep choice patient depression use extensively psychiatric practice metabolism involve several cytochrome cyp p450 enzyme transporter pgp",
    "OBJECTIVE": "primary objective study correlation concentration metabolite odesmethylv odemethylv drug metabolism variability assess phenotypic approach secondary objective compare responder non responder well patient without side effect cyp2c19 activity prevalence profile metabolism cyp2d6 activity prevalence profile metabolism cyp3a4 activity prevalence profile metabolism pgp activity prevalance profile transport study correlation odemethylv concentration dose odemethylv concentration antidepressant efficacy tolerance study correlation ratio odemethylv cyp2d6 activity study correlation concentration hour auc hour metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analysis blood biomarkers candidate mrna mirna tolerance efficacy analyse role genetic variation dna determination cyp2c19 2d6 phenotype patient pm profile criteria assessment odemethylv concentration cyp2c19 activity 5hydroxyomeprazole omeprazole hour auc metabolic ratio hour omeprazole oral administration cyp2d6 activity dextrorphan dextromethorphan ratio two hour dextromethorphan oral administration cyp3a4 activity 1hydroxymidazolam midazolam ratio two hour midazolam oral administration pgp activity fexofenadine auc base fexofenadine concentration hour fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prisem fisber antidepressant observance mars circulating mrna mirna transcript allelic variation cyp2c19 cyp2d6",
    "DESIGN": "experimental design interventional study recherche biomedicale",
    "INCLUSION CRITERIA": "population involve patient major depressive disorder madrs despite regardless dose inclusion criterion patient hospitalized outpatient major depressive disorder madrs visit selection patients non responder regardless dose decision psychiatrist increase dose visit selection male female age understanding french language able give write inform consent informed consent sign participate study individuals cover social security regimen",
    "EXCLUSION CRITERIA": "noninclusion criterion patients treat one antidepressant mirtazapine mianserine patients currently treat one drug substrate cocktail esomeprazole sensitivity contraindication substrate drug use current pregnancy desire get pregnant breastfeed bipolar disorder schizophrenia",
    "INTERVENTION": "challenge agent assessment drugmetabolizing enzyme activity patient give cocktail probe drug oral route one time study capsule omeprazole oral liquid formulation dextromethorphane bromhydrate tussidane syrup injectable solution midazolam oral administration midazolam injectable solution tablet fexofenadine",
    "STATISTICS": "statistical analysis statistical analysis perform sample size reach end point measure available hypothesis prevalence patient cyp2c19 um profile twice high nonresponders comparison responder cyp2c19 metabolic profile comparable caucasians demonstrate prevalence two fold observe nonresponders type1 error statistical power sample size tabulate accord prevalence response thus anticipate potential large disproportion responders non responder define study inclusion decide include patient allow control type1 type2 error rate comparison prevalence cyp2c19 um profile among group addition sample size allow study sufficient number cyp2d6 pm im um determine effect cyp2d6 variation odemethylv plasma level efficacy risk adverse event type1 error rate fix test twosided compare thus multiple imputation popular approach handle pervasive problem miss data biostatistics use usually perform miss random assumption multiple imputation chained equation knowledge flexible approach handle complex pattern miss data include categorical data quantitative data survival data primary analysis perform intenttotreat basis secondary exploratory analysis consider population compliers complete treatment accord schedule protocol"
  },
  "PIPAC": {
    "TITLE": "full title pressurized intraperitoneal aerosol chemotherapy pipac gastric carcinomatosis phase2 randomize study",
    "JUSTIFICATION": "scientific justification peritoneal metastasis common pattern advanced gastric cancer lead terminal condition short time whatever recent progress regard systemic chemotherapy use multi drug association median survival limit altered quality life patient postulate new innovative health technology deliver intraperitoneal pressurize aerosol chemotherapy doxorubicin cisplatin laparoscopy transform situation offering double survival quality life preservation interestingly pipac procedure make apply repeatedly every therapeutic strategy allow improve ip drug impregnation maintain iv chemotherapy meanwhile pipac estok project support six main carcinomatosis national center gather medical surgical team daily support peritoneal carcinomatosis demonstrate efficacy pipac procedure gastric carcinomatosis make radical shift management patient break past strategy",
    "OBJECTIVE": "main objective primary endpoint main objective clinical study primary objective evaluate compare progression freesurvival patient peritoneal carcinomatosis gastric cancer treat either iv chemotherapy pressurized intraperitoneal aerosol chemotherapy pipac iv chemotherapy alone preservation quality life primary endpoint primary endpoint corresponds progression freesurvival define number patient clinical morphological sign progression death treatment secondary objective endpoint secondary objectives assessment criterion patients relate morbidity evaluate postoperative claviendindo classification comprehensive complication index range calculate website https www assessurgery com cci calculator evaluation treatmentrelated toxicity base ct cae classification v5 postoperative pain measure use numeric rating scale postoperative every hour obligatory sleep night break quality life evaluate visit patient eortc qlqsto22 questionnaire specific gastric cancer annexe eortc qlqc30 questionnaire annexe quality health status evaluate visit patient eq5d5l questionnaire annexe treatment relate feasibility successive pipac procedure define possibility perform pipac problem access peritoneal cavity disease relate overall survival define time randomization death secondary resecability rate define ipc laparoscopy treatment",
    "DESIGN": "design trial prospective multicenter randomize openlabel control parallelgroup phase2 clinical trial design evaluate effect pipac doxorubicin cisplatin patient gastric peritoneal metastasis pci scope trial peritoneal carcinomatosis gastric cancer",
    "INCLUSION CRITERIA": "population trial subject major subject peritoneal carcinomatosis gastric cancer inclusion criterion patients relate age performance status white blood cell neutrophil platelet creatinemia dl creatinine clearance serum total bilirubin dl acceptable nutritional condition bmi albumin pre albumin effective contraception patient childbearing age written consent obtain prior act research patient social insurance disease relate patient synchronous metachronous peritoneal ovarian metastasis pathologically proven gastric siewert iii adenocarcinoma cancer include adci adenocarcinoma independent cell linitis patients without primary gastric tumor include pci peritoneal cancer index",
    "EXCLUSION CRITERIA": "exclusion criterion patients relate weight loss total body weight last three presence uncontrolled comorbidities include severe chronic disease organ insufficiency contraindication drug contain chemotherapy regimen accord summary product characteristic rcp contraindication cisplatin iv doxorubicin iv accord summary product characteristics force allergy severe toxicity cisplatin renal function impairment contraindicate calculated cockcroft formula measure creatinine clearance less measure creatinine adequately reflect renal function cisplatin cumulative nephrological toxicity doxorubicin risk cardiotoxicity occur immediately delay sinus tachycardia electrocardiogram abnormality cf rcp following website http agence prd ansm sante fr php ecodex rcp r0289737 htm complete deficiency enzyme dihydropyrimidine dehydrogenase patient arm pipac debulking surgery ovariectomy omentectomy permit pipac surgical procedure schedule accordance protocol successive pipac debulking surgery pipac procedure authorize pregnancy breastfeed patient guardianship disease relate malignancy within last curatively treat basal cell carcinoma skin situ carcinoma cervix systemic metastasis liver lung bone brain lomboaortic lymph node involvement pleural effusion require evacuation respiratory failure small bowel occlusion possible food intake ascites liter participation clinical trial treatment gastric peritoneal metastasis precede inclusion",
    "INTERVENTION": "investigational medicinal product intraperitoneal pressurized aerosol chemotherapy cisplatin doxorubicin laparoscopy give 37c mmhg 6weeks interval least successive pipac schedule protocol patient receive pipac procedure progression toxicity nonfeasibility procedure research open sponsor center already practice pipac procedure part treatment investigator declare part research undergo training use new pipac procedure comparator treatment patient receive standard poly chemotherapy propose oncologist eox epirubicin oxaliplatin capecitabine ecx epirubicin cisplatin capecitabine folfox folfiri ecf epirubicin cisplatin fluorouracil flot new standard validate study progression toxicity",
    "STATISTICS": "statistical analysis progression freesurvival estimate use kaplan meier estimator total sample per arm estimation confidence intervals give test survival curve perform use logrank test hazard ratio estimate use cox model sensitivity analysis perform consider per protocol population"
  },
  "JAKAHDI": {
    "TITLE": "full title jak inhibitor acquired hemophagocytic syndrome intensive care unit",
    "JUSTIFICATION": "scientific justification hemophagocytic syndrome rare condition responsible severe organ failure therapeutic guideline mainly base observational study expert opinion therapeutic advance develop explain mortality hemophagocytic syndrome remain high icu mortality range etoposide remain gold standard critically ill hemophagocytic syndrome patient nearly patient refractory therapy treatment escalation common often require administration intensive treatment generate high toxicity ruxolitinib first approve jak inhibitor associate improvement hemophagocytic syndrome manifestation survival preclinical murine model data human scarce promising",
    "OBJECTIVE": "main objective primary endpoint aim demonstrate ruxolitinib association standard care may reverse organ failure represent sofa score good standard care alone critically ill patient acquire hemophagocytic syndrome primary end point survival decrease sofa score point secondary objective endpoint demonstrate ruxolitinib may improve overall survival hemophagocytic syndrome critically ill patient demonstrate ruxolitinib may reverse clinical temperature sofa score biological ferritin level cd25 soluble receptor dosage fibrinogen level triglyceride level hemoglobin level white blood cell count platelet count manifestation relate hemophagocytic syndrome analyse impact ruxolitinib biological inflammatory marker il2 il6 il10 il12 gmcsf ifn gamma tnf alpha demonstrate safety ruxolitinib critically ill hemophagocytic syndrome patient",
    "DESIGN": "design study multicenter national uncontrolled phase2 trial base fleming 2stage design",
    "INCLUSION CRITERIA": "population study participant adult patient inclusion criterion adult patient acquire hemophagocytic syndrome regardless etiology define presence hlh2004 criterion hscore admission icu need symptomatic treatment hemophagocytic syndrome relation organ failure define sofa score informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per l11116 emergency situation absence family members trustworthy person patient enrol consent participate research request soon condition patient allow inclusion woman childbearing potential require use highly effective contraceptive measure contraception maintain treatment one",
    "EXCLUSION CRITERIA": "exclusion criterion moribund define life expectancy hour pregnant lactating patient woman childbearing potential must negative urine blood human chorionic gonadotropin pregnancy test prior trial entry affiliation health insurance known hypersensitivity ruxolitinib lactose intolerance hypersensitivity cellulose microcrystalline magnesium stearate silica colloidal anhydrous sodium starch glycolate type povidone k30 hydroxypropylcellulose cps preexisting decision withholding withdrawing care history progressive multifocal leukoencephalopathy uncontrolled cutaneous cancer persons psychiatric care would impede understanding informed consent optimal treatment followup adults subject legal protection measure guardianship curatorship safeguard justice patients deprive liberty judicial administrative decision participation another interventional research",
    "INTERVENTION": "investigational medicinal product patients receive oral ruxolitinib twice association standard care hemophagocytic syndrome comparator treatment none",
    "STATISTICS": "statistical analysis based 2stage fleming design interim analysis perform status 21th consecutively enrolled patient observe terminal analysis base intentiontotreat population perform patient recruit unless early stopping"
  },
  "GRAALL-2014": {
    "TITLE": "",
    "JUSTIFICATION": "",
    "OBJECTIVE": "objectives primary objective prospectively validate new risk model base mrd1 response level kmt2a mll ikzf1 gene status compare historical result graall graall2014 identical population patient lineage acute lymphoblastic leukemia age evaluate efficacy blinatumomabbased consolidation maintenance therapy term disease free survival high risk patient graallquest substudy compare historical result graall2005 identical population patient high risk feature graallquest study secondary objective appreciate tolerance blinatumomabbased consolidation cycle bridge allosct within consolidation maintenance therapy evaluate minimal residual disease level monitor igtcr evaluate cumulative incidence relapse nonrelapse mortality diseasefree survival overall survival evaluate relapsefree survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin sct first complete remission evaluation criterion primary evaluation criterion disease free survival anti thrombin depend status kmt2a mll ikzf1 gene mrd1 assess induction cure consolidation disease free survival anti thrombin graallquest study secondary evaluation criterion cumulative incidence relapse non relapse relate mortality overall survival disease free survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin allosct first complete remission minimal residual disease followup anti thrombin different treatment time cf infra minimal residual disease monitoring adverse event blinatumomab graallquest",
    "DESIGN": "type study multicenter open control study standard risk patient phase2 multicenter open non control graallquest high risk patient",
    "INCLUSION CRITERIA": "indication patients age de novo phnegative blineage acute lymphoblastic leukemia graall2014 inclusion criteria patient whose blood bone marrow exploration complete steroid prephase aged previously treat include intrathecal injection blineage acute lymphoblastic leukemia newly diagnose accord definition bone marrow blast whose karyotype show absence molecular biology bcrabl eastern cooperative oncology group without central nervous system testis involvement without evolve cancer except basal cell carcinoma skin situ carcinoma cervix radiotherapy chemotherapy treatment finish anti thrombin least since sign write informed consent efficient contraception woman childbearing age exclude estrogen intrauterine device health insurance coverage receive receive steroid prephase secondary acute lymphoblastic leukemia antecedent chemo radiotherapy include graallquest inclusion criterion patient included graall2014 high risk acute lymphoblastic leukemia eastern cooperative oncology group complete remission one two induction cure receive three block consolidation n1 without allogeneic donor",
    "EXCLUSION CRITERIA": "graall2014 non inclusion criteria patient lymphoblastic lymphoma bone marrow blast burkitttype acute lymphoblastic leukemia antecedent chronicmyelogenous leukemia myeloproliferative neoplasm contraindication anthracyclines general visceral contraindication intensive therapy except consider relate acute lymphoblastic leukemia aspartate amino transferase alanineaminotransferase upper limit normal total bilirubin upper limit normal creatinine 5x upper limit normal creatinine clearance mn myocardial infarction within prior inclusion trial cardiomyopathy new york heart association grade3 intravenous lvef rf hiv htlvi hcv seropositivity chronic hbv hepatitis hbsagpositive pregnant hcg positive nurse woman able bear procedure frequency visit plan trial unable consent tutelage curatorship judiciary safeguard women childbearing potential willing use effective form contraception participation study anti thrombin least three thereafter patients willing ensure beget child participation study anti thrombin least three thereafter treated investigational agent participation another trial within prior enter study graallquest non inclusion criterion patient eastern cooperative oncology group status consolidation abnormal laboratory value define consolidation ast alt upper limit normal total bilirubin upper limit normal creatinine upper limit normal creatinine clearance serum amylase lipase upper limit normal active uncontrolled infection concurrent disease medical condition deem interfere conduct study judge investigator new york heart association grade34 cardiac disease infection human immunodeficiency virus hiv chronic infection hepatitis virus hbsag positive hepatitis virus antihcv positive primary monitoring asparaginase activity ammoniemia annex 48h 3rd injection theoretically secondary monitoring 6th injection theoretically acute lymphoblastic leukemia patient sample collection must perform immediately 7th injection able bear procedure frequency visit plan trial",
    "INTERVENTION": "experimental drug prescription outside blinatumomab blincyto high risk patient enrol graallquest study experimental drug prescription accord cyclophosphamide methotrexate vincristine cytarabine etoposide dexamethasone mercaptopurin daunorubicin idarubicin prednisone lasparaginase granulocyte colony stimulate factor cerebro spinal fluid reference treatment induction patient receive induction course patients without hematologic complete remission anti thrombin end induction receive salvage therapy differential diagnosis blineage acute lymphoblastic leukemia prephase patient receive graaph2014 igtcr mrd1 level evaluate anti thrombin end induction cycle orat first consolidation phase consolidation patient hematologic complete remission induction eventually follow salvage receive interim standby block first consolidation comprise block chemotherapy block s1 s2 s3 standby block allow recover potential toxicity induction notably hepatic avoid modify order following consolidation block respect dosage intensity high risk versus standard risk patients attribute risk group first consolidation accord mrd1 level need salvage obtain chr presence ikzf1 gene deletion kmt2a mll gene rearrangement high risk patient propose phase2 graallquest study inclusion number reach high risk patient would eligible graall quest continue participate study followup plan graall igtcr mrd2 level evaluate anti thrombin end consolidation one consolidation consolidation first consolidation standard risk patient continue standard protocol receive consolidation block s4 s5 s6 high risk patient traited phase2 graallquest study receive blinotumomab consolidation compose block b4 blina b5 high dose arac b6 high dose methotrexate high risk versus high risk minimal residual disease high risk minimal residual disease define mrd1 need salvage cure reach hematologic complete remission mrd2 patients eligible allosct suitable donor receive blinatumomab continuous infusion condition regimen igtcr mrd3 level evaluate anti thrombin late intensification prior sct allografted patient late intensification administer acute lymphoblastic leukemia nonallografted patient whatever risk group consolidation late intensification patient standard risk receive third consolidation block s7 s8 s9 high risk patient receive second investigational blinatumomabbased consolidation compose block b7 blina b8 high dose arac b9 high dose methotrexate igtcr mrd4 level evaluate anti thrombin maintenance therapy sct maintenance therapy whole duration two classical maintenance therapy acute lymphoblastic leukemia patient base association mercaptopurin methotrexate monthly reinductions associate vincristine prednisone first patients high risk patient receive blinatumomab course instead vincristine pulse anti thrombin allogeneic stem cell transplantation sct allogeneic sct first complete remission offer acute lymphoblastic leukemia high risk minimal residual disease patient genoidentical familial unrelated donor allosct early possible second consolidation phase patient conditioning myeloablative total body irradiation gy fractionate cyclophophamide anti thymoglobulin case unrelated allosct patients age comorbidity criterion benefit reduce intensity condition total body irradiation fractionate gy dose fludarabine anti thymoglobulin case unrelated allosct patients high risk becarfull sct earlier end first blinatumomab cycle central nervous system involvement patients central nervous system disease anti thrombin diagnosis receive intensified intrathecal therapy lumbar puncture induction central nervous system irradiation perform consolidation intrathecal central nervous system irradiation maintenance chemotherapy induction graall2014 prednisone vincristine ivd daunorubicin intravenous intravenous cyclophosphamide intravenous 3h lasparaginase ui slow intravenous 1h cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol age 45y reduce age 45y anti thrombin age 45y substitute erwinase immunization coli lasparaginase salvage idarubicin intravenous 1h aracytine 12h intravenous 3h cerebro spinal fluid subcutaneous intravenous neutrophil standard consolidation standard risk patient weekly standby block need etoposide intravenous 1h aracytine 12h blocks s1 s4 s7 d1d14 aracytine 12h intravenous 2h dexamethasone 12h cerebro spinal fluid subcutaneous intravenous tod12 blocks s2 s5 s8 d15d28 methotrexate continuousintravenous 24h vincristine ivd 6mercaptopurin cerebro spinal fluid subcutaneous intravenous intrathecal methotrexate arac depomedrol h24 start methotrexate minute hour minute follow folinic acid rescue reduce age 45y block s3 s6 s9 d29d35 cyclophosphamide intravenous 3h etoposide intravenous 1h methotrexate cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol late intensification patient receive salvage induction prednisone vincristine ivd daunorubicin intravenous cyclophosphamide intravenous 3h lasparaginase ui slow intravenous 1h cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol age 45y age 45y anti thrombin age 45y substitution erwinase immunization coli lasparaginase late intensification patient receive salvage induction idarubicin intravenous 1h aracytine 12h intravenous 3h cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol maintenance therapy vincristine ivd prednisone month1 methotrexate wk 6mercaptopurin intrathecal methotrexate arac depomedrol blinatumomab consolidation patient proceed asct begin block s3 blocks b4 b7 d1d34 dexamethasone blina blinatumomab ivc intrathecal methotrexate arac depomedrol blocks b5 b8 d35d49 aracytine 12h intravenous 2h dexamethasone 12h cerebro spinal fluid subcutaneous intravenous tod12 blocks b6 b9 d50d65 max methotrexate continuousintravenous 24h vincristine ivd 6mercaptopurin cerebro spinal fluid subcutaneous intravenous intrathecal methotrexate arac depomedrol h24 start methotrexate minute hour minute follow folinic acid rescue reduce age 45y late intensification patient receive salvage induction prednisone vincristine ivd daunorubicin intravenous cyclophosphamide intravenous 3h lasparaginase ui slow intravenous 1h cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol age 45y age 45y anti thrombin age 45y substitution erwinase immunization coli lasparaginase late intensification patient receive salvage induction idarubicin intravenous 1h aracytine 12h intravenous 3h cerebro spinal fluid subcutaneous intravenous neutrophil intrathecal methotrexate arac depomedrol blinatumomabbased maintenance therapy dexamethasone 1h blinatumomab blinatumomab ivc vincristine ivd prednisone methotrexate wk 6mercaptopurin intrathecal methotrexate arac depomedrol except blinatumomab blinatumomab consolidation patient proceed asct begin block s3 dexamethasone blina blinatumomab ivc intrathecal methotrexate arac depomedrol high risk patient suitable donor receive blinatumomab continuously allosct condition regimen stop",
    "STATISTICS": "statistical justification sample size approximately patient phnegative bcell precursor acute lymphoblastic leukemia may recruit frontline graall2014 trial hematologic complete remission achievement one may anticipate approximately standard risk patients high risk patients include high risk minimal residual disease patient consolidation standard risk patient treat standard graall protocol without new agent haematopoietic stem cell transplantation first chr objective demonstrate uncontrolled study noninferiority term disease free survival must anti thrombin least control group historical reference margin inferiority justify absence allosct first complete remission unilateral alpha risk power calculated sample size patient high risk patients eligible graallquest study disease free survival primary endpoint disease free survival compare historical graall2005 result anti thrombin objective demonstrate disease free survival improvement alpha risk power twosided setting calculated sample size patient considering dropout rate patient include present study ref sample size table clinical study machin campbell et al wiley"
  },
  "METIMGAST": {
    "TITLE": "full title phase2 trial evaluate combination capmatinib spartalizumab advanced oesogastric adenocarcinoma",
    "JUSTIFICATION": "scientific justification oesoastric advance adenocarcinoma poor prognosis without improvement last decade recently immunotherapy antipd1 antibody provide encouraging result subset patient capmatinib met inhibitor show imunomodulatory effect synergy spartalizumab pd1 inhibitor combination currently evaluate treatment hepatocellular carcinoma whatever met expression",
    "OBJECTIVE": "main objective primary endpoint evaluate tumor response regimen inclusion overall response rate assess image every define proportion patient least one objective tumour response complete partial accord recist v1 criterion within secondary objective endpoint evaluate safety regimen first second cycle administration cf chap evaluate safety tolerability regimen whole course treatment kind toxicity immunotherapyrelated toxicity cf chap characterize tumor response regimen duration time response estimate progression free survival inclusion estimate overall survival inclusion according result interim analysis evaluate tolerance efficacy spartalizumab monotherapy patient nonamplified met tumor ancillary study evaluate pharmacokinetics capmatinib accord presence gastrectomy concurrent treatment proton pump inhibitor evaluate tumor response specific subgroup according residual level capmatinib cycle day1 c2d1 according met amplification level fish archival tumor sample according baseline c2d1 neutrophil count circulate hgf level",
    "DESIGN": "design study multicenter singlearm phase2 trial cohort accord met amplification level cohort tumor without met amplification copy cohort tumor met amplification copy treatment capmatinib mgbid spartalizumab300 q3w maximum progression patient refusal unacceptable toxicity cohort interim analysis primary endpoint first evaluable enrolled patient rule stop continue trial specify table paragraph",
    "INCLUSION CRITERIA": "population study participant patients advanced oesogastric adenocarcinoma receive least one previous chemotherapy line platinium salt fluoropyrimidin documented progression chemotherapy inclusion criterion histologically cytologically document locally advanced metastatic oesogastric adenocarcinoma unresectable tumor patients must receive least one prior systemic chemotherapy base platinium salt fluoropyrimidine documented progression chemotherapy patients must receive trastuzumab case her2 positive tumor her2 her2 fish sish determination tumor met amplification fish available ecog performance status measurable tumoral disease accord recist criterion patients must willing able swallow retain oral medication age women childbearing potential male sexually active must agree follow instruction method contraception duration study treatment capmatinib spartalizumab last dose capmatinib last dose spartalizumab consent participate trial information affiliated social security system",
    "EXCLUSION CRITERIA": "exclusion criterion previous treatment immunotherapy met inhibitor impossibility take oral medication persistent toxicity relate prior treatment grade great except alopecia grade grade2 neuropathy relate previous treatment platinium salt presence history another malignant disease diagnose require therapy within past exceptions exclusion include completely resect basal cell squamous cell skin cancer completely resect carcinoma situ type use live vaccine within initiation study treatment history severe hypersensitivity reaction monoclonal antibody mabs history current interstitial lung disease non infectious pneumonitis active autoimmune disease documented history autoimmune disease patients vitiligo control type1 diabetes mellitus stable insulin dose residual autoimmunerelated hypothyroidism require hormone replacement psoriasis require systemic treatment permit allogenic bone marrow solid organ transplant uncontrolled active infection human immunodeficiency virus infection untreated active hepatitis infection hbsag positive patients active hepatitis hbsag positive may enrol provided viral load hbv dna screening ui patients may receive antiviral treatment lamivudine tenofovir entecavir antiviral agent initiation study treatment suppress viral replication untreated active hepatitis hcv rna positive patient achieve sustained virological response antiviral treatment show absence detectable hcv rna cessation antiviral treatment eligible untreated symptomatic central nervous system lesion however patient eligible know central nervous system lesion treat radiotherapy surgery patient remain without evidence central nervous system disease progression treatment patient must corticosteroid therapy clinically significant uncontrolled heart disease recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii iv define new york heart association long qt syndrome woman men family history idiopathic sudden death congenital long qt syndrome uncontrolled hypertension define systolic blood pressure hg diastolic blood pressure hg without antihypertensive medication initiation adjustment antihypertensive medication allow prior screen surgery less radiotherapy less pregnancy breastfeeding woman childbearing potential unless use highly effective method contraception sexually active male unless use condom intercourse take capmatinib stop treatment father child period participants receive treatment strong inducer cyp3a could discontinue prior start treatment systemic chronic steroid therapy prednisone equivalent immunosuppressive therapy prior plan date first dose study treatment patient range laboratory value define total bilirubin upper limit normal alkaline phosphatase alp upper limit normal alanine aminotransferase alt upper limit normal aspartate aminotransferase ast upper limit normal coagulation prothrombin time second upper limit normal international normalized ratio absolute neutrophil count platelet count hemoglobin dl creatinine clearance calculate use cockcroft gault formula measure serum lipase upper limit normal cardiac troponin ctni elevation upper limit normal potassium magnesium phosphorus total calcium correct serum albumin outside normal limit patient may enrol correct within normal limit supplement screen patients legal protection participation another interventional study whith treatment",
    "INTERVENTION": "investigational medicinal product capmatinib bid spartalizumab q3w maximum progression patient refusal unacceptable toxicity comparator treatment applicable",
    "STATISTICS": "statistical analysis two cohort constitute cohort enrol patient met amplification copy specifically total patient ensure power type1 error rate detect response rate compare reference include interim analysis patient include futility stopping rule use bayesian optimal timeto event phase2 design lin et al jnci case trial terminate early futility inclusion continue spartalizumab monotherapy additional patient cohort total case sample patient spartalizumab monotherapy allow detect response rate patient monotherapy unacceptable power type1 error rate use binomial exact comparison cohort enrol patient met amplification copie exploratory purpose enrolment cohort ongoing cohort complete maximum patient sequential continuous toxicity montoring conduct across cohort ivanova et al clin invest endpoints describe count percentage categorical endpoint toxicity aes mean median confidence interval credibility interval appropriate interquartile range continuous endpoint timeto event endpoint pfs os estimate use nonparametric kaplan meier estimator obtain survival estimate inclusion analyses perform use statistical platform along datamanagement analysis conduct department biostatistics medical information hopital saint louis paris pr sylvie chevret labelled centre de traitement de donnees inca"
  },
  "RUBI": {
    "TITLE": "full title multicenter randomize multiarm trial compare efficacy safety adalimumab anakinra tocilizumab subjects noninfectious refractory uveitis",
    "JUSTIFICATION": "scientific justification rubi first prospective randomize head head study compare adalimumab either anakinra tocilizumab refractory niu firm evidence randomize controlled trial directly address best biologic agent severe refractory niu niu cause devastate visual loss legal blindness corticosteroids immunosuppressant fail demonstrate sustainable remission refractory relapsing severe uveitis incidence blindness niu dramatically reduce recent use biologics raise question whether compound use earlier treatment severe non infectious uveitis contrasting immunosuppressor biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma despite strong rationale compound yet approve uveitis guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "primary objective assessment criterion primary objective evaluate efficacy adalimumab compare anakinra tocilizumab subject refractory noninfectious intermediate posterior pan uveitis niu prednisone dose prednisone equivalent oral corticosteroid primary endpoint efficacy measure percentage patient least 2step reduction vitreous haze accord miami 9step scale dose prednisone equivalent oral corticosteroid secondary objective assessment criterion secondary objectives evaluate change best correct visual acuity evaluate safety adalimumab anakinra tocilizumab patient niu evaluate change macular edema evaluate change sign ocular inflammation evaluate effect retinal vessel leakage evaluate effect adalimumab anakinra tocilizumab steroid sparing evaluate change ocular inflammation anterior chamber evaluate effect underlie systemic disease appropriate evaluate effect ocular disease evaluate number time relapse uveitis characteristic uveitis worsen evaluate time treatment failure secondary endpoints measure best correct visual acuity change macular edema change sign ocular inflammation retinal vessel leakage steroid spar ocular inflammation anterior chamber underlying systemic disease appropriate ocular disease number time relapse uveitis characteristic uveitis worsen adverse event time treatment failure",
    "DESIGN": "experimental design prospective phase2 clinical trial multicenter multiarm randomize clinical trial compare efficacy safety adalimumab anakinra tocilizumab subject active refractory noninfectious intermediate posterior panuveitis oral corticosteroid stable dose prior first study drug administration systemic immunosuppressant must discontinue prior first study drug administration patients access oral corticosteroid need",
    "INCLUSION CRITERIA": "population involve adult patient active refractory noninfectious uveitis niu active disease either presence vh miami 9step scale macular edema crt micron sign intraocular inflammation eg perivascular sheathing retinal vessel leakage retinal vessel fa recently active disease evidence activity within prior inclusion visit per vh miami 9step scale vh accord standardization uveitis nomenclature classification macular edema crt micron sign intraocular inflammation perivascular sheathing retinal vessel leakage retinal vessel fa activity status active disease recently active disease confirm patient randomization reading center evaluation vh optical coherence tomography fa assessment refractory disease inclusion subject must receive oral corticosteroid prednisone equivalent least one immunosuppressive azathioprine methotrexate mycophenolate mofetyl cyclosporine leflunomide cyclophosphamide interferon ifn intolerant immunosuppressive therapy inclusion criterion eligibility criterion check selection visit take place four maximum prior inclusion visit inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature standardization uveitis nomenclature criterion posterior pan uveitis confirm documented medical history currently uncontrolled uveitic disease uncontrolled uveitic disease define fulfil two follow criterion within prior inclusion active inflammatory chorioretinal inflammatory retinal vascular lesion macular edema crt micron vitreous haze grade4 miami 9step scale vh accord standardization uveitis nomenclature national eye institute classification patient receive prednisone equivalent dose another corticosteroid stable dose prior first study drug administration receive least systemic immunosuppressant systemic immunosuppressant must discontinue prior first study drug administration patient receive ifn systemic immunosuppressant must discontinue prior first study drug administration intolerant immunosuppressant best correct visual acuity early treatment diabetic retinopathy study either eye stable dose two prior inclusion topical corticosteroid nsaids male female age inclusion weight lb inclusion chest xray thoracic ct scan result posteroanterior lateral within prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing age negative serum urine pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study stop therapy roactemra adalimumab respectively birth control method may consider highly effective method achieve failure rate less per use consistently correctly consider highly effective birth control method accord ctfg recommendation method include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject quantiferontuberculosis test within prior screening",
    "EXCLUSION CRITERIA": "noninclusion criterion subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible contraindication mydriasis either eye presence posterior synechiae study eye mydriasis inadequate posterior segment examination intraocular pressure 25mmhg goldmann tonometry advanced glaucoma either eye monocular patient active tuberculosis known positive syphilis serology human immunodeficiency virus antibody hepatitis surface antigen antinucleocapsid antibody hepatitis virus hepatitis virus within prior inclusion history malignancy within prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody infectious disease fever infection require treatment antibiotic within prior inclusion history recurrent infection predisposition infection known immunodeficiency history multiple sclerosis demyelinate disorder laboratory value assess inclusion hemoglobin dl white blood cell count platelet count glomerular filtration rate gfr transaminases time upper normal value use following systemic treatment specify period previous systemic biologic therapy treatment systemic alkylating agent within prior inclusion inclusion cyclophosphamide chlorambucil live attenuate vaccine within prior inclusion use following ocular treatment specify period previous antivegf intravitreal therapy applies eye within prior inclusion anticipated use study period treatment dexamethasone intravitreal implant ozurdex within prior inclusion intravitreal corticosteroid within prior inclusion previous subtenons corticosteroid injection permit administer least prior inclusion stage iii intravenous new york heart association nyha cardiac insufficiency",
    "INTERVENTION": "treatment test eligible patient active refractory niu randomize ratio arm adalimumab subcutaneously arm anakinra subcutaneously arm tocilizumab subcutaneously three treatment group receive corticosteroid regimen patient niu receive oral prednisone maximum prednisone equivalence following schedule reduction prednisone apply group long disease inactive prednisone prednisone prednisone prednisone prednisone due csi recommendation inclusion anakinra arm stop investigational medicinal product anakinra discontinue patient undergo follow thus modify plan analysis randomisation accordingly inclusion randomisation patient next patient randomize either remain arm arm adalimumab subcutaneously arm tocilizumab subcutaneously practice mean remain planned patient randomize arm arm",
    "STATISTICS": "statistical analysis use bayesian multiarm multistage mams design aim compare several new treatment multiarm order select drop treatment arm move forward evidence already exist base interim analyse randomization stratify retinal vasculitis macular oedema underlying disease randomization patient treatment prednisone single therapy"
  },
  "MSC-AT-SSC": {
    "TITLE": "full title phase1 ii randomize clinical trial allogeneic adipose tissuederived mesenchymal stromal cell systemic infusion severe systemic sclerosis",
    "JUSTIFICATION": "scientific justification systemic sclerosis rare severe chronic systemic autoimmune disease characterize vasculopathy immune dysregulation fibrosis lead multiorgan dysfunction primarily skin lung heart gastrointestinal tract kidney high morbidity mortality alter healthrelated quality life high cost patient society treatment mostly symptomatic autologous hematopoietic stem cell transplantation show long term improvement overall eventfree survival diseasemodifying property however autologous hematopoietic stem cell transplantation contraindicated case advanced visceral involvement eligible patient still associate risk toxicity urgent need identify safe effective treatment severe systemic sclerosis mesenchymal stromal cell multipotent cell carry immunomodulatory proangiogenic anti fibrotic property target systemic sclerosis pathogenesis clinical manifestation increase use mesenchymal stromal cell harvest bone marrow mesenchymal stromal cell adipose tissue mesenchymal stromal cell umbilical cord mesenchymal stromal cell uc variety indication provide consistent evidence support safety human efficacy mesenchymal stromal cell intravenous injection treat acute graft versus host disease lead marketing approval mesenchymal stromal cell alofisel approve severe crohns fistula mesenchymal stromal cell represent promising therapeutic approach systemic sclerosis previously show diseasespecific abnormality mesenchymal stromal cell systemic sclerosis patient provide strong rationale use allogeneic mesenchymal stromal cell treat systemic sclerosis patient publish first phase1 ii dose escalation trial use allogenic mesenchymal stromal cell infusion severe systemic sclerosis patient clinicaltrials gov nct02213705 phrc aom safety issue significant improvement skin fibrosis infusion appear low thereafter thereby support need repeated infusion vitro experimental clinical study suggest mesenchymal stromal cell property vary accord tissue origin source demonstrate compare mesenchymal stromal cell mesenchymal stromal cell easy harvest display high proliferative capability enter senescence high genetic stability superior immunosuppressive property considering rationale hypothesize use healthy donor allogeneic mesenchymal stromal cell produce etablissement francais du sang efs demonstrate safety issue efficacy profile increase repeated infusion allogeneic mesenchymal stromal cell treat systemic sclerosis",
    "OBJECTIVE": "main objective primary endpoint main objective evaluate safety one allogeneic mesenchymal stromal cell intravenous administration twice interval severe systemic sclerosis patient primary endpoint rate treatmentrelated severe adverse events define adverse events grade equal use nci common terminology criteria adverse events ctcae v5 classification one infusion adverse event adjudicate data safety monitoring committee secondary objective endpoint secondary objective safety infusion within first hour infusion study followup efficacy signal inform future study use outcome measure skin sclerosis lung function quality life previously validate systemic sclerosis use cell therapy trial analysis response treatment progressionfree survival global rank composite score m6and acr provisional composite response index clinical trials early diffuse cutaneous systemic sclerosis early systemic sclerosis patient analysis overall survival assess cause death impact allogeneic mesenchymal stromal cell intraveinous twice interval immune response include immunophenotyping alloimmunization start therapy cost effectiveness allogeneic mesenchymal stromal cell infusion twice versus treatment severe systemic sclerosis patient secondary endpoint rate treatmentrelated severe adverse event define adverse event grade equal ctcae v5 time within first hour infusion followup main efficacy endpoint modify rodnan skin score difference efficacy disease related endpoint modify rodnan skin score performance status ps healthrelated quality life questionnaire sclerodermahealth assessment questionnaire short form health survey sf36v2 euroqol 5dimension 5level forced vital capacity diffusing capacity lung carbon monoxide response treatment define following decrease modify rodnan skin score increase force vital capacity increase diffuse capacity lung carbon monoxide without need immunosuppression except low dose steroid daily progressionfree survival progression define following decrease forced vital capacity diffuse capacity lung carbon monoxide decrease lvef decrease weight decrease creatinine clearance increase modify rodnan skin score increase sclerodermahealth assessment questionnaire global rank composite score value acr provisional composite response index clinical trial early diffuse cutaneous systemic sclerosis value early systemic sclerosis patient overall survival myeloid lymphocyte subpopulations included patient alloimmunization include patient detection identification donorspecific antihla antibody extracost per qualityadjusted life qualityadjusted life gain unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis extracost per severe adverse event grade equal ctcae avoid unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis",
    "DESIGN": "design study multicentre threearm randomize placebocontrolled doubleblind phase3 trial",
    "INCLUSION CRITERIA": "population study participant adult patient refractory severe systemic scleroderma inclusion criterion provide sign date informed consent willing comply study procedure available duration study male female age age systemic sclerosis patient accord american college rheumatology european league rheumatism classification criterion systemic sclerosis severe disease either disease duration less modified rodnan skin score abnormal crp hemoglobin dl modify rodnan skin score without restriction disease duration plus least one major organ involvement define respiratory involvement consisting lung diffusion capacity carbon monoxide force vital capacity predict evidence interstitial lung disease chest xray high resolution compute tomography hrct scan moderate pulmonary hypertension baseline rest systolic pulmonary arterial pressure mmhg mmhg cardiac echocardiography mean pulmonary artery pressure mmhg hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explain cause systemic sclerosis cardiac involvement consist reversible congestive heart failure atrial ventricular rhythm disturbance recurrent episode atrial fibrillation flutter recurrent atrial paroxysmal tachycardia 2nd 3rd degree avblock mild moderate pericardial effusion presence mri involvement increased t1 t2 mapping late gadolinium enhancement septal sign cause organ involvement attribute systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determine patient physician judgement contraindication inadequate response unwillingness adverse event necessitate discontinuation conventional immunosuppressive therapy mycophenolate mofetil methotrexate women reproductive potential must use highly effective contraception men reproductive potential must use condom health insurance nb authorize contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion age pregnancy unwillingness use adequate contraception lifethreatening endorgan damage define diffuse capacity lung carbon monoxide correct hemoglobin predict left ventricular ejection fraction cardiac echocardiography pulmonary hypertension baseline rest systolic pulmonary arterial pressure mmhg cardiac echocardiography mean pulmonary artery pressure mmhg right heart catheterization glomerular filtration rate active chronic hepatitis asat alat upper limit normal neoplasms less except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection hiv1 hiv2 infection body mass index severe psychiatric disorder bone marrow insufficiency define neutropenia thrombopenia anemia dl lymphopenia inability provide informed consent patient include another interventional clinical trial patient tutelle",
    "INTERVENTION": "investigational medicinal product allogeneic adipose tissue derivedmscs mesenchymal stromal cell placebo inject slow intravenous infusion accord recipient body weight study experimental arm arm placebo arm mesenchymal stromal cell cells injection placebo injection arm mesenchymal stromal cell cells injection mesenchymal stromal cell cells injection allogeneic mesenchymal stromal cell administer intravenously 1h infusion second infusion drug product mesenchymal stromal cell placebo perform absence treatmentrelated severe adverse events trsae patients include arm arm opportunity accord willingness receive either arm arm mesenchymal stromal cell cells injection end study unblinding evidence mesenchymal stromal cell injection safety provide comparator treatment placebo",
    "STATISTICS": "statistical analysis propose conduct multicenter threearm randomize doubleblind placebocontrolled trial enroll total systemic sclerosis patient patient randomize one two treatment arm infusion mesenchymal stromal cell infusion mesenchymal stromal cell placebo arm total patient per arm use randomization block size inclusions stagger allow detection severe adverse event prior inclusion subsequent patient accord follow waiting rule least one two consecutive randomization interval least one every three randomization continuous monitoring primary endpoint sponsor implement allow continuous bayesian toxicity monitoring stopping rule implement primary endpoint cell infusion see section detail first analysis first patient complete visit analysis trsae visit final analysis stopping rule define base estimate probability risk treatmentrelated severe adverse events trsae criterion probability posteriori probability severe adverse event posterior probability trsae trsae estimate use bayesian approach beta density stopping rule fulfil criterion mean high probability great risk trsae interim analysis result present dsmb recommendation case early stopping subsequent patient randomize patient treat thus far follow result analyze describe formal statistical test sample size bayesian framework nevertheless one invoke frequentist framework anticipate expected precision term safety indeed infusion patient infusion patient infusion able estimate risk severe adverse events width exact confidence interval equal consider independence infusion"
  },
  "UVB": {
    "TITLE": "full title multicenter randomize prospective trial compare efficacy safety adalimumab tocilizumab severe uveitis behcets disease",
    "JUSTIFICATION": "scientific justification uvb first randomized prospective head head study compare adalimumab tocilizumab sight threaten uveitis bd antitnf use bd uveitis incidence blindness bd dramatically reduce recent use biologics firm evidence randomize controlled trial directly address best induction therapy severe bd uveitis bd uveitis consider devastating inflammatory ocular disease risk visual loss reach patient bilateral involvement contrasting immunosuppressor interferonalpha biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma however antitnf fail demonstrate sustainable complete remission severe sight threaten uveitis little publish information use biologics antitnf severe bd uveitis tocilizumab use success severe resistant case one promising biologics bd il6 expression correlate bd activity immunological data provide strong rationale target bd tocilizumab despite strong rationale compound yet approve bd guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "main objective primary endpoint assess benefit tocilizumab comparatively adalimumab sightthreatening behcets disease uveitis primary endpoint efficacy define complete remission ocular involvement complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market low equal randomization secondary objective endpoint estimate compare change best correct visual acuity time complete remission evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change sign ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid spar evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristic uveitis worsen evaluate compare time treatment failure patients consider treatment failure following criterion meet least eye new active inflammatory retinal vascular lesion macular edema worsen best correct visual acuity line 2step increase anterior chamber cell grade 2step increase vitreous haze grade relative baseline estimate compare effect extra ophthalmologic manifestation behcets disease estimate compare mean change sf36 quality life behcets disease quality life measure bdqol estimate compare change behcets disease current activity form behcets syndrome activity score secondary endpoint measures corticosteroid sparing percent meeting target low prednisone prednisolone prednisone stock market mean dose cumulative dose time response onset measures acutephase reactant erythrocyte sedimentation rate esr creactive protein crp rate time occurrence relapse worsen study relapse define reappearance clinical paraclinical feature active disease occurrence new lesion progression preexist lesion changes behcets disease current activity form changes behcets syndrome activity score changes organ involve bd changes quality life sf36v2 tm health survey behcets disease quality life measure bdqol safety tolerability treatment bd patient assess frequency severity adverse clinical event time treatment failure time occurence changes tyndall flare vitreous haze changes best correct visual acuity snellen score changes central retinal thickness measure optical coherence tomography percentage patient central retinal thickness micron percentage patient without retinal vessel leakage retinal angiography case retinal vasculitis",
    "DESIGN": "design study bayesian design phase2 randomize clinical trial aim compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial",
    "INCLUSION CRITERIA": "population study participant adult patient sightthreatening behcets disease associate uveitis inclusion criterion age inclusion provide write informed consent prior performance studyspecific procedure diagnosis behcets disease accord international criteria behcet disease see appendix history aphtosis diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis sight threaten uveitis define accord validated international definition line drop visual acuity scale retinal inflammation macular oedema retinal vasculitis chest xray posteroanterior lateral ctscanner result within prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing potential premenopausal female capable become pregnant negative serum pregnancy test plasmatic urinary subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study stop therapy tocilizumab adalimumab respectively birth control method may consider highly effective method achieve failure rate less per use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence negative tb test obtain within prior inclusion potential subject positive interferongamma release assay quantiferontb gold tspot tb test eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course treatment start late inclusion affiliation social security system patients affiliate universal medical coverage cmu eligible study",
    "EXCLUSION CRITERIA": "non inclusion criterion infectious uveitis masquerade syndrome uveitis due cause bd uveitis active tuberculosis history untreated tuberculosis severe infection positive hiv antibody positive hepatitis surface antigen positive hepatitis rna result obtain within prior inclusion history malignancy within prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody history multiple sclerosis demyelinate disorder hypersensitivity active substance excipient imp auxiliary medicine active suspect ocular infection active suspect systemic infection history intestinal ulceration diverticulitis known porphyria laboratory value assess inclusion neutrophil platelet count asat alat uln treatment antitnf tocilizumab therapy within prior inclusion patient azathioprine mycophenolate mofetil methotrexate time inclusion drug must withdraw prior receive tocilizumab adalimumab dose stage iii iv new york heart association cardiac insufficiency severe renal glomerular filtration rate liver insufficiency prothrombin without cause live attenuate vaccine within prior inclusion breastfeeding pregnant woman",
    "INTERVENTION": "investigational medicinal product collection free informed consent eligible patient sight threaten behcets disease uveitis randomize one group randomization visit arm adalimumab subcutaneous arm tocilizumab subcutaneous comparator treatment applicable",
    "STATISTICS": "statistical analysis experimental design open multicenter randomize clinical trial stratify characteristic initial uveitis behcets disease retinal inflammation retinal vascularitis macular edema accord diagnosis newly diagnose relapse disease evaluation primary assessment criterion primary assessment criterion review scientific committee blind randomization rct use bayesian design phase2 randomize national multicenter clinical trial aim compare new treatment reference base binary endpoint complete remission offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial use betabinomial model noninformative prior berry posterior probability remission rate least estimate arm probability rate remission arm arm compute indicate tocilizumab group adalimumab group use bayesian inference framework denote probability remission arm inclusion patient arm complete remission observe using beta prior posterior probability still beta distribution give due natural conjugate property beta family binomial sampling setting efficacy drug arm first assess comparison historical minimal value interest sometimes call minimum required treatment remission rate set trial thus compute similar analysis perform arm however randomized phase2 setting selection new drug mostly base evaluate potential benefit experimental treatment thus one may consider drop new drug study rather low posterior probability drug beneficial target minimal level compute posterior probability difference remission rate two experimental arm kawasaki great zero tocilizumab group adalimumab group consider bayesian design interim analysis perform without alpha spending inclusion patient trial stop correspond arm stop following patient include arm trial stop"
  },
  "COMBINATION-LOCK01": {
    "TITLE": "full title combinationlock01 impact aminoglycosidesbased antibiotic combination protective isolation outcome criticallyill neutropenic patient sepsis randomized factorial design randomize pragmatic trial",
    "JUSTIFICATION": "scientific justification sepsis remain lead cause icu admission neutropenic patient condition remain associate high morbidity mortality hospital mortality vasopressor require full protective isolation include geographic isolation technical isolation highefficiency air filtration digestive decontamination prove efficient patient profound prolong neutropenia regard infection rate however study bias perform ago recent study perform patient less profound neutropenia perform without digestive decontamination partial protective isolation lead however negative result importantly isolation demonstrate limit access patient room associate suboptimal monitoring increased rate severe avoidable adverse event may explain uneven use protective isolation hematology ward expert suggestion appraise protective isolation benefit use large well conduct rct neutropenic patient suspected sepsis urgent broad antibiotic therapy mandatory failure initiate adequate antibiotic therapy within hour associate fold increase adjusted mortality current idsa guideline recommend use preferentially large antipseudomonas betalactam therapy routine antibiotic combination use aminoglycosides controversial recommend one hand meta analysis suggest notonly lack benefit association also increase rate renal failure trend towards high mortality rate aminoglycosides use hand subgroup analysis lowlevel evidence study suggest however benefit aminoglycosides criticallyill patient patient severe sepsis documented gram negative infection along line recent cochran systematic review recent french guideline focus neutropenia management criticallyill patient advocate additional trial field focus sick patient current study aim assess benefit protective isolation systematic use aminoglycosides combination antibiotic therapy criticallyill patient cancerrelated neutropenia sepsis septic shock intend perform factorial design randomize pragmatic trial compare one hand benefit protective isolation versus protective isolation hand benefit systematic aminoglycosides antibiotic combination versus systematic combination",
    "OBJECTIVE": "main objective primary endpoint evaluate impact day90 mortality two strategy separately use factorial design rct intervention routine association aminoglycoside initial antibiotic therapy compare standard care intervention lack routine use protective isolation compare standard care primary endpoint day90 mortality secondary objective endpoint evaluate impact studied intervention day28 hospital outcome incidence severity duration aki incidence clinically apparent loss hear rate adherence hand hygiene rate select adverse event rate nosocomial bacterial viral fungal infection episodes organ support icu stay organ support duration failure initial antibiotic therapy antibiotic duration rate aminoglycosides overdosage overuse secondary endpoint day28 hospital mortality incidence severity aki accord kdigo definition major adverse kidney events day28 composite death new renal replacement therapy persistent renal dysfunction incidence clinically apparent loss hear end icu stay rate adherence adequate hand hygiene assess external observer incidence density select serious adverse event include unexpected cardiac arrest incidence density new bacterial viral fungal episode number free organ support therapy mechanical ventilation vasopressor rrt rate clinical cure frequency initial antibiotic therapy inadequate regard microbiological documentation number free antibiotic therapy day28 duration aminoglycoside therapy rate aminoglycoside overdosage accord residual concentration overuse compare expert recommendation",
    "DESIGN": "design trial prospective randomize open label control multicenter factorial pragmatic clinical trial scope trial check eligibility criterion patient randomize accord balanced scheme allocate one arm intervention aminoglycoside either systematic addition aminoglycosides probabilistic antibiotic therapy maximum aminoglycoside specific predefined indication isolation either protective isolation geographical technical air filtration universal measure expand mask viral epidemic episode",
    "INCLUSION CRITERIA": "population trial subject adult patient admit intensive care inclusion criterion age admitted one participate icu sepsis septic shock define sepsis3 definition underlying tumor allogeneic stem cell transplantation hematological malignancy neutropenia define either absolute neutrophil count leucocyte relate underlying malignancy treatment informed defer consent",
    "EXCLUSION CRITERIA": "exclusion criterion pregnancy breastfeed moribund patient death expect within hour attend physician previous participation study affiliation social security patients legal protection accord french law patient receive injection aminoglycosides precede icu admission contraindication aminoglycosides mention spc section hypersensitivity amikacin antibiotic aminoglycoside family excipient amikacin use patients documented allergy aminoglycosides myasthenia gravis concomitant administration intravenous polymyxin delay onset sepsis inclusion hour",
    "INTERVENTION": "investigational strategy medicinal product intervention association aminoglycoside initial antibiotic therapy intervention lack routine use protective isolation weak protective isolation comparator strategy treatment intervention antibiotic therapy without systematic adjunction aminoglycosides intervention standard care protective isolation",
    "STATISTICS": "statistical analysis according previous study study group day90 mortality studied population expect assuming target effect intervention compare respective control type1 error rate power group include patient basis twosided logrank test correlation expect intervention main effect estimate interaction intervention test aucune analyse intermediaire nest prevue"
  },
  "INTORETAK": {
    "TITLE": "full title multicentre randomize prospective trial evaluate efficacy safety infliximab tocilizumab refractory relapse takayasu arteritis",
    "JUSTIFICATION": "scientific justification takayasu arteritis vasculitis unknown origin result progressive thickening stenosis large medium artery aorta major branch pulmonary artery first line therapy takayasu arteritis consist high dose corticosteroid mukhtyar et al case respond corticosteroids alone subsequent resolution symptom stabilization vascular abnormality shelhamer et al maksimowicz mckinnon et al although secondline agent methotrexate azathioprine mercaptopurine mycophenolate mofetil may result initial remission relapse remain common prednisone taper maksimowiczmckinnon et al thus corticosteroid resistant relapse takayasu arteritis patient may achieve sustain remission addition methotrexate hoffman et al last decade biologics antitumor necrosis factor alpha anti tnf antiinterleukin6 antiil6 use thirdline treatment refractory relapse takayasu arteritis almost corticosteroid methotrexate resistant takayasu arteritis case respond infliximab anti tnf sustain remission obtain case schmidt et al comarmond et al mekinian et al tocilizumab antiil6 give similar result sustained remission refractory takayasu arteritis abisror et al irrespective classical cardiovascular risk factor systemic inflammation corticosteroid use play pivotal role occurrence cardiovascular thrombotic event cves roubille et al cves overlap takayasu arteritis complication primordial drastically taper corticosteroid vasculitis therefore hypothesize infliximab tocilizumab achieve remission refractory relapsing takayasu arteritis case corticosteroid associate secondline agent intoretak first randomize prospective study takayasu arteritis original design test infliximab tocilizumab propensity achieve sustained remission refractory relapsing takayasu arteritis evaluate jointly arm",
    "OBJECTIVE": "primary objective assessment criterion obtain arm patient posttreatment prednisone prednisolone per inactive disease national institute health score last proportion posttreatment patient prednisone prednisolone per sustain inactive disease national institute health score biological therapy since treatment among randomized patient arm secondary objective assessment criterion estimate incidence relapse post treatment arm estimate incidence traitement failure post treatment arm estimate incidence revascularization procedure endovascular surgical require due disease posttreatment arm estimate cumulative dose prednisone prednisolone posttreatment arm estimate incidence adverse event post treatment arm estimate mean change sf36 qualityoflife value treatment posttreatment arm estimate proportion new vascular lesion posttreatment arm measure angiocomputorized tomography magnetic resonance imaging angiography incidence relapse define national institute health criterion day1 treatment incidence revascularization procedure endovascular surgical treatment posttreatment incidence traitement failure day1 treatment disease still active accord national institute health criterion proportion day1 treatment patient prednisone prednisolone per sustain inactive disease modified national institute health score without criterion biological therapy day1 treatment among randomized patient arm incidence relapse define modified national institute health criterion without criterion day1 treatment incidence traitement failure day1 treatment disease still active accord modify national institute health criterion without criterion cumulative dos prednisone prednisolone arm day1 treatment incidence adverse event grade3 iv day1 treatment mean change quality life questionnaire sf36 treatment treatment proportion new vascular lesion day1 treatment assess measure angioct mr angiography",
    "DESIGN": "experimental design open randomize clinical trial base simon twostage design simon use separately arm randomization thus allocation concealment arm insure absence selection bias allocate experimental treatment patient betweenarm comparison test estimate difference end point treatment arm provide",
    "INCLUSION CRITERIA": "population involve adult patient refractory relapse takayasu arteritis inclusion criterion diagnosis takayasu arteritis least criteria american college rheumatology meet appendix age disease onset 1st symptom limb claudication anisotension hg brachial systolic arterial pressure decreased brachial artery pulse one artery bruit subclavian artery aorta arteriogram abnormality arteriographic narrowing occlusion entire aorta primary branch large artery proximal upper low extremity due arteriosclerosis fibromuscular dysplasia similar cause change usually focal segmental otherwise least two major one major two minor criterion four minor criterion ishikawas criterion modify sharma meet appendix three major criterion left mid subclavian artery lesion severe stenosis occlusion present mid portion point proximal vertebral artery orifice distal orifice determine angiography right mid subclavian artery lesion severe stenosis occlusion present mid portion right vertebral artery orifice distal orifice determine angiography characteristic sign symptom least one duration include limb claudication pulselessness pulse difference limb unobtainable significant blood pressure difference mmhg systolic blood pressure difference limb fever neck pain transient amaurosis blur vision syncope dyspnea palpitation ten minor criterion high esr unexplained persistent high esr westergren diagnosis presence evidence patient history carotid artery tenderness unilateral bilateral tenderness common artery palpation neck muscle tenderness unacceptable hypertension persistent blood pressure mmhg brachial mmhg popliteal aortic regurgitation annuloaortic ectasia auscultation echocardiography angiography pulmonary artery lesion lobar segmental arterial occlusion equivalent determine angiography perfusion scintigraphy presence stenosis aneurysm luminal irregularity combination pulmonary trunk unilateral bilateral pulmonary artery determine angiography left mid common carotid lesion presence severe stenosis occlusion mid portion length point distal orifice determine angiography distal brachiocephalic trunk lesion presence severe stenosis occlusion distal third determine angiography descending thoracic aorta lesion narrowing dilation aneurysm luminal irregularity combination determine angiography tortuosity alone unacceptable abdominal aorta lesion narrowing dilation aneurysm luminal irregularity aneurysm combination coronary artery lesion document angiography age absence risk factor like hyperlipidemia diabetes mellitus active disease accord international criterion national institute health appendix least following criterion meet criterion least following systemic characteristic without cause identify erythema nodosum fever 38c polyarthralgia arthritis episcleritis criterion least following clinical sign appear since previous visit carotidodynia vascular claudication pain along arterial pathway constitute transient ischemic stroke acute coronary syndrome angina abolition pulse vascular bruit anisotension criterion least following biological sign creactive protein fibrinogen orosomucoide haptoglobine criterion least following radiological sign arterial wall thickening wall contrast measurement angiomri angiotdm appearance new vascular lesion angiomri angio tdm refractory relapsing disease symptomatic severe arterial involvement refractory relapsing disease consider one following condition meet inability taper corticosteroid within disease still active inability taper corticosteroid within inability discontinue corticosteroid treatment relapse disease gradual decrease corticosteroid therapy symptomatic severe arterial involvement define follow stroke retinopathy symptomatic coronary artery stenosis symptomatic pulmonary artery stenosis symptomatic mesenteric artery celiac trunk stenosis symptomatic renal artery stenosis patients one immunosuppressive agent methotrexate azathioprine mercaptopurine mycophenolate mofetil leflunomide ciclosporine hydroxychloroquine change dosage within last unless allergy intolerance contraindication immunosuppressive agent age weight medical followup university general hospital france social insurance willing able provide write informed consent willing able comply treatment followup procedure require study protocol female subject childbearing age negative serum pregnancy test pregnancy plan within subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study adequate contraceptive measure include hormonal method use two cycle prior screening oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence chest xray result posteroanterior lateral chest ct within prior inclusion randomization visit evidence active tuberculosis active infection malignancy tuberculosis assessment meet one following condition active tuberculosis infection treatment achieve completion least treatment latent tuberculosis infection negative tuberculin skin test interferon gamma release assay quantiferon tb gold tspot tb test potential subject positive tuberculin skin test interferon gamma release assay inclusion eligible chest xray show evidence suggestive active tuberculosis infection clinical sign symptom pulmonary extrapulmonary tuberculosis infection subject latent tuberculosis infection complete full currently receive since least treatment latent tuberculosis infection negative human immunodeficiency virus serology negative hepatitis rna hepatitis surface antigen within",
    "EXCLUSION CRITERIA": "noninclusion criterion active tuberculosis untreated latent tuberculosis infection currently treat less evidence active infection include chronic infection infection require treatment antibiotic within prior inclusion randomization visit infection positive human immunodeficiency virus serology positive hepatitis rna positive hepatitis surface antigen pregnancy lactation inability comply study guideline inability provide informed consent alcohol drug abuse investigator opinion could prevent subject fulfil study requirement would increase risk study procedure severe renal insufficiency creatinine clairance 73m2 hepatic dysfunction show aspartate transaminase ast alanine transaminase alt level 5fold upper limit normal heart failure stage iii iv nyha history malignant neoplasm except adequately treat basal squamous cell carcinoma skin solid tumor treat curative therapy disease free least history multiple sclerosis demyelinate disorder history severe allergic anaphylactic reaction infliximab chimeric murine monoclonal antibody tocilizumab respective excipients prednisone prednisolone history immediate hypersensitivity reaction iodinate gadoliniumbased contrast medium cytopenia hemoglobin dl absolute neutrophil platelet count live attenuate vaccine enrolment recombinant kill virus vaccine inclusion ransomization visit use following systemic treatment specify period atreatment biologic therapy infliximab adalimumab certolizumab pegol golimumab anakinra tocilizumab etanercept abatacept ixekizumab secukinumab ustekinumab alemtuzumab within prior inclusion randomization visit bpast treatment rituximab within past past treatment rituximab ago lymphocytes count return normal time inclusion randomization visit ctreatment systemic alkylating agent within prior inclusion randomization visit cyclophosphamide chlorambucil indication initiate infliximab tocilizumab another active disease takayasu arteritis lack affiliation social security benefit plan beneficiary assignee presence following onongoing ontreatment disease process microscopic polyangiitis granulomatosis polyangiitis eosinophilic granulomatosis polyangiitis polyarteritis nodosa cogans syndrome behcets disease kawasakis disease atypical mycobacterial infection deep fungal infection lymphoma lymphomatoid granulomatosis type malignancy mimic vasculitis cryoglobulinemic vasculitis systemic lupus erythematosus rheumatoid arthritis mixed connective tissue disease overlap autoimmune syndrome known constitutive immunodeficiency",
    "INTERVENTION": "treatment test arm patient receive infliximab intravenously follow prescription recommendation arm patient receive tocilizumab intravenously follow prescription recommendation",
    "STATISTICS": "statistical analysis randomize patient arm arm null hypothesis response rate test onesided alternative response rate type1 error rate power first stage include patient arm response observe patient arm stop otherwise additional patient accrue null hypothesis reject response observe patient"
  },
  "TRIBECA": {
    "TITLE": "full title multicenter randomize doubleblind study compare efficacy safety belimumab treatment noninfectious active cryoglobulinemia vasculitis compare placebo",
    "JUSTIFICATION": "scientific justification cryoglobulinemia vasculitis associate significant morbidity mortality require therapeutic intervention management noninfectious mixed cryoglobulinemia vasculitis currently base corticosteroid rituximab last decade several group report efficacy anti cd20 monoclonal antibody rituximab patient cryoglobulinemia vasculitis rituximab infusion prove effective main vasculitis sign complete clinical response patient however cryoglobulinemic vasculitis relapse note patient within nineteen last rituximab infusion previously show serum blys concentration correlate serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associate non hodgkins lymphoma agreement data systemic lupus erythematosus sjogrens syndrome also observe decrease blys binding br3 stain correlate disease severity following rituximab serum blys concentration significantly increase may favour survival autoreactive cell clone relapse cryoglobulinemia vasculitis recent study show rituximab reset defective early cell tolerance checkpoint obvious solution prevent rise baff level precipitate flare disease follow rituximab therapy thus achieve sustain remission disease would combine rituximab baff blockade mouse combination cell depletion baff inhibition remove cell marginal zone follicular compartment effectively either treatment alone combination cell depletion baff blockade superior cell depletion alone respect reduce number plasmablast plasma cell well reduce disease severity three different mouse model lupus addition promise result observe patient cryoglobulinemia vasculitis treat rituximab plus belimumab good safety profile",
    "OBJECTIVE": "main objective primary endpoint evaluate efficacy belimumab compare placebo patient noninfectious active cryoglobulinemia vasculitis complete clinical response rate vasculitis symptom corticosteroid withdrawal prednisone secondary objective endpoint secondary objective safety tolerability treatment assess frequency severity adverse clinical event complete partial improvement organ involve baseline non clinical clinical improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate non clinical response clinical relapse rate time relapse two treatment group cumulative dose corticosteroid receive two treatment group evolution gammaglobulin cd19 cell level quality life score sf36 appendix two treatment group rate infection severe complication lymphoma bvas activity score appendix secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event complete partial non clinical response rate complete renal response rate rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level rate early failure non clinical response clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis follow rate time relapse baseline cumulative dose prednisone quality life score sf36 baseline rate infection severe complication followup evolution gammaglobulin cd19 level baseline bvas activity score baseline",
    "DESIGN": "design trial bayesian phase2 randomize clinical trial aim evaluate best treatment strategy cryoglobulinemia vasculitis base difference response rate measure randomization scope trial phase2 prospective randomize multicentre double blind study group belimumab administer subcutaneously weekly group ii placebo belimumab administer subcutaneously weekly randomization centralize stratify previous treatment history naive patient versus relapse patient severity vasculitis extensive skin necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive central nervous system specific involvement ratio group group corticosteroid taper scheme initial dose following schedule reduction prednisone apply group long disease inactive 0w2 w2w4 w4w6 w6w8 w8w10 w10w12 strategy stop glucocorticoid leave investigator discretion stopping glucocorticoid therapy step prednisone dose reduce absence sign vasculitis activity",
    "INCLUSION CRITERIA": "population trial subject adult patient noninfectious active cryoglobulinemia vasculitis inclusion criterion age written inform consent active cryoglobulinemia vasculitis initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system receive rituximab induction therapy within infusion dose discretion investigator female subject childbearing potential must negative serum urinary pregnancy test inclusion visit confirm monthly study least half life post last dose subject reproductive potential male female willingness use contraceptive measure adequate prevent subject subject partner become pregnant study prior administration 1st dose study agent last dose study agent therefore subject agree following complete abstinence intercourse prior administration 1st dose study agent last dose study agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal post ovulation method withdrawal acceptable method contraception consistent correct use follow acceptable method birth control prior start study agent study last dose study agent oral contraceptive either combine progestogen alone injectable progestogen implants levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patch intrauterine device iud intrauterine system ius failure rate state product label male partner sterilization vasectomy documentation azoospermia prior female subject entry study male sole partner subject definition document refers outcome investigator designees medical examination subject review subject medical history study eligibility obtain via verbal interview subject subject medical record double barrier method condom occlusive cap diaphragm cervical vault cap plus spermicidal agent foam gel film cream suppository allow method contraception effective use consistently correctly accordance product label investigator responsible ensure subject understand properly use method contraception hiv negative serology negative hbs ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within inclusion neutrophils anc",
    "EXCLUSION CRITERIA": "exclusion criterion patient vasculitis unrelated cryoglobulinemia patient non active cryoglobulinemia vasculitis initiation rituximab patients inactive vasculitis follow rituximab administration may include excluded concomitant medication prior investigational medicinal product belimumab placebo biologic investigational agent abetimus sodium anti cd40l antibody bg9588 idec investigational agent applies drug approve sale country use days prior investigational medicinal product belimumab placebo intravenous cyclophosphamide days prior investigational medicinal product belimumab placebo half life whichever great nonbiologic investigational agent investigational agent applies drug approve sale country use live vaccine within prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last carcinoma situ cervix excise basal cell squamous cell carcinoma skin lowgrade hemopathy indication specific treatment progressive multifocal leukoencephalopathy evidence serious suicide risk include history suicidal behaviour last suicidal ideation last investigator judgment pose significant suicide risk history primary immunodeficiency significant igg deficiency igg level dl significant iga deficiency iga level dl accord result obtain within prior inclusion visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within inclusion visit current drug alcohol abuse dependence history drug alcohol abuse dependence within prior inclusion visit historically positive hiv test accord result obtain within prior inclusion visit hepatitis status accord result obtain within prior inclusion visit serologic evidence current past hepatitis infection base result test hbsag hbcab follow patients positive hbsag hbcab exclude positive test hepatitis rna history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroid excipients treatment administer study women child bearing potential included please see special instruction inclusion criterion pregnant breast feeding woman intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable study patients legal protection unable consent participation another interventional study",
    "INTERVENTION": "investigational medicinal product belimumab benlysta administer subcutaneously weekly comparator treatment placebo belimumab administer subcutaneously weekly",
    "STATISTICS": "statistical analysis bayesian phase2 randomize clinical trial aim evaluate treatment strategy cryoglobulinemia vasculitis base difference response rate measure randomization randomized phase2 trial still poorly use still large use singlearm phase2 trial result interpret relative historical control subject introduce selection bias confound may limit validity conclusion thus plan phase2 randomize trial appear worthy investment consider finite patient financial resource design adapt binary outcome observe end fixed followup period analyze use absolute difference proportion show greatly reduce sample size requirement thus use approach phase2 randomize trial propose simon wittes ellenberg ss aim control probability detect give difference response rate hypothesize patient receive placebo belimumab treat belimumab achieve complete remission cryoglobulinemia vasculitis steroid therapy stop"
  },
  "MSC-SLE": {
    "TITLE": "full title treatment severe refractory systemic lupus erythematosus injection allogeneic mesenchymal stem cell derive umbilical cord",
    "JUSTIFICATION": "scientific justification systemic lupus erythematosus rare prevalence person heterogeneous autoimmune autoinflammatory disease affect sex race peak incidence prevalence among black people predilection woman 3rd4th decade life systemic lupus erythematosus characterize successive period flare remission may vary duration quality prognosis severe form systemic lupus erythematosus affect lung heart brain addition renal involvement improve still evolution remain pejorative subset patient whose mortality remain even tertiary referral center new prospective clinical trial course systemic lupus erythematosus demonstrate effectiveness new biological therapy yet make long awaited breakthrough treatment severe systemic lupus erythematosus antiblys monocolonal antibody gain indication moderately active systemic lupus erythematosus addition serious adverse side effect progressive multifocal leukoencephalopathy observe several biologics auto disease patient dampen expect benefit systemic lupus erythematosus subject resistant 1er 2nd line conventional treatment need develop effective therapy long term side effect base new immunomodulatory immunosuppressive strategy according vitro immunomodulatory property ability induce tissue repair mechanism mesenchymal stem cell propose new therapy several auto disease include systemic lupus erythematosus use allogeneic umbilical cordderived mesenchymal stem cell base experimental human clinical data particularly produce nanjing team pr sun china also logical select systemic lupus erythematosus patient severity criterion use worldwide validate efficacy antiblys therapy similarly analysis expected result take account criterion similar comparable use pivotal clinical trial trial unique opportunity set collaboration saintlouis aphp clinical expert center cell therapy auto disease university college london cell manufacturing",
    "OBJECTIVE": "main objective primary endpoint main objective assess tolerance allogeneic umbilical cord derive mesenchymal stem cell administration severe systemic lupus erythematosus refractory standard therapy cyclophosphamide mycophenolate mofetil corticosteroid without anti cd20 primary endpoint immediate tolerance assess first injection allogeneic mesenchymal stem cell injection accord standard ctcae side effect secondary objective endpoint secondary objective feasibility allogeneic uc mesenchymal stem cell administration treatment severe systemic lupus erythematosus subject refractory conventional therapy tolerance three injection consider observed morbidity overall survival systemic lupus erythematosus treat subject procedure analysis biological clinical response routine clinical biological examination criterion monitor lupus use selena sledai bilag sf36 eq5d sri slicc systemic lupus erythematosus score analysis efficacy 3months injection allogeneic uc mscs accord proportion subject major clinical response rcm percentage subject partial clinical response cpr followup study evaluation immunomodulatory effect mesenchymal stem cell routine laboratory criterion include immunophenotyping every followup period analysis specific cytokine production analysis mesenchymal stem cell immunogenicity secondary endpoint safety tolerance assess injection within first follow mesenchymal stem cell injection accord side effect define ctcae standard miller results cancer treatment cancer treatmentrelated toxicity analyze accord international world health organization maximum degree toxic attack body injection consider tolerate toxicity criterion grade3 proportion subject major clinical response proportion subject partial response clinic pcr study followup disease activity measure bilag score selenasledai every compare inclusion end followup period sri response rate measure every three followup sri response define point reduction selena sledaiscore new bilag score organ one new bilag score worsening increase overall evaluation physician compare inclusion value presence comorbidities accord sclicc systemic lupus erythematosus index every three study followup charlson comorbidity index eligibility quality life assess short form version sf36v2 eq5d injection every end monitoring period percentage subject average dose prednisone reduce compare world health organization average daily corticosteroid dose measure every end monitoring period mo number treatment failure define one following end stage renal disease require dialysis transplantation sustain double creatinine value two low value observe screen baseline confirm four later active lupus nephritis attribute active systemic lupus erythematosus define either two criterion double value proteinuria proteinuria hour subject world health organization hour baseline proteinuria hour subject world health organization hour baseline ii nephropathy increase serum creatinine respect value baseline simultaneously value proteinuria double least hour hematuria two positive urine test strip presence cell cylinder two criterion must confirm twice interval need steroid therapy intravenously plasmapheresis immunoglobulin iv immunosuppressive therapy treat aggravation systemic lupus erythematosus standard immunological biological marker include lymphocyte immunophenotyping complete blood count creatinine proteinuria 24h autoantibody antidna antibody native anas complement system c3 c4 ch50 immunophenotyping every three followup period study specific cytokine production inclusion analysis mesenchymal stem cell immunogenicity accord antihla antibody dosage crossmatch analysis",
    "DESIGN": "design trial single center phase3 open study national recruitment within fai2r network scope trial immunosuppressive immunomodulatory action allogeneic mscs umbilical cord healthy donor allow beneficial action patient severe systemic lupus erythematosus resistant conventional treatment",
    "INCLUSION CRITERIA": "population trial subject systemic lupus erythematosus active subject refractory prior standard therapy inclusion criterion patient age diagnosis systemic lupus erythematosus accord acr criterion positive antinuclear antibody subjects sustained disease activity define selena sledai systemic lupus erythematosus activity index baseline inefficacy adverse effect necessitate discontinuation first second line therapy systemic lupus erythematosus include prednisone orally equivalent least least one following immunosuppressive therapy total cyclophosphamide iv bolus minimum ii mycophenolate mofetil orally equivalent dose least iii azathioprine orally dose least iv methotrexate orally parenterally dos least leflunomide orally dose least vi rituximab anticd20 intravenous bolus four total dose twice two vii cyclosporine orally dose least viii belimumab intravenously subcutaneous monthly bolus infusion least patient world health organization receive treatment systemic lupus erythematosus stable dos minimum prior eligibility include one following treatment prednisone equivalent alone combine antimalarial treatment antiinflammatory steroidal immunosuppressant negative pregnancy test woman childbearing age men woman using effective contraceptive method treatment within end treatment men partner childbearing age signed informed consent affiliation social security",
    "EXCLUSION CRITERIA": "exclusion criterion subjects pregnancy breastfeeding lack appropriate contraception study duration presence renal failure calculated creatinine clearance cardiac failure clinical sign congestive heart failure leave ventricular ejection fraction echocardiography uncontrolled ventricular arrhythmia hepatitis define abnormal level transaminase ast alt normal relate disease activity respiratory disease mean pap mmhg echocardiography respiratory failure define rest blood pressure oxygen pao mmhg paco2 mmhg without oxygen severe psychiatric disorder include severe psychosis relate systemic lupus erythematosus would prevent give informed consent undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure define neutropenia thrombocytopenia anemia dl lymphopenia cd4 cause another disease systemic lupus erythematosus acute chronic uncontrolled infection hiv htlv1 hepatitis hbs ag surface antigen hepatitis positive pcr optional pcr patient receive belimumab intravenously subcutaneous within baseline receive rituximab cell deplete biologic therapy within baseline current substance abuse recent within history substance abuse patient period exclusion national roster researcher patient linguistic psychological incapacity sign informed consent patient already include another study time poor patient compliance patient legal protection",
    "INTERVENTION": "investigational medicinal product phase3 allogeneic umbilical cord derivedmscs inject slow intravenous infusion accord weight recipient patient group study dos csm csm csm injection 1h intravenous infusion comparator treatment na",
    "STATISTICS": "statistical analysis initially subject initial dose csm recipient weight include follow subject enrol dose ms high probability excessive toxicity mesenchymal stem cell csm low probability excessive toxicity csm toxicity criterion describe ctcae classification patient cohort scan sequential bayesian approach estimate probability toxicity administer dose allow adaptation function toxicity observe dose previous subject"
  },
  "PCL-2": {
    "TITLE": "full title primary plasma cell leukemia prospective phase2 study incorporating daratumumab chemotherapy stem cell transplantation",
    "JUSTIFICATION": "scientific justification primary plasma cell leukemia ppcl rare form plasma cell malignancy multiple myeloma poor prognosis overall survival conventional chemotherapy bortezomibbased regimen show promising result small retrospective study transplantation auto allograft may improve overall survival select young patient ifm group recently publish prospective study ppcl patient alternate bortezomibdexamethasone doxorubicin cyclophosphamide pad vcd induction high dose melphalan plus autologous stem cell transplantation hdm autologous stem cell transplantation follow reduced intensity conditioningallograft ricallo second hdm autologous stem cell transplantation plus consolidation maintenance bortezomiblenalidomidedexamethasone lenalidomide overall patient responder induction achieve good partial response good one patient underwent syngeneic allograft hdm autologous stem cell transplantation subsequently receive ricallograft second transplant follow consolidation maintenance median progressionfree survival overall survival respectively overall survival seem superior double transplant maintenance group compare allotransplant group landmark analysis italian group also recently report prospective trial ppcl involve patient treat lenalidomidedexamethasone overall median progressionfree survival overall survival respectively nine patient eligible transplant could receive hdm autologous stem cell transplantation induction progressionfree survival overall survival reach respectively daratumumab monoclonal antibody cd38 highly express plasma cell highly effective relapsed refractory patient multiple myeloma alone combination lenalidomide combination daratumumab bortezomiblenalidomidedexamethasone dara bortezomiblenalidomidedexamethasone recently test newly diagnose multiple myeloma patient impressive result acceptable tolerability subcutaneous formulation daratumumab also test context new safety concern aim improve hematological response survival ppcl patient propose combine daratumumab subcutaneous bortezomiblenalidomidedex dara bortezomiblenalidomidedexamethasone induction follow double hdm autologous stem cell transplantation prolonged consolidation dara bortezomiblenalidomidedexamethasone lenalidomide",
    "OBJECTIVE": "main objective primary endpoint primary objective determine best overall response rate completion induction phase good partial response good primary endpoint good partial response good rate completion induction phase accord international myeloma work group response criterion secondary objective endpoint main secondary objective evaluate progressionfree survival secondary objective assess overall hematological response rate evaluate overall survival assess safety toxicity accord national cancer institute ctcae assess cytogenetic abnormality tumoral plasma cell analyze prognostic value minimalresidual disease sequence completion induction second consolidation len consolidation end treatment evaluate quality life eortc qlqc30 domain score secondary endpoint progressionfree survival overall survival time progression duration response overall hematological response rate assess safety type frequency severity relationship adverse event study treatment change vital sign physical exam incidence treatment emergent adverse event serious adverse event laboratory abnormality use national cancer institute common toxicity criterion common toxicity criterion v4 evaluate response accord chromosomal structural abnormality del 17p amp 1q del 1p minimal residual disease assess nextgeneration sequence quality life eortc qlqc30 domain score",
    "DESIGN": "design study induction phase inclusion trial patient receive dexamethasone according local practice one dose doxorubicine iv cyclophosphamide iv may also add reduce tumoral mass minimize risk tumor lysis syndrome tls induction treatment subject receive cycle dara bortezomiblenalidomidedexamethasone induction therapy describe agent dose route cycle daratumumab cycle cycle bortezomib lenalidomide cycle dexamethasone iv start dose lenalidomide reduce depend renal function patients impaired renal function calculate measure creatinine clearance minute lenalidomide dose reduction otherwise receive full dose lenalidomide tumorlysis prophylaxis monitoring require induction treatment accord local practice ii disease assessment local assessment perform end induction determine patient continue study responding patient response sd circulate plasma cell pursuit study nonresponding patient response sd circulate plasma cell study mobilization harvesting stem cells stem cell mobilization perform use cyclophosphamide recommend dose cycle stem cell harvest base response mobilization use gcsf plerixafor permit per institutional practice sufficient stem cell harvest enable two transplant cd34 high dose melphalan autologous stem cell transplantation n1 eligible patient start intensification high dose melphalan stem cell collection mephalan conditioning therapy patient creatinine clearance melphalan dose reduce stem cell reinfusion subject single reinfusion stem cell minimum cd34 hour highdose melphalan permit tolerance engraftment recovery post autologous stem cell transplantation subjects monitor successful engraftment support therapy administer accord institutional study group standard first consolidation consolidation therapy start time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within autologous stem cell transplantation subjects receive cycle dara bortezomiblenalidomidedexamethasone daratumumab bortezomib lenalidomide dexa iv high dose melphalan autologous stem cell transplantation n2 subjects receive melphalan conditioning therapy patient creatinine clearance melphalan dose reduce stem cell reinfusion subject single reinfusion stem cell minimum cd34 hour highdose melphalan permit tolerance engraftment recovery post autologous stem cell transplantation second consolidation phase2 consolidation therapy start time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within autologous stem cell transplantation phase conduct accord two step consolidation patients receive dara bortezomiblenalidomidedexamethasone every cycle daratumumab bortezomib lenalidomide dexamethasone iv consolidation patient receive lenalidomide every lenalidomide note treatment period lenalidomide dose readjust accord patient renal function status dose adaptation follow usual recommendation",
    "INCLUSION CRITERIA": "population study participant screening eligibility investigator responsible keep record subject sign informed consent form entry study subject screen eligibility must take place within prior initiation therapy patient must meet eligibility criterion enter study inclusion criterion male female patient patient primary plasma cell leukemia disease define recent international myeloma working group international myeloma work group circulate plasma cell peripheral blood smear voluntary write consent must give performance study related procedure part standard medical care understanding consent may withdraw patient time without prejudice future medical care eastern cooperative oncology group performance status performance status eligible high dose melphalan therapy autologous stem cell transplantation total bilirubin upper limit normal range alanine aminotransferase aspartate aminotransferase upper limit normal range calculated creatinine clearance mdrd formula use calculate creatinine clearance value female patient postmenopausal least screening visit surgically sterile childbearing potential agree practice effective method contraception time time sign informed consent form last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception male patient even surgically sterilize status post vasectomy must agree one following agree practice effective barrier contraception entire study treatment period last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception patients agree share study medication person return unused study drug investigator abstain donate blood take study drug therapy one follow discontinuation study drug therapy must able adhere study visit schedule protocol requirement affiliated appropriate social security system",
    "EXCLUSION CRITERIA": "exclusion criterion male female patient history malignancy within date inclusion exception squamous basal cell carcinoma skin carcinoma skin carcinoma situ cervix breast noninvasive lesion opinion investigator concurrence coordinate investigatior consider cured minimal risk recurrence within prior history symptomatic myeloma previous chemotherapy myeloma except corticotherapy dexamethasone max uncontrolled medical condition comorbidity might interfere subject participation pregnant breast feeding females known positive hiv known seropositive hepatitis except setting sustained virologic response svr define viremia least completion antiviral therapy seropositive hepatitis define positive test hepatitis surface antigen hbsag subjects resolved infection ie subject hbsag negative positive antibody hepatitis core antigen antihbc antibody hepatitis surface antigen antihbs must screen use realtime polymerase chain reaction pcr measurement hepatitis virus hbv dna level pcr positive exclude exception subjects serologic finding suggestive hbv vaccination anti hbs positivity serologic marker known history prior hbv vaccination need test hbv dna pcr patient severe renal failure require dialysis clairance creatinine prior local irradiation within two first dose however exception patient allow remain treatment phase study make radiation therapy pathological fracture site enhance bone healing treat postfracture pain refractory narcotic analgesic pathologic bone fracture fulfil criterion disease progression evidence central nervous system cns involvement unable take corticotherapy daratumumab bortezomib lenalidomide study entry ongoing active infection especially ongoing pneumonitis ongoing cardiac dysfunction specify uncontrolled hypertension mi within unstable angina pectoris cardiac arrhythmia grade2 high patients left ventricular ejection fraction lvef use experimental drug therapy within screen grade2 toxicity unresolved inability unwillingness comply birth control requirement unable take antithrombotic medicine study entry major surgery within enrolment serious medical psychiatric illness could investigator opinion potentially interfere completion treatment accord protocol known allergy study medication analogue excipients various formulation agent known gastro intestinal disease gastro intestinal procedure could interfere oral absorption tolerance daratumumab lenalidomide include difficulty swallow adult guardianship curatorship legal protection",
    "INTERVENTION": "investigational medicinal product bortezomib daratumumab lenalidomide dexamethasone",
    "STATISTICS": "statistical analysis primary endpoint trial good partial response good rate completion induction phase accord international myeloma work group response criterion previous publish phase2 trial patient achieve good partial response good induction using phase2 one stage ahern design lowest acceptable response rate p0 expect response rate p1 type1 type2 error level patient need account nonevaluable patient patient recruit"
  },
  "ITAC": {
    "TITLE": "full title multicenter randomize prospective trial compare efficacy safety infliximab cyclophosphamide severe behcets disease",
    "JUSTIFICATION": "scientific justification itac first randomized prospective head head study compare infliximab cyclophophamide severe manifestation behet disease behcets disease systemic vasculitis arterial venous vessel size involve young patient behet disease significantly increase morbidity mortality therape utic management behet disease depend clinical presentation organ involve although colchicine nonsteroidal antiinflammatory agent topical treatment often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agent warrant severe manifestation retinal vasculitis cardiovascular neurological involvement early recognition vigorous use immunosuppressive high dose steroid change prognosis patient severe behet disease behet disease severe systemic vasculitis lead mortality rate patient major vessel neurological involvement cyclophosphamide use lifethreatening behet disease however outcome severe complication behet disease still poor european league rheumatism eular recommendation update management behet disease advocate cyclophosphamide antitnf plus glucocorticoid lifethreatening manifestation neurological major vessel involvement recommendation vascular disease neurological involvement base largely expert opinion uncontrolled evidence open trial observational study need properly design control clinical trial apparent tnfa antagonist use success severe resistant case addition incidence blindness behet disease dramatically reduce recent use antitnf however firm evidence randomize controlled trial directly address best induction immunosuppressive therapy severe behet disease manifestation physicians still prescribe compound offlabel use therefore aim assess best induction therapy severe difficult treat behet disease patient",
    "OBJECTIVE": "main objective primary endpoint assess benefit infliximab comparatively cyclophosphamide severe lifethreatening behcets disease primary assessment criterion complete clinical response randomization secondary objective endpoint estimate compare rate time occurrence relapse worsen estimate compare cumulative dose steroid estimate compare adverse event estimate compare mean change sf36 qualityoflife see appendix estimate compare rate remission accord organ involve compare change acutephase reactant estimate compare change cns involvement estimate compare change cardiovascular involvement survival event free survival estimate compare change behet disease manifestation estimate compare change behcets disease current activity form see appendix assess serum concentration measurement tnfa inhibitor secondary endpoint complete clinical response remission cns cardiovascular involvement measures corticosteroid sparing percent meeting target prednisone mean dose cumulative dose time response onset measures acutephase reactant creactive protein crp every relapse time relapse relapse define reappearance clinical paraclinical feature active disease occurrence new lesion rate relapse worsening time occurrence worsen worsening define progression preexist lesion rate worsen gobal survival event free survival define occurrence death relapse worsening safety tolerability treatment behet disease patient assess frequency severity adverse clinical event change quality life sf36v2tm health survey see appendix changes cns involvement physical exam cerebral medullar magnetic resonance imaging changes vascular involvement physical exam vascular doppler us angioct imaging biologically normalization reactive protein changes cardiological involvement physical exam echocardiography normalization left ventricular function disappearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin reactive protein changes organ involve behet disease serum concentration measurement tnfa inhibitor change behcets disease current activity form see appendix",
    "DESIGN": "design trial bayesian design phase2 randomize clinical trial aim compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial scope trial collection free informed consent eligible patient active behcets disease randomize one group randomization visit arm infliximab intravenously arm cyclophosphamide intravenously patient receive corticosteroid regimen patient inclusion randomisation visit oral prednisone following schedule reduction prednisone apply group long disease inactive",
    "INCLUSION CRITERIA": "population trial subject adult pediatric patient severe lifethreatening behcets disease inclusion criterion age written inform consent informed consent obtain legal guardian accordance regional law regulation patient age diagnosis behet disease accord international criterion behet disease icbd see appendix life threaten active behet disease define following disease category accord validated international definition major vessel disease arterial aneurysm arterial stenosis myocarditis major deep vein thrombosis inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessel renal mesenteric vessel diagnosis major vessel involvement use vascular doppler sonography echocardiography angioct scan cardiac magnetic resonance imaging central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neurobehcets cns involvement base objective neurological symptom associate neuroimaging cns medullar magnetic resonance imaging finding suggestive behet disease related cns involvement cerebrospinal fluid csf findings show aseptic inflammation may associate chest xray result posteroanterior lateral within prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing age negative pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study stop therapy adequate contraceptive measure include hormonal method use two cycle prior inclusion oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence potential subject positive interferon gamma release assay quantiferontb gold tspot tb test positive tuberculin skin test eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course hiv negative serology negative hbs ag test",
    "EXCLUSION CRITERIA": "non inclusion criterion subjects include study meet following criterion evidence active tuberculosis hiv active hbv infection hbs ag pregnancy lactation take oral daily dose glucocorticoid prednisone equivalent continuously prior inclusion visit take methylprednisolone prior inclusion visit alcohol drug dependance severe renal creatinine clairance 73m2 preexisting hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction heart failure stage iii iv nyha history malignancy within prior inclusion carcinoma situ cervix excise basal cell squamous cell carcinoma skin history multiple sclerosis demyelinate disorder history severe allergic anaphylactic reaction cyclophosphamide infliximab infectious disease infection require treatment intravenous antibiotic within prior inclusion history recurrent infection laboratory value assess inclusion hemoglobin dl wbc platelet count use following systemic treatment specify period treatment systemic biologic therapy cyclophosphamide within prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drug must withdraw prior receive cyclophosphamide infliximab dose live attenuate vaccine within prior inclusion recombinant kill virus vaccine permit lack affiliation social security benefit plan beneficiary assignee patients affiliate universal medical coverage cmu eligible study",
    "INTERVENTION": "investigational medicinal product infliximab intravenously comparator treatment cyclophosphamide intravenously",
    "STATISTICS": "statistical analysis experimental design multicentric open multicenter randomize clinical trial stratify characteristic initial behcets disease evaluation primary assessment criterion primary assessment criterion final measure corticosteroid sparing review scientific committee blind randomization rct use bayesian design phase2 randomize national multicentre clinical trial aim compare new treatment reference base binary endpoint complete clinical response offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial"
  },
  "FOCUS": {
    "TITLE": "full title randomized control multicenter study compare efficacy safety adalimumab mycophenolate mofetil steroid dependent non infectious uveitis",
    "JUSTIFICATION": "scientific justification focus first prospective randomize study compare standard care mycophenolate mofetil adalimumab recently active non infectiuous uveitis steroid dependency firm evidence randomize trial compare classical immunosuppressive compound biological agent identify best treatment condition burden non infectiuous uveitis reduce use immunosuppressive agent biologics raise question compound preferentially use recently active non infectiuous uveitis steroid dependency",
    "OBJECTIVE": "main objective primary endpoint primary objective objective compare efficacy adalimumab subcutaneously standard care mycophenolate mofetil orally recently active noninfectious intermediate posterior uveitis panuveitis steroid dependency primary endpoint primary efficacy endpoint treatment failure rate treatment failure define following least one eye new active inflammatory chorioretinal retinal vascular lesion worsening best correct visual acuity line step increase anterior chamber cell grade vitreous haze relative baseline noabsence steroid discontinuation per protocol without aor additional immunosuppressive drug injectable steroid study treatment permanent discontinuation secondary objective endpoint secondary objectives comparing adalimumab subcutaneously standard care mycophenolate mofetil orally evaluate cumulative incidence treatment failure inclusion evaluate change best correct visual acuity best correct visual acuity logmar baseline evaluate change ocular inflammation anterior chamber vitreous baseline evaluate change sign include vessel leakage baseline evaluate presence macular edema baseline evaluate quality life relate uveitis inclusion evaluate steroid spar effect baseline evaluate number time relapse uveitis characteristic uveitis worsen baseline evaluate effect underlie systemic disease appropriate baseline evaluate safety adalimumab mycophenolate mofetil secondary endpoints time treatment failure logmar best correct visual acuity eye anterior chamber cell grade vitreous haze grade sun criterion eye central retinal thickness eye baseline proportion patient central macular thickness micron time optical coherence tomographic evidence macular edema least one eye nei visual functioning questionaire25 vfq25 composite score measures corticosteroid sparing percent meeting target prednisone mean change mean dose cumulative dose cumulative incidence relapse number relapse clinical manifestation underlying disease depend underlying disease evaluate safety tolerability treatment assess frequency severity adverse event treatment discontinuation baseline",
    "DESIGN": "design study prospective phase3 clinical trial multicenter openlabel two arm randomize clinical trial compare efficacy safety adalimumab standard care mycophenolate mofetil subject recently active intermediate posterior uveitis panuveitis despite steroid use oral prednisone prednisone available use oral corticosteroid replacement prednisone equivalent prednisone dose oral corticosteroid stable dose least prior first study drug administration",
    "INCLUSION CRITERIA": "population study participant adult patient recently active noninfectious uveitis despite oral prednisone equivalent prednisone doseoral corticosteroid equivalent dose prednisone stock market prednisone available use oral corticosteroid replacement prednisone equivalent dose oral corticosteroid equivalent recently active disease define presence least follow parameter either eye within prior inclusion visit active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature sun criterion vitreous haze national eye institute nei sun criterion inclusion criterion eligibility criterion check screen visit take place four maximum prior inclusion visit inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure age diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis confirm documented medical history recent activity non infectiuous uveitis define presence least follow parameter either eye within prior inclusion visit despite oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature sun criterion vitreous haze national eye institute nei sun criterion chest xray posteroanterior lateral ctscanner result within prior inclusion evidence active tuberculosis active infection malignancy potential subject positive interferongamma release assay quantiferontb gold tspot tb test inclusion eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course female subject childbearing potential negative pregnancy test inclusion subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study stop therapy mmf adalimumab respectively unless sterility confirm simultaneous use two complementary method contraception preferable methods may consider highly effective method achieve failure rate less per use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence affiliated social security system",
    "EXCLUSION CRITERIA": "exclusion criterion subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis monocular patient active tuberculosis positive hiv serology hcv hbs ag test history malignancy within prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody mycophenolate mofetil rifampicin isoniazid fluorescein infection require treatment intravenous antibiotic within prior inclusion history multiple sclerosis demyelinate disorder laboratory value assess inclusion hemoglobin dl wbc platelet count glomerular filtration rate transaminases time upper normal value use following systemic treatment specify period treatment systemic alkylating agent within prior inclusion cyclophosphamide chlorambucil live attenuate vaccine within prior inclusion stage iii iv new york heart association cardiac insufficiency pregnancy breastfeed legal protection participation another interventional study involve human participant exclusion period end previous study involve human participant applicable",
    "INTERVENTION": "investigational medicinal product eligible patient recently active non infectiuous uveitis randomize ratio arm adalimumab subcutaneously arm standard care define mycophenolate mofetil orally treatment group receive corticosteroid regimen patient non infectiuous uveitis receive oral prednisone oral corticosteroid equivalent maximum prednisone oral corticosteroid equivalent prednisone dose prednisone stock marketif prednisone available use oral corticosteroid replacement prednisone equivalent dose equivalence common prednisonetapering programme apply group decrease discontinuation long disease inactive comparator arm standard care define mycophenolate mofetil orally treatment",
    "STATISTICS": "statistical analysis prospective twoarm randomize openlabel phase3 trial compare adalimumab standard care mycophenolate mofetil base binary primary endpoint treatment failure treatment randomization stratify retinal vasculitis presence macular oedema underlie disease idiopathic uveitis underlying disease associate steroid dose inclusion versus trial conduct use group sequential design one interim analysis primary observation complete efficacy futility early stopping rule specifically assume probability treatment failure primary endpoint soc control population versus alternative hypothesis adalimumab total number patient per randomization arm require ensure power one sided type1 error risk account one interim analysis primary observation complete use lan demets obrien flemingtype riskspending function define efficacy futility nonbinding early stopping rule moreover plan include total patient per randomization arm account potential losttofollowup"
  },
  "ICE": {
    "TITLE": "full title isatuximab type1 cryoglobulinaemia prospective pilot study",
    "JUSTIFICATION": "scientific justification cryoglobulinaemia define presence immunoglobulin serum reversibly precipitate form gel temperature drop 37c redissolve upon rewarming classification include three subgroup base ig composition type1 cryoglobulinaemia consists one isotype subclass immunoglobulin types2 iii classify mixed cryoglobulinaemia include igg igm component overall cryoglobulinaemia consider rare disease general european north american population although prevalence likely high area mediterranean basin mixed cryoglobulinaemia vasculitis multiorganic disease involve kidney joint skin peripheral nerve type1 cryoglobulinaemic vasculitis search underlying plasmacell neoplasm mandatory cryoglobulinaemia compose igg often find multiple myeloma monoclonal gammapathy unknown significance course mixed cryoglobulinaemia vasculitis varies widely prognosis influence mixed cryoglobulinaemia induced damage vital organ co morbidity associate underlying disease type1 cryoglobulinaemic vasculitis plasma cell associate disorder crossroad autoimmunity plasmacell neoplasm treatment modulate accord underlie associated disease severity internal organ involvement overall survival diagnosis cryoglobulinaemic syndrome range case renal involvement main therapeutic goal must cure underlying haematological disease overwhelmingly plasmacell neoplasm common neoplasia multiple myeloma predominantly associate type1 cryoglobulinaemia hyperviscosity case treating underlying monoclonal disorder associate improvement stabilization cryoglobulinaemic symptom patient type1 cryoglobulinemia although negativation serum cryoglobulins achieve half patient alkylating agent bortezomib main therapeutic option associate side effect include neuropathy patients present symptomatic hyperviscosity require urgent therapeutic intervention use plasma exchange plasmapheresis remove cryoglobulins circulation standard care international guideline treatment type1 cryoglobulinemia isatuximab anticd38 monoclonal antibody effective treat relapsed refractory multiple myeloma autoreactive plasma cell represent key player autoimmune disorder particularly type1 cryoglobulinemia type1 cryoglobulinemia model plasma cell associate disorder crossroad autoimmunity plasmacell neoplasm however rituximab fails target population poorly effective condition thus unmeet need plasma cell target therapy type1 cryoglobulinemia clonal plasma cell type1 cryoglobulinemia express surface cd38 provide rationale use isatuximab cryoglobulinemia although biology clonal plasma cell type1 cryoglobulinemia distinct al amyloidosis model hematological disease associate monoclonal ig whose tumor mass low al amyloidosis anticd38 target therapy highly efficient monotherapy treatment naive patient relapsers thus isatuximab represent highly promising therapy type1 cryoglobulinemia could use monotherapy",
    "OBJECTIVE": "main objective primary endpoint primary objective assess complete clinical response rate isatuximab type1 igg cryoglobulinemia primary endpoint complete clinical response rate cryoglobulinemia vasculitis symptom secondary objective endpoint secondary objective safety tolerability treatment assess frequency severity adverse clinical event early complete response rate complete partial improvement organ involve baseline non clinical clinical improvement response rate rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate non clinical response clinical relapse rate time relapse course plasma cell associate disorder evolution gammaglobulin level quality life score sf36 appendix rate infection severe complication birmingham vasculitis activity score appendix immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event complete partial nonclinical response rate rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level rate early failure nonclinical response rate renal complete remission define proteinuria 24h proteinuria creatininuria mmol disappearance hematuria glomerular filtration rate 73m2 clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis followup rate time relapse baseline course plasma cell associate disorder mean change gammaglobulin level baseline quality life assess mean variation sf rate infection severe complication followup proportion patient remain remission birmingham vasculitis activity score baseline evolution immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire baseline",
    "DESIGN": "design study phase2 pilot prospective study patient type1 igg cryoglobulinemia treat isatuximab isatuximab perform intravenously every total infusion scope trial phase2 prospective multicenter study french plasma cell neoplasm cryoglobulinemia network compose hematologist internist rheumatologist dermatologist nephrologists patient receive subsequently therapy patient type1 igg cryoglobulinaemia treat isatuximab isatuximab administred intravenously every total infusion",
    "INCLUSION CRITERIA": "population study participant adult patient type1 igg active cryoglobulinemia vasculitis inclusion criterion age written inform consent monoclonal gammopathy unknown significance monoclonal igg component active cryoglobulinemia vasculitis define positive history positive type1 igg cryoglobulinemia clinically active cryoglobulinemia skin joint renal pulmonary cardiovascular muscular digestive central peripheral neurological involvement treated naive relapsers type1 cryoglobulinemia patient affiliated national french social security system contraception male participant male participant must agree use highly effective method contraception participation period least last dose study treatment refrain donate sperm period female participant female participant eligible participate pregnant breastfeed least one following condition female childbearing potential fcbp fcbp must negative serum urine pregnancy test sensitivity least miu within hour start study medication must apply highly effective method contraception participation period least last dose study treatment refrain donate oocyte period hiv negative serology negative hbs ag test hcv negative serology negative hcv rna positive hcv serology within prior inclusion",
    "EXCLUSION CRITERIA": "exclusion criterion patient vasculitis unrelated cryoglobulinemia patient nonactive cryoglobulinemia vasculitis patient diagnosis multiple myeloma except indolent myeloma patient treat immunosuppressant alkylating agent rituximab chemotherapy plasma cell neoplasm introduce increase prior inclusion live vaccine within prior baseline concurrently isatuximab infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within prior active tuberculosis hiv positive positive ag hbs positive hcv rna clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result hypersensitivity history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer sucrose component study therapy amenable premedication steroid h2 blocker would prohibit treatment agent hypersensitivity active substance isatuximab premedication excipients received investigational drug within prior inclusion within halflives investigational drug whichever long participation another interventional study exclusion period end previous study vulnerable population pregnant breastfeed woman persons deprived liberty judicial administrative decision persons psychiatric care without consent adults subject legal protection measure persons unable express consent neutrophils platelets",
    "INTERVENTION": "investigational medicinal product isatuximab administer intravenously every total infusion comparator treatment none",
    "STATISTICS": "statistical power sample size justification use onesample multiple testing procedure phase2 clinical trial report definitions fleming biometrics volume page calculate sample size report definitions p0 maximum response proportion poor drug p1 minimum response proportion good drug sample size number response p0 reject number response p1 reject alpha probability reject p0 true beta probability reject p1 true summary statements ice study require subject decide whether proportion responding less equal great equal number response hypothesis reject target error rate actual error rate number response less hypothesis reject target error rate actual error rate statistical analysis pilot prospective phase2 clinical trial aim evaluate safety efficacy isatuximab type1 cryoglobulinemia vasculitis hypothesize patient receive isatuximab achieve complete remission cryoglobulinemia vasculitis continuous variable cf variable describe primary secondary objective present median iqr mean sem categorical variable present count proportion statistical comparison perform use mannwhitney test quantitative unpaired data ttest quantitative pair data kruskalwallis multiple comparison spearman correlation test correlation ttest quantitative pair data analysis use compare immunological change isatuximab statistical test twotailed significance level"
  },
  "ETOLE": {
    "TITLE": "full title evaluation tomosynthesis characterization management breast",
    "JUSTIFICATION": "rationale tomosynthesis innovative technique develop digital mammography obtain sectional image breast mammography main disadvantage image projection create overlay eliminate tomosynthesis",
    "OBJECTIVE": "objective primary endpoint evaluate birads classification obtain tomosythesis superior classification obtain conventional mammography term specificity noninferior term sensitivity joint analysis true negative false negative rate accord birads scale compare histological result followup outcome see gold standard objectives secondary endpoint evaluate tomosynthesis synthetic tomography allow good detection certain sign poor prognosis malignant lesion size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic tomography modify number additional view number additional examination include ultrasound breast mri biopsy assess whether tomosynthesis reduce necessary number ultrasound compare difference rating birads obtain tomosynthesis synthetic mammography ultrasound difference obtain conventional mammography alone combine ultrasound tomosynthesis synthetic mammography change radiation dose receive patient tomosynthesis synthetic mammography improve reproducibility birads classification abnormality cost analysis tomosynthesis synthetic mammography compare mammography mammography ultrasound",
    "DESIGN": "experimental design randomized multicentric study phase3 diagnostic study accord classification gluud gluud inclusion phase18 tomosynthesis system instal site manufacturer patient clinical breast imaging abnormally site study period give informed consent randomize either conventional mammography tomosynthesis incidence synthetic mammography diagnostic method evaluation tomosynthesis characterization management breast reference diagnostic method conventional digital mammography",
    "INCLUSION CRITERIA": "population concern women clinical breast imaging abnormality inclusion criteria patient clinical breast imaging abnormality classify birads table patient signed informed consent",
    "EXCLUSION CRITERIA": "noninclusion criteria patients high risk breast cancer mutation brca carrier li fraumeni history thoracic radiation exclude great sensitivity ionize radiation patient unable give informed consent physical mental legal reason patient affiliate french social security insurance patient treatment breast cancer mammography recommended accord good practice french health authority pregnant patient",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis analysis comparison birads classification obtain mammography tomosynthesis rely construction simultaneous confidence interval ratio true negative rate specificity false negative rate 1sensitivity obtain technics mammography tomosynthesis arm describe alonzo et al"
  },
  "MAC-HAPLO-MUD": {
    "TITLE": "full title randomized prospective phase3 clinical trial compare hla match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen",
    "JUSTIFICATION": "scientific justification unrelated adult donor hlamatched recipient allelelevel hlaa dqb1 drb1 consider best choice absence hlamatched sibling patient need hematopoietic stem cell transplantation however use match unrelated donor limit prolonged time identify schedule donation match unrelated donor allow patient relapse transplantation perform limit availability fully hla match unrelated donor noncaucasian population alternative donor single hla mismatch unrelated donor unrelated umbilical cord blood graft haploidentical related donor still associate high nonrelapse mortality delay immune reconstitution recent strategy haploidentical haplo relate donor stem cell transplantation haplo stem cell transplantation improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early hla mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective study haplo stem cell transplantation ptcy associate similar overall progressionfree survival matched unrelated donor stem cell transplantation match unrelated donor stem cell transplantation low rate toxicity graft versus host disease thus potentially good result matched unrelated donor stem cell transplantation reduce intensity condition regimen phase3 randomize trial currently address question france elderly patient use reduced intensity condition regimen haplomudelederly01 phrck pi blaise institut paoli calmettes randomized prospective phase3 clinical trial compare hla match unrelated donor haplo stem cell transplantation myeloablative conditioning regimen urgently need answer question",
    "OBJECTIVE": "main objective primary endpoint main objective improve progression free survival without acute grade iiiv graft versus host disease without moderate severe chronic graft versus host disease use haplo donor compare 10hla matched unrelated donor myeloablative stem cell transplantation primary endpoint progression free survival without grade iiiv acute graft versus host disease without moderate severe chronic graft versus host disease haplo stem cell transplantation versus 10hla match unrelated donor secondary objective endpoint secondary objective compare two arm term clinical biological outcome kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval inclusion transplant rehospitalizations treatment related morbidity quality life chimerism immune reconstitution search prognostic factor main outcome globally arm search treatmentbycovariate interaction main outcome secondary endpoint interval inclusion transplant absolue number neutrophil platelet chimerism acute graft versus host disease incidence grade chronic graft versus host disease incidence grade relapse incidence progression free survival severe infection ctcae grade34 incidence veinoocclusive disease incidence cardiac toxicity nonrelapse mortality overall survival quality life questionnaire ebmt number new hospitalization hospitalization transplantation immune reconstitution lymphocytes cd4 cd8 nk lymphocytes gammaglobulines",
    "DESIGN": "design trial randomized prospective phase3 clinical trial compare hla match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative condition regimen scope trial goal show superiority haplo stem cell transplantation primary endpoint even similar result arm obtain study might revolutionize strategy stem cell transplantation since haplo donor use priority compare match unrelated donor quick procedure cheap available almost patient",
    "INCLUSION CRITERIA": "population trial subject patients age high risk hematological malignancy indication allogeneic hematopoietic stem cell transplantation inclusion criterion patients aged aml smd smp require allogeneic stem cell transplantation least partial response malignant disease without hla match related donor strong probability related haplo donor hla10 match donor available patient need least match unrelated donor identify outside book bmdw bone marrow donors worldwide use easy match software include usual criterion hsct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine mol except abnormality link hematological disease health insurance coverage understand informed consent optimal treatment followup prescription two effective contraception method must prescribe duration study sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "exclusion criterion patients cancer last except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity hiv htlv1 active hepatitis yellow fever vaccine heart failure accord nyha ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance pregnancy hcg positive breastfeeding debilitate medical psychiatric illness preclude realization stem cell transplantation understanding protocol protection law tutorship curatorship unwilling unable comply protocol",
    "INTERVENTION": "experimental group haplo donor myeloablative stem cell transplantation use cyclophosphamide intravenous route stem cell transplantation treatment transplant modality conditioning regimen patient myeloid malignancy haploidentical stem cell transplantation thiotepa fludarabine day5 to2 iv busulfan day5 to3 hlamatched unrelated donor stem cell transplantation fludarabine day6 to2 iv busulfan to3 patient fludarabine tbi cgy twice daily total dose cgy stem cell source bone marrow haploidentical stem cell transplantation peripheral blood stem cell hlamatched unrelated transplantation graft versus host disease prophylaxis haploidentical stem cell transplantation cyclophosphamide ciclosporine mycophenolate mmf hlamatched unrelated donor stem cell transplantation antithymocyte globuline thymogobuline total dose cyclosporine mmf absence graft versus host disease mmf stop arm",
    "STATISTICS": "statistical analysis justification sample size hypothesize progression free survival without grade iiiv acute graft versus host disease without moderate severe chronic graft versus host disease haplo stem cell transplantation versus 10hla match unrelated donor patient arm overall require demonstrate difference base twosided logrank test power hazard ratio required total number event bayesian interim analysis inflate interim analysis midinclusion base bayesian computation stop rule base modeling log hazard ratio main endpoint spiegelhalter non informative prior loghr consider terminal analysis observation required number event"
  },
  "SHORTCUT": {
    "TITLE": "full title efficacy versus antibiotic therapy acute pyelonephritis kidney transplant recipient multicentre randomize noninferiority trial",
    "JUSTIFICATION": "scientific justification infections major cause morbidity mortality solid organ transplant recipient kidney transplant recipient urinary tract infection represent infection hospitalization sepsis acute transplant pyelonephritis common complication occur patient mainly first transplantation associate increase risk acute kidney rejection longterm kidney graft dysfunction gram negative bacteria mainly coli account urinary tract infection kidney transplant recipient infection favor urinary tract modifications defects immunosuppression often recurrent necessitate repeat course antibiotic selective pressure due antibiotic consumption along frequent hospital admission immunosuppression well know risk factor development antibiotic resistant infection multidrug extensively xdr drug resistant enterobacteriaceae include esbl carbapenemaseproducing organism thus increasingly observe transplant unit represent global threat new antibiotic expect next decade one main strategy limit antimicrobial resistance reduce duration antibiotic treatment course recommend simple acute pyelonephritis apn treat fluoroquinolones parenteral lactams prolong presence underlying disease risk complication kt team treat patient recommend american guideline however need extend treatment duration immunosuppressed patient poorly define concept optimal duration treatment apn kidney transplant recipient know patient exclude study urgent need reduce antibiotic consumption population high risk develop infection due resistant pathogen hypothesis daytreatment sufficient cure apn good clinical response 48h treatment kidney transplant recipient effective",
    "OBJECTIVE": "main objective primary endpoint show dayantibiotic therapy inferior dayantibiotic therapy treatment acute pyelonephritis kidney transplant recipient primary endpoint clinical cure additional antibiotic treatment since end antibiotic treatment main evaluation clinical cure define fever 38c symptom urinary tract infection secondary objective endpoint compare arm clinical cure microbiological cure tolerance safety antibiotic hospitalization length stay antibiotic consumption total follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection total cost evaluate risk factor failure relapse recurrence evaluate efficacy antibiotic treatment end treatment experimental arm control group secondary endpoint clinical cure microbiological cure incidence relapse recurrence incidence adverse event imputable antibiotic treatment kidney function assess accord mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi hospitalization length stay define delay date inclusion date hospital discharge antibiotic consumption rectal carriage antibiotic resistant enterobacteriaceae inclusion microbiological cure define sterile urine uropathogene cfu urine culture",
    "DESIGN": "design trial multicenter control randomize noninferiority open label clinical trial parallel group versus antibiotic treatment randomization stratify date renal transplantation center sex potential confounders scope trial phase4 trial",
    "INCLUSION CRITERIA": "population trial subject kidney transplant recipient acute pyelonephritis inclusion criterion age kidney transplant recipient apn define fever t38c without clinical sign symptom urinary tract infection pyuria white blood cells positive urine culture uropathogen cfu susceptible empirically administrate antibiotic confirm suspect febrile non urinary bacterial infection urologic renal complication baseline imaging abscess obstruction favourable early response antibiotic treatment hour first dose antibiotic effective causative uropathogen define 38c improvement resolution sign symptom urinary tract infection present diagnosis written inform consent",
    "EXCLUSION CRITERIA": "exclusion criterion patients following condition severe complicate condition rapidly progressing disease immediately life threaten illness include limited septic shock current impede respiratory failure acute heart liver failure admission stay intensive care unit baseline obstruction urinary tract renal perinephric prostatic abscess prior inclusion study current participation another interventional study dual antibiotic therapy prophylactic antibiotic cotrimoxazole allow dose aminoside allow randomization first post transplantation current indwell catheter include bladder catheter ureteral stent percutaneous nephrostomy tube neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy relate kidney transplantation include hematologic favourable early response antibiotic treatment malignancy cancer asplenia neutropenia neutrophils pregnancy breastfeed hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy patient legal guardianship without healthcare coverage homeless patient women childbearing potential use adequate contraception",
    "INTERVENTION": "comparator treatment standard antibiotic duration",
    "STATISTICS": "statistical analysis sample size group achieve power detect noninferiority margin difference group proportion reference group proportion treatment group proportion assume null hypothesis inferiority power compute case actual treatment group proportion test statistic use onesided test unpooled significance level test"
  },
  "CAMOVID": {
    "TITLE": "full title camovid multicenter randomize trial evaluate efficacy safety camostat mesylate treatment sarscov2 infection covid19 ambulatory adult patient",
    "JUSTIFICATION": "scientific justification since december novel coronavirus call sarscov2 severe acute respiratory syndrome coronavirus cause international outbreak respiratory illness describe covid19 22nd march confirm case covid19 include death report world health organization march severe case france include death spectrum symptomatic infection range mild critical infection severe infected patient require hospitalization require intensive care unit admission diagnosis sarscov2 infection relies clinical symptom microbiological testing test sarscov2 infection test center use reverse transcription polymerase chain reaction nasal swab patient productive cough number investigational agent explore antiviral treatment covid19 however date control data support use specific treatment antiviral drug immunomodulatory drug efficacy covid19 unknown sarscov2 infects human cell binding spike protein membranous aminopeptidase call angiotensin convert enzyme angiotensin converting enzyme among tissue angiotensin convert enzyme expression mainly find pneumocytes enterocytes renal tubular cell podocytes cellular entry sarscov2 require protein priming cellular serine protease cellular serine protease entail protein cleavage allow fusion viral cellular membrane murine model sarscov pneumonia iwatayoshikawa et al show cellular serine protease ko mouse weaken inflammatory cytokine response reduced lung injury control mouse hoffmann et al find cellular serine protease inhibitor camostat mesylate block viral entry reduce infection human primary pneumocytes lung cell line sarscov2 also show serum convalescent sars patient crossneutralized sars2s driven entry another study perform bojkova et al show camostat mesylate reduce cytopathogenic effect due sarscov2 human colonic cell line camostat mesylate serine protease inhibitor commonly use japan dose successfully safely use treat pancreatitisassociated pain postoperative reflux oesophagitis side effect report rare dos nausea diarrhea hypersensitivity case cytopenia less hyperkaliemia abnormal hepatic function less hypothesize camostat mesylate initiate early sarscov2 infection reduce viral infection viral cytopathogenic effect block sarscov2 entry cell therefore prevent deterioration toward severe form covid19",
    "OBJECTIVE": "main objective primary endpoint objective evaluate efficacy camostat mesylate treatment sarscov2 infection highrisk adult patient confirmed covid19 require initial hospitalization term hospitalization need randomization primary endpoint proportion patient hospitalize covid19 deterioration world health organization die without hospitalization indicative basis criterion hospitalization presence following respiratory rate rest sp02 room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly haut conseil la sant publique reason require hospitalization leave discretion physician secondary objective endpoint secondary objective adult patient diagnose laboratory confirm covid require initial hospitalization evaluate impact camostat mesylate compare placebo safety efficacy term need hospitalization covid19 management independent blinded committee review overall clinical improvement clinical efficacy term intensive care need clinical efficacy term time hospitalization clinical efficacy respiratory function overall survival randomization patientreported outcome initial symptom virological serological immunological efficacy include surrogacy assessment candidate marker renal complication liver complication covid19 transmission within household secondary endpoint adverse event aes number aes number serious aes saes investigational medication discontinuation reason independent endpoint adjudication committeereviewed proportion patient hospitalize covid19 deterioration independent eac review patientsfiles blind randomize group determine whether hospitalization criterion relate covid19 world health organization covid19 clinical improvement ordinal scale oms descriptor score progression scale uninfected clinical virological evidence infection ambulatory limitation activity limitation activity hospitalized hospitalized oxygen therapy mild disease hospitalized oxygen mask nasal prong hospitalized hospitalized oxygen non invasive ventilation severe high flow disease intubation mechanical ventilation mechanical ventilation additional organ support pressor renal replacement therapy extra corporeal membrane oxygenation dead dead admission intensive care unit within inclusion number alive without hospitalization initiation invasive mechanical ventilation covid19 severe within inclusion initiation oxygentherapy covid19 within inclusion overall survival number alive without symptom sarscov2 virological assessment nasal swab droplet quantification sars cov2 rnaemia sarscov2 serological assessment plasma il6 il1b tnfa il8 level peripheral blood lymphocyte phenotyping telomere length measurement acute kidney failure define least serum creatinine increase dl time baseline oliguria kdigo2012 scale within serum electrolyte estimate glomerular filtration rate liver transaminase gammagt alkaline phosphatase percentage covid19 affected individual share household",
    "DESIGN": "design study multicenter singleblinded placebocontrolled twoarm parallel randomized phase3 trial",
    "INCLUSION CRITERIA": "population study participant ambulatory adult highrisk patient laboratory confirm covid19 require initial hospitalization inclusion criterion patients patients increase risk severe covid19 belonging one following group age body mass index diabetes hypertension chronic renal failure egfr chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemia active currently treat diagnose cancer active currently treat diagnose malignant blood disease immunosuppressive treatment observe laboratory confirm sarscov2 infection mild covid19 fulfil following criterion positive sarscov2 rtpcr nasal saliva swab sample positive sarscov2 antigen test perform within 96h inclusion visit clinical symptom sign consistent sarscov2 infection include limited fever upper respiratory tract infection sign digestive sign muscle pain anosmia dysgueusia informed consent participate trial patients must able willing comply study visit procedure",
    "EXCLUSION CRITERIA": "exclusion criterion initial need hospitalization covid19 management define following severity criterion respiratory rate rest sp02 room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendation haut conseil la sant publique reason require immediate hospitalization leave discretion physician pregnancy breastfeed participation another interventional drug trial subject protect law guardianship curatorship absence health insurance known hypersensitivity camostat mesylate known person share household already include study participation another covid19 ambulatory interventional study patients complete full sarscov2 vaccine immunization procedure less prior covid19 diagnosis last vaccine injection perform less prior covid19 diagnosis",
    "INTERVENTION": "investigational medicinal product camostat mesylate oral administration every hour comparator treatment placebo tablet follow schedule investigational drug",
    "STATISTICS": "statistical analysis descriptive analysis use either frequency percentage categorical variable median interquartile range quantitative variable number miss value report primary endpoint probability hospitalization within compare group use twosided test secondary endpoint compare across group use fishers exact test compare probability group wilcoxons rank sum test compare quantitative endpoint analysis perform intentiontotreat principle twosided significancelevel use comparison secondary endpoint"
  },
  "GREEN": {
    "TITLE": "full title randomized doubleblind multicenter placebocontrolled efficacy safety study glenzocimab used addon therapy top mechanical thrombectomy acute ischemic stroke",
    "JUSTIFICATION": "scientific justification emergent reperfusion main goal acute ischemic stroke therapy endovascular therapy recommend within hr stroke onset hr follow perfusion image criterion despite major benefit associate mechanical thrombectomy patient remain disabled reperfusion rate mechanical thrombectomy critical determine functional outcome however complete reperfusion obtain patient due least part erratic embolus noreflow process thrombus composition analysis show platelet rich clot resistant alteplase suggest platelet inhibition represent relevant target improve reperfusion nevertheless currently available molecule recommend acute phase due associate sich risk therefrom still need safe efficient antithrombotic agent administrable acute phase without induce bleeding risk order reduce size clot favour cerebral reperfusion result obtain escalate dose phase actimis study show promising safety data completion five cohort dose progression carry study dsmb member recommend use high dose consolidation phase acute ischemic stroke patient recruit treat high dose experience symptomatic ichs low rate asymptomatic intracranial hemorrhage similar incidence saes susars comparison patient treat low dose placebo consolidation phase conduct additional acute ischemic stroke patient parallelgroup design glenzocimab versus placebo addon reperfusion standard care global safety result combine phase concern incidence symptomatic ichs observe dose event patient event patient glenzocimab group low one show placebo group events patient incidence nonsymptomatic ichs observe alldose events patient events patient glenzocimab group low compare placebo group events patient kaplanmeier curve show reduced mortality dose glenzocimab group compare placebo group value respectively twenty death occur phase ib phase 2a strokerelated outcome glenzocimab show favorable safety profile term hemorrhagic event well generally include patient age population despite concomitant medical condition though power showing efficacy study glenzocimab show real benefit term death rate show decrease proportion patient severe level handicap encouraging result confirm ongoing future study platelet glycoprotein vi gpvi belong immunoglobulin superfamily expression restrict megakaryocyte platelet lineage gpvi key receptor collagen play major role platelet activation platelet recruitment thrombus growth studies also demonstrate gpvi platelet receptor polymerized fibrin interaction contribute thrombus growth reformation furthermore inhibition gpvi impair hemostasis subject genetic acquire gpvi deficiency prone excessively bleed gpvi therefore major target growth stabilization thrombus offer new therapeutic approach high safety profile study aim evaluate efficacy gpvi inhibitor glenzocimab addition endovascular therapy current protocol allow standard care use thrombolysis depend routine practice study site particular simpler mode administration tenecteplase single bolus injection lead many site adopt tenecteplase alternative alteplase acute ischemic stroke patient",
    "OBJECTIVE": "study objectives primary objective evaluate efficacy glenzocimab addition endovascular therapy compare endovascular therapy plus placebo whether associate intravenous thrombolysis functional outcome secondary objectives evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo overall survival evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo reperfusion end endovascular therapy early clinical improvement hr symptomatic intracranial haemorrhage hr overall intracranial haemorrhage hr serious adverse event saes suspect unexpected serious adverse reaction susars hr bleedingrelated event bres hr quality life evaluate cost effectiveness glenzocimab addition endovascular therapy compare endovascular therapy plus placebo study endpoints primary efficacy endpoint primary efficacy endpoint functional outcome assess modified mrs secondary endpoints efficacy favourable functional outcome define mrs score proportion patient severe handicap mrs overall survival day90 early reperfusion outcome stroke volume brain imaging hr reperfusion end mechanical thrombectomy procedure assess etici score early neurological improvement nihss hrs eq5d5l safety incidence symptomatic nonsymptomatic intracranial hemorrhages hrs incidence symptomatic intracranial hemorrhages hrs incidence nonsymptomatic intracranial hemorrhages hr incidence nature severity adverse events saes susars bleedingrelated events bres treatmentemergent adverse events teaes hr discharge incidence bleedingrelated event antiglenzocimab antibody baseline predose least patient cost effectiveness cost per qaly quality adjust life gain use glenzocimab addition endovascular therapy cost per patient mrs score gain use glenzocimab addition endovascular therapy",
    "DESIGN": "design phase category national multicenter prospective randomize ratio parallel group doubleblinded placebo control phase2 iii study category",
    "INCLUSION CRITERIA": "population study participant patients clinical diagnosis acute ischemic stroke large cerebral vessel occlusion hr symptom onset patient see last time well eligible endovascular therapy base perfusion imaging time window hour inclusion criterion age age18 significant prestroke disability prestroke mrs must equal indication endovascular therapy within timewindow hr participant treat without intravenous thrombolysis present clinico radiological mismatch define nihss10 aspect score occlusion cervical intracranial internal carotid artery proximal middle cerebral artery middle cerebral artery magnetic resonance angiography possible ct angiography informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent postmenopausal woman define menses without alternative medical cause wocbp highly effective birth control method place achieve failure rate less per last least imp administration birth control method may consider highly effective wocbp include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomized partner birth control method may consider highly effective men last imp administration include vasectomy use condom combine highly effective birth control method wocb partner please note hormonal contraception risk factor thromboembolic event attention call reconsider pass acute stroke phase7 women childbearing potential wocbp must negative serum urine pregnancy test baseline women childbearing potential fertile define woman follow menarche become post menopausal unless permanently sterile undergone hysterectomy bilateral salpingectomy bilateral oophorectomy affiliation social security health insurance",
    "EXCLUSION CRITERIA": "non inclusion criterion contraindications endovascular therapy contraindication contrast agent preexisting neurologic psychiatric disease mrs unknown symptom onset last seem well hour patients need immediate dual antiplatelet therapy administration significant mass effect midline shift confirm ct magnetic resonance imaging gastrointestinal urinary tract hemorrhage previous patient intracranial haemorrhage known platelet count pregnant breastfeed woman known hypersensitivity glenzocimab excipients known severe renal insufficiency grades45 glomerular filtration rate 73m2 participation another interventional clinical trial within prior inclusion persons deprive liberty judicial administrative decision person subject psychiatric care section et person admit health social institution purpose research adults subject legal protection measure patient family patient unable give opinion express inability return protocol visit patient receive anticoagulant heparin within hour elevated aptt greater upper limit normal laboratory current use oral anticoagulant ex warfarin inr current use direct thrombin inhibitor direct factor xa inhibitor already mention nonauthorized concomitant treatment patient already receive another humanized fragment monoclonal antibody suspicion hypersensitivity exclusion criterion withdrawal consent patient wish withdraw trial persons deprive liberty judicial administrative decision person subject psychiatric care section person admit health social institution purpose research",
    "INTERVENTION": "concomitant treatment nonauthorized concomitant treatments patients receive experimental therapy study participation addition aforementioned exclusion criterion patient receive dual antiplatelet therapy require intra extracranial stent thrombolysis tenecteplase glenzocimab infusion authorized concomitant treatments symptomatic treatment use routinely disease relate symptom allow patient involve trial specific treatment adverse event also permit thrombolysis alteplase antiplatelet monotherapy allow glenzocimab start soon possible addition alteplase details treatment procedure must record ecrf investigational medicinal product glenzocimab act017 acticor biotech formulate iv administration sterile product sodium citrate sodium chloride buffer supply clinical trial use vial contain drug product concentration vial contain glenzocimab two vial glenzocimab administer concomitantly eligible patient total daily dose comparator treatment placebo glenzocimab nacl acticor biotech iv administration supply clinical trial use vial two vial placebo glenzocimab administer concomitantly eligible patient study intervention administered study treatment glenzocimab placebo per central randomization allocation study group patient randomize one arm receive glenzocimab arm placebo addition endovascular therapy endovascular therapy add research glenzocimab placebo intend administer iv infusion hr dose administer 15minute bolus dose administer 5h45min slow infusion proposed scheme obtain rapid effect emergency phase cover period time long enough avoid downstream complication",
    "STATISTICS": "statistical analysis interim analysis perform patient enrolment achieve patient control group consider distribution mrs calculate sample patient would yield power detect treatment effect associate consider twosided value plan interim analysis patient obrien fleming scheme increase sample size first interim analysis consider statistically significant value final analysis consider statistically significant value interim analysis also allow stop futility futility bound calculate use brien fleming type beta spending inclusion patient statistic wald test value associate favour placebo group trial terminate futility"
  },
  "TEOREM": {
    "TITLE": "full title multicenter randomize doubleblind clinical trial assess benefit adherent invasive coli eradication adult ileal ileocolonic crohn disease",
    "JUSTIFICATION": "scientific justification current medical treatment crohn disease consist immunosuppressive drug therapy corticosteroid azathioprine methotrexate antitnf monoclonal antibody agent control symptom crohn disease patient withdrawal lead disease relapse also associate serious side effect infection lymphoma cancer liver toxicity antitnf monoclonal antibody efficient cost prohibitive moreover roughly responder antitnf become refractory treatment often become tolerized drug future crohn disease drug small molecule biologics antagonize proinflammatory cytokine gut homing lymphocyte yet similar safety issue immunosuppressive agent currently use current therapeutic algorithm crohn disease take account site inflammation composition intestinal microbiota moreover dysregulated intestinal immunity overproduction proinflammatory cytokine component crohn disease pathophysiology intestinal microbiota abnormal play important role pathogenesis crohn disease coli specie adhesive invasive property adherentinvasive coli describe ileal mucosa patient crohn disease adherent invasive coli find patient ileal crohn disease control role adherent invasive coli crohn disease thoroughly investigate several laboratory around world show adherent invasive coli proinflammatory could play important role intestinal inflammation associate crohn disease may important therapeutic target randomized trial propose novel approach treatment crohn disease individualize patient colonize adherent invasive coli prescribe fdaapproved antibiotic show active bacteria vitro treatment discontinue hope obtain clinical endoscopic remission patient randomize experimental arm trial successful first kind facilitate new era clinical research patient crohn disease concomitant infection adherent invasive coli",
    "OBJECTIVE": "primary objective assessment criterion primary objective trial assess whether treatment ciprofloxacin rifaximin superior placebo obtain endoscopic remission adherent invasive coli colonized patient ileal crohn disease without involvement caecum right colon primary endpoint overall response use centralize anonymous blind reading ileocolonoscopies overall response define segmental response least one segment cdeis baseline increase cdeis segment cdeis segment segmental response segment cdeis baseline define case isolated aphtoid ileitis colitis decrease lesion otherwise either decrease surface ulceration either deep superficial loss deep ulceration present inclusion increase superficial ulcerated surface secondary objective assessment criterion secondary objective cid test correlation endoscopic remission adherent invasive coli eradication cid assess evolution endoscopic lesion cid assess rate clinical remission without steroid antitnf surgery patient whose adherent invasive coli eradicate patient reach primary endpoint cid assess rate biological remission study cid assess side effect experimental placebo group secondary endpoint endoscopic remission assess centralized reading ileocolonoscopies define cdeis segment cid mean variation segmental cdeis centralized reading ileocolonoscopies cid complete endoscopic remission centralized reading ileocolonoscopies define cdeis segment cid ulceration cid clinical remission define cdai without steroid antitnf resection surgery crohn disease cid biological remission defined crp serum level fecal calprotectin cid side effect",
    "DESIGN": "experimental design phase2 clinical trial multicentre prospective randomize doubleblind placebocontrolled adaptive clinical trial two parallel arm cid experimental arm oral ciprofloxacin bid oral rifaximin bid cid control arm placebo ciprofloxacin bid placebo rifaximin bid",
    "INCLUSION CRITERIA": "population involve crohn disease adult patient infect adherent invasive coli preinclusion criterion cid age cid crohn disease ileum without involvement caecum right colon cid severe lesion confine within ileum right colon define segmental cdeis ileum right colon segmental cdeis segment transverse leave colon rectum cid informed consent participate study cid crohn disease either clinically inactive active severe cdai cid patient clinically active disease cdai prescription steroid treatment budesonide prednisone prednisolone independently entry study note patient without previous surgery crohn disease without crohn disease anal lesion without drain fistula seton enrol inclusion criterion cid patients clinically active disease cdai respond budesonide initial dose prednisone prednisolone initial dose point decrease cdai pre inclusion inclusion visit patient clinically inactive disease cdai cid patients colonize adherent invasive coli initial ileal biopsy",
    "EXCLUSION CRITERIA": "nonpreinclusion noninclusion criterion cid ileal stenosis cross endoscope cid infliximab treatment receive less preinclusion study cid methotrexate azathioprine start less three preinclusion cid adalimumab treatment receive less preinclusion study cid vedolizumab treatment receive less preinclusion study cid hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide e171 macrogol cid treatment tizanidine probenecid theophylline xanthine derivatives phenytoin oral anticoagulant ropinirole cid hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide e172 cid previous extensive ileal surgery meter measure pathology surgical report cid short bowel syndrome cid need intestinal resection fistula abscess intestinal obstruction cid renal failure creatinine clearance 73m2 cid liver failure factor cid past history epilepsy cid health insurance cid pregnant lactate woman cid refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective method contraception hormonal contraceptive combine oral contraceptive patch vaginal ring injectables implant intrauterine device iud intrauterine system ius vasectomy tubal ligation effective method barrier method contraception male condom female condom cervical cap diaphragm contraceptive sponge cid patients already include biomedical research observational study registry cohort",
    "INTERVENTION": "treatment test association two antibiotic cid oral ciprofloxacin tablet every hour cid oral rifaximin tablet every hour benchmark treatment association two placebo placebo correspond antibiotic manufacture tablet appearance administrate every hour",
    "STATISTICS": "statistical analysis data analyze intenttotreat basis trial base upon adaptive scheme allow reestimation required number included patient sample size reestimation ssr design take account uncertainty endoscopic remission rate placebo arm thus one interim unblind statistical analysis perform one half patient successively enrol primary endpoint analysis concern comparison main end point ie percentage endoscopic remission group compare use chisquare test unless validity violate fisher exact use secondary endpoint analyze whole sample size reach"
  },
  "SALMA": {
    "TITLE": "full title phase1 ii clinical trial assessing combination sulfasalazine standard care induction therapy newly diagnosed acute myeloid leukemias patients salma study",
    "JUSTIFICATION": "scientific justification nonfavorable acute myeloid leukemia patient unmet medical need acute myeloid leukemia heterogeneous clonal myeloid neoplasm abnormal proliferation impaired differentiation hematopoietic stem myeloid progenitor cell impede normal hematopoiesis despite significant progress make understand acute myeloid leukemias oncogenesis past decade disease remain devastate new case every europe fiveyear overall survival median age diagnosis acute myeloid leukemia cure rate patient improve recent decades standard care newly diagnose acute myeloid leukemia include cytarabine anthracyclin combination follow repeated course high dose cytarabine without allogeneic hematopoietic stem cell transplantation recent advance standard care approach include addition multikinase inhibitor midostaurine induction consolidation patient flt3 gene mutations maintenance oral azacitidine completion induction without consolidation patient ineligible transplantation use liposomal formulation cytarabinedaunorubicin combination instead conventional patient highrisk features patient 60y adequate performance status comorbidities deem fit intensive chemotherapy induction course combine idarubicin continuous cytarabine arac infusion induce complete remission complete remission incomplete platelet recovery case nonfavorable cytogenetics recent advance supportive care patient notably progress antifungal armementarium lower toxicity induction course early date rate within range however despite high complete remission low early date rate median eventfree survival remain patient nonfavorable cytogenetics owe frequent relapses improving antileukemic efficacy induction course contribute good long term prognosis patients however modification induction course must rely additional toxicity limit risk early date jeopardize postremission therapy repositioning drug excellent safety profile appear promising approach regard nonfavorable risk acute myeloid leukemia patient represent unmet medical need novel option improve efficacy induction course thus necessary end induction measurable residual disease predict longterm outcome acute myeloid leukemia patient treat intensively standardization molecular technique development multiparameter flow cytometry assay make possible assess measurable residual disease different time point course acute myeloid leukemia therapy virtually patients patient treat measurable residual disease measure end induction course time point base npm1c transcript npm1mutated patient multiparameter flow cytometry assay leukemia aberrant immunophenotypes laip leukemic stem cell lsc method predict longterm outcome npm1mutated patient young role end induction measurable residual disease assess relative npm1c transcript level also well established although data scarcer patients altogether end induction measurable residual disease appear relevant surrogate endpoint estimate efficacy alternative induction regimen acute myeloid leukemia patient non favorable cytogenetics cystine import targetable vulnerability acute myeloid leukemia metabolic rewiring leukemic cell increasingly recognize targetable vulnerability acute myeloid leukemia leukemic stem cells endow increased quiescence chemoresistance specific metabolic profile may instance underpin remarkable efficacy azacitidinevenetoclax combination patient ineligible leukemic stem cell notably rely high level cysteine amino acid fuel glutathione synthesis maintain low level reactive oxygen species chemical depletion intracellular pool cysteine precursor cystine preclinical antileukemic activity vitro query transcriptional profile multiple acute myeloid leukemia patient cohort identify close correlation expression stemness program active cysteine metabolism pathway querying crispr screen conduct cancer cell line reveal specific dependence acute myeloid leukemia cell line cysteine metabolism among gene belong pathway high expression slc7a11 identify bear poor prognostic relevance acute myeloid leukemia cohort genetic silencing slc7a11 reduce viability colony formation acute myeloid leukemia cell line cysteine dependent fashion slc7a11 encode xct neutral amino acid antiporter import cystine glutamate xct antiport broadly express acute myeloid leukemia cell line three chemical inhibitor xct different chemical backbone include erastin s4 carboxyphenylglycine sulfasalazine highly concordant cystinedependent anti leukemic activity panel acute myeloid leukemia cell line data suggest cystine import could represent targetable vulnerability acute myeloid leukemia sulfasalazine repurposed inhibit cystine import acute myeloid leukemia sulfasalazine broadly available well tolerate antiinflammatory medicine approve treatment ulcerative colitis rheumatoid arthritis intact sulfasalazine metabolite 5aminosalicylic acid sulfapyridine competitively inhibit xct sulfasalazine thus ideal candidate drug repurposing acute myeloid leukemia vitro sulfasalazine inhibit viability primary acute myeloid leukemia specimen 10fold increase sensitivity compare cd34 hematopoietic stem progenitor cell heathly donor sulfasalazine ic50 acute myeloid leukemias 176m 40m versus healthy cd34 cell sulfasalazine 250m concentration range peak plasma concentration sulfasalazine healthy individuals also significantly reduce vitro longterm culture initiate potential primary acute myeloid leukemia sample finally twicedaily intraperitoneal administration single agent sulfasalazine significantly reduce leukemic burden two distinct acute myeloid leukemias patientderived xenograft model finally compassionate administration oral sulfasalazine period patient advanced refractory acute myeloid leukemia result transient clinically meaningful cytoreduction mechanistic study find sulfasalazine induce global metabolic rewiring cysteine onecarbon pathway result glutathione depletion reactive oxygen specie dependent cell death partly correspond ferroptosis total protein expression slc7a11 correlate sulfasalazine activity thus sulfasalazine repurposed inhibit cystine import impair leukemic viability acute myeloid leukemia sulfasalazine improve efficacy anthracycline cytarabine combination chemotherapy preclinical acute myeloid leukemia model two distinct acute myeloid leukemia cell line anthracycline daunorubicin identify among panel acute myeloid leukemia drug one top synergism combine sulfasalazine observation may underpin reactive oxygen specie inducing potential anthracyclins cohort primary acute myeloid leukemia sample addition sulfasalazine low concentration mimic trough concentration healthy donors significantly increase antileukemic activity combination daunorubicin arac total leukemic bulk gpr56 leukemic stem cell nichelike ex vivo drug screen platform combine stromal coculture hypoxia plasmalike medium finally addition sulfasalazine regimen combine anthracycline adriamycin cytarabine maximally tolerate regimen immunocompromised nogexl mouse far decrease leukemic burden patient derive xenografts model significantly prolong survival adriamycincytarabine chemotherapy alone pardieu et al manuscript preparation data present annual meeting european hematology association data support clinical evaluation addition sulfasalazine acute myeloid leukemia addition sulfasalazine standard care chemotherapy manageable repurposing sulfasalazine inhibit xct investigate alone standard care chemotherapy solid tumors first study conduct singleagent sulfasalazine highly debilitated patient high grade progress glioblastoma terminate prematurely base lack efficacy trial toxicity sulfasalazine low dos mostly neurological suggestive tumorspecific poor tolerability possibly cause drug related peritumoral edema conversely another doseescalation study single agent sulfasalazine patient advanced gastric cancer identify maximal tolerate dose grade3 anorexia dose limit toxicity grade3 aes include elevate ast bilirubin fatigue nausea vomit hyponatremia grade3 hematological grade4 non hematological adverse event trial median number sulfasalazine cycle range mean relative dose intensity dose level maximal tolerate dose finally phase1 study combine sulfasalazine thrice daily cisplatin pemetrexed sulfasalazine cycle conduct patient advanced nonsmallcell lung cancer maximal tolerate dose recommended phase2 dose rp2d dose limit toxicity include grade3 elevation ast alt aminotransferase level hypotension pneumonitis anorexia overall combination appear manageable promise activity note term overall response rate progressionfree survival compare historical controls antitumor activity sulfasalazine continue explore solid tumor nct nct04205357 overall addition sulfasalazine chemotherapy appear feasible carefully design dose escalation phase1 trial collectively preclinical finding provide strong rationale clinical evaluation addition sulfasalazine standard care induction regimen nonfavorable acute myeloid leukemia patient purpose phase1 study evaluate safety feasibility strategy provide preliminary signal efficacy identify potential biomarkers",
    "OBJECTIVE": "main objective primary endpoint primary objective phase1 assess safety characterize doselimiting toxicity identify maximal tolerate dose anticipate recommended phase2 dose rp2d combination sulfasalazine idarubicin cytarabine arac patient newly diagnose nonfavorable acute myeloid leukemia probability dose limit toxicity exceed end induction cycle idarubicin arac sulfasalazine treatment phase2 assess preliminarily antileukemia efficacy combination idarubicin arac sulfasalazine mainly phase2 newly diagnose nonfavorable acute myeloid leukemia reference historical data complete remission rate define eln guideline measurable residual disease centralize flow cytometry primary endpoint phase1 documentation dose escalation dose limit toxicity identification maximal tolerate dose anticipate recommended phase2 dose rp2d dose limiting toxicity dose limit toxicity define safety observation period correspond induction cycle idarubicin arac sulfasalazine events occur onset second treatment cycle salvage consolidation consider dose limit toxicity following event consider dose limiting toxicity unless event attribute investigator clearly identifiable cause underlying illness disease progression concurrent illness concomitant medication prolonged myelosuppression define grade3 neutropenia thrombocytopenia start therapy later without evidence leukemia assess bone marrow aspiration biopsy grade3 hemorrhage grade3 non hematological toxicity exception grade3 infection grade3 fever neutropenia nb grade4 infection grade4 fever neutropenia consider dose limit toxicity grade3 nausea vomit diarrhea manage grade2 within hour symptomatic treatment grade3 asymptomatic liver enzymes elevation improve grade2 within hour onset grade3 tumor lysis syndrome resolve within hour onset medical treatment maximal tolerated dose maximal tolerate dose define target dose limiting toxicity rate assess dose escalation phase continual reassessment method recommended phase2 dose rp2d rp2d anticipate maximal tolerate dose however could equal one dose level low maximal tolerate dose determine interaction data safety monitor board insofar dose level validate pharmacokinetics pharmacodynamics study efficacy preliminary data phase2 measurable residual disease negative complete response end induction per eln criteria complete response define complete remission complete remission cri complete remission incomplete hematologic recovery mean complete remission platelet count absolute neutrophil count crh complete remission partial hematologic recovery mean complete remission fulfil complete remission cri peripheral blood count criterion platelet count absolute neutrophil count measurable residual disease negativity define 8color bone marrow fcm measurable residual disease end induction note npm1transcript base measurable residual disease bm pb carry exploratory endpoint npm1mutated patient secondary objective endpoint secondary objective characterize pharmacokinetics pharmacodynamics sulfasalazine idarubicin arac administer combination dose escalation phase 1a confirm phase2 trial describe phase1 trial response leukemia treatment survival patient end induction visit document far phase2 trial safety profile confirm rp2d idarubicin arac sulfasalazine combination secondary endpoint assessment safety safety outcome measure assess continuously study monitoring ecgs clinical laboratory value integral safety assessment adverse event treatment emergent adverse event treatmentrelated teaes evaluate accord nci ctcae version serious adverse event define per protocol accord ema ich criterion causality relationship experimental treatment assess investigator frequency duration maximal severity treatment emergent adverse event treatmentrelated teaes teaes lead treatment discontinuation serious adverse event death document phase1 ii trial patients follow treatment relate teaes return grade1 baseline deem irreversible investigator pharmacokinetics assess sulfasalazine metabolite idarubicin metabolite arac allow determine pharmacokinetics model sulfasalazine early late time point confirm lack interaction sulfasalazine idarubicin arac pharmacokinetics plan detail section pharmacokinetic study conduct patient recruit phase1 part trial assess pharmacokinetics sulfasalazine main metabolite asa mesalazine sulfapyridine mostly involve adverse event pharmacokinetics perform pharmacokinetics profiling cytarabine idarubicine idarubicinol confirm lack drugdrug interaction following pharmacokinetics parameter determine use non compartmental analysis winnonlin pharsight corporation maximum plasma concentration cmax maximum plasma concentration time tmax area plasma concentration time curve auc clearance mean residence time distribution volume vd pharmacokinetic analysis dose sulfasalazine administer orally together water patient fast overnight meal permit blood sampling drug give blood sample obtain predose 8h first sulfasalazine dose predose 1h 24h start idarubicin injection predose 6h first sulfasalazine dose blood sample collect heparinized tube immediately collection tube invert several time keep approximately centrifugation tube centrifuge within collection separate plasma plasma separate aliquot polypropylene screwcap tube place 80c analysis sample label patient identification study identification sample number actual date time sample collect plasma concentration sulfasalazine metabolite determine validated ultraperformance liquid chromatography tandem mass spectrometry method pharmacodynamics pharmacodynamic assay aim demonstrate reactive oxygen specie induction upon sulfasalazine exposure relative pretreatment level peripheral blood repeat bone marrow aspiration shorttime period unethical blood sample pharmacodynamics effect sulfasalazine alone combined effect sulfasalazine idarubicin arac pharmacodynamics assay include plasma level malondialdehyde glutathione reduced oxidized two robust biomarkers oxidative stress biomarkers previously involve ferroptosis sulfasalazine mode action preclinical result assess patient time point regardless white blood cell count percentage circulate leukemic cell patient circulate leukemic cell reactive oxygen specie level peripheral blood mononuclear cell flow cytometry h2dcfda antileukemia activity response end induction assessment per eln criteria morphologic leukemiafree state blastic criterion response bone marrow aspirate absence extramedullary disease requirement hematologic recovery partial response absence circulate blast absence extramedullary disease decrease bone marrow blast percentage decrease pretreatment bone marrow blast percentage least overall response rate define complete remission cri crh morphologic leukemia free state partial response rate primary refractory disease define patient lack criterion define response complete remission cri crh morphologic leukemia free state partial response end induction assessment exclude patient death aplasia death due indeterminate cause define per eln criterion death aplasia death due indeterminate cause define per eln criterion survival assessment eventfree survival event define non achievement hematologic response include complete remission cri crh hematologic relapse progressive disease initiation subsequent antileukemic therapy exclude hydroxyurea deaths prior one event mention reasons subsequent therapy initiation include intolerance resistance hematologic relapse unsatisfactory measurable residual disease evolution type intensive lessintensive best supportive care frame clinical trial offlabel compassionate use prospectively record duration response relapse free survival overall survival incidence subsequent allogeneic hematopoietic stem cell transplantation overall respond patient specifically apart specific mention hematological endpoint define accord late recommendation european leukemia network eln currently eln recommendation",
    "DESIGN": "design study phase3 open label multicenter clinical trial subsequent phase phase1 doseescalation design use survival continual reassessment method identify maximal tolerate dose recommend phase2 dose rp2d phase2 extension rp2d choose data safety monitoring board confirm safety rp2d preliminarily document clinical efficacy",
    "INCLUSION CRITERIA": "population study participant patients recently diagnose non favorable acute myeloid leukemia eligible intensive chemotherapy inclusion criterion patients age newly diagnose acute myeloid leukemia short course treatment hydroxyurea steroid acceptable patients acute myeloid leukemia secondary antecedent myelodysplastic syndrome mds myeloproliferative neoplasm mpn eligible therapyrelated acute myeloid leukemia eligible intensive chemotherapy accord investigator opinion multiparameter flow cytometry screen compatible multiparameter flow cytometry based measurable residual disease monitor accord eln criterion phase2 ecog performance status ast alt upper limit normal total direct serum bilirubin upper limit normal unless consider due leukemia estimated glomerular filtration rate accord mdrd equation written inform consent obtain prior screening procedure eligible national health insurance france",
    "EXCLUSION CRITERIA": "exclusion criterion myeloid sarcoma bone marrow blast patient receive vaccine injection live attenuated virus last three proven central nervous system leukemic involvement favorable risk cytogenetics inv pmlrara runx1runx1t1 cbfb myh11 fusion transcript presence flt3itd tkd mandate treatment midostaurin concurrent therapy cytotoxic drug within first study dose hydroxyurea control blood count permit patients plan receive cpx351 myelodysplasiarelated change therapyrelated acute myeloid leukemia previous treatment sulfasalazine last ongoing treatment sulfasalazine aminosalicylic acid 5asa ulcerative colitis inflammatory rheumatism history allergic reaction sulfonylarylamines sulfonamide salicylate sulfasalazine excipients history allergic reaction idarubicin idarubicin excipients history allergic reaction cytarabine cytarabine excipients known glucose 6phosphate dehydrogenase deficiency known acute intermittent porphyria porphyria variegata uncontrolled systemic fungal bacterial viral infection define ongoing signs symptoms relate infection without improvement despite appropriate treatment uncontrolled active malignant disease within prior exclude myelodysplastic syndrome cutaneous basal cell carcinoma insitu carcinoma cervix breast local malignancy excise known human immunodeficiency virus infection human immunodeficiency virus related malignancy clinically active hepatitis hepatitis infection inability swallow known malabsorption syndrome condition may significantly impair absorption oral study medication participation another therapeutic interventional clinical study within enrolment administration therapy consider investigational use nonapproved indication context research investigation within drug halflives whichever longer prior first dose study drug previous treatment anthracyclines contraindication use anthracyclines include uncontrolled coronary disease severe renal failure severe hepatic failure recent myocardial infarction symptomatic congestive heart failure severe cardiomyopathy significant arrhythmia estimate investigator lvef assess echocardiography muga anterior treatment idarubicin anthracyclines anthracenediones beyond maximum cumulative dose contraindication use cytarabine include degenerative toxic encephalopathy condition require treatment digoxin concurrent severe uncontrolled medical condition could compromise participation study females pregnant breastfeeding man whose sexual partner woman childbearing potential unwillingness inability man woman use highly effective contraceptive method entire treatment period least completion protocol treatment highly effective contraception method include combine estrogen progestogen containing hormonal method associate inhibition ovulation intrauterine device surgical sterilization include bilateral tubal occlusion partner vasectomy sexual abstinence preferred usual lifestyle patient male patient must freeze donate sperm start screening throughout treatment period administration final dose study medication heterosexually active woman childbearing potential unwillingness inability use highly effective contraceptive method describe entire treatment period least administration final dose study medication women regard childbearing potential postmenopausal least without menses surgically sterile least enrollment female patient must donate retrieve use ovum time screening throughout treatment period administration final dose study medication female patient must agree breastfeed time screening throughout protocol period life administration final dose study medication adults subject legal protection order unable give consent persons deprive freedom judicial administrative decision person hospitalize without consent virtue article l3213 subject provision article",
    "INTERVENTION": "investigational medicinal product auxiliairy medicinal product investigational medicinal product sulfasalazine approve market treatment inflammatory disease tablets dose oral route water follow dose level test phase1 dose level bid hence dose level tid hence dl1 tid hence dl2 tid hence dl3 tid hence dl4 tid hence dl5 four time per hence dose level patient receive standard care idarubicin arac backbone consider auxiliary medicinal product clinical trial consist drug dose administration days time idarubicin iv 30mn cytarabine civ 24h two drug body area cap dose escalation conduct accord survival continual reassessment method number patient assess dose level depend safety observation patients hospitalize induction course least achievement neutrophil count thereafter discharge accord judgment investigator medical condition allow nonhematological treatmentemergent aes resolve grade2 patients adequate iv hydration sulfasalazine exposure following end induction visit patient continue follow treatment relate teaes follow end sulfasalazine exposure postinduction therapy relapse survival end induction visit treatments beyond end induction leave clinician choice may include consolidation chemotherapy oral maintenance allogeneic stem cell transplantation alfa guideline postremission therapy acute myeloid leukemia patient treat intensively provide protocol appendices minimal followup transplantation relapse death additional study exit undertake comparator treatment none",
    "STATISTICS": "statistical analysis phase1 bayesian adaptive dose escalation design use trial objective allow sequential monitoring data trial use current evidence straightforward inference safety efficacy decision making select evaluate optimal dose design rely bayesian continual reassessment method phase1 cohort size maximum sample size patients target dose limiting toxicity rate definition maximal tolerate dose within end induction observation window timetoevent extension continual reassessment method survcrm design use depend anticipated accrual rate compare dose limit toxicity observation window allow accounting rightcensored toxicity observation sequential maximal tolerate dose estimation dose assignment process phase2 phase1 complete provide estimate maximal tolerate dose rp2d determine base data safety monitor board recommendation accord safety data efficacy signal phase1 inclusion criterion phase1 addition additional inclusion criterion laip detect baseline fcm assessment relate primary endpoint complete response negative measurable residual disease based historical data rate measurable residual disease negative complete response study population estimate british aml16 data spanish pethema data british aml17 data freeman pers comm simon minimax twostage design use phase simon optimal twostage designs phase2 clinical trials controlled clinical trials phase2 assessment require maximum total subject decide whether proportion responding less equal great equal first stage among first included patient number response low equal r1 phase2 stop early futility otherwise r1 enrollment continue maximum patient overall number response become hypothesis reject target type1 error rate total number response less hypothesis reject target type2 error rate note phase1 patient treat rp2d choice include analysis assessable fcm measurable residual disease presence laip"
  },
  "ERYTHROSIM": {
    "TITLE": "full title randomized prospective trial evaluate efficacy anticd38 monoclonal antibody isatuximab treatment pcra major abo mismatch allogeneic hematopoietic stem cell transplantation",
    "JUSTIFICATION": "scientific justification quarter allogeneic hematopoietic stem cell transplantation perform situation major abo mismatch expose patient risk immunological pure red cell aplasia transplant pcra transplant define anemia low reticulocyte count despite good leucocyte platelet engraftment full donor chimerism associate persistence recipient hemagglutinins antia antib antibody bone marrow evaluation perform show erythroid hypoplasia red blood cell transfusion necessary every two remission lead impaired quality life anemia repeat hospitalization iron overload need iron chelation therapy treatments currently use inefficient anti cd20 monoclonal antibody epo steroid plasma exchange proteasome inhibitor risk severe acute gvhd donor lymphocytes infusion pure red cell aplasia demonstrate associate persistence recipient plasma cell anticd38 monoclonal antibody target plasma cell secrete hemagglutinins responsible pcra promising treatment case report literature support rapid sustain efficacy chapuy nejm bathini amjhematol rautenberg bmt salas et al eur haematol preethi et al blood cell mol dis yates et al transfusion prospective randomized evaluation efficacy safety context necessary",
    "OBJECTIVE": "main objective primary endpoint main objective efficacy treatment pure red cell aplasia isatuximab allogeneic hematopoietic stem cell transplant compare supportive care control group reduction pure red cell aplasia resolution time primary endpoint time obtention transfusion independence patient pure red cell aplasia time interval randomization correspond posttransplant resolution pure red cell aplasia date resolution reticulocytopenia treat anticd monoclonal antibody isatuximab secondary objective endpoint secondary objective evaluate two arm term clinical biological outcome reduction red blood cell transfusion need isatuximab evolution iron overload adverse event relate isatuximab context allogeneic sct ctcae grade2 group posttransplant quality life functional repercussion chronic anemia iterative transfusion iron overload randomization overall survival without relapse posttransplant identify prognostic factor spontaneous resolution pure red cell aplasia major abo mismatch type donor cell stem cell condition regimen occurrence acute chronic graft versus host disease discontinuation immunosuppression evaluate interest followup group hemagglutinins compare arm term ofcost effectiveness cost isatuximab treatment hospitalization transfusion support chelation treatment secondary endpoints number red blood cell transfusion randomization ferritin level posttransplant adverse event ctcae grade2 randomization quality life questionnaire eortc qlqc30 v3 posttransplant factors associate spontaneous resolution pure red cell aplasia posttransplant antibody level anti anti titer posttransplant visit post randomization number hospitalization transfusion support chelation treatment",
    "DESIGN": "design study randomized prospective phase2 clinical trial assess efficacy safety anticd38 antibody isatuximab patient persistent pure red cell aplasia allogeneic hsct including patient transplant help define factor associate unresolved pure red cell aplasia thus identify patient could benefit isatuximab treatment earlier future interim analysis perform observation event primary endpoint trial",
    "INCLUSION CRITERIA": "population study participant allogeneic stem cell transplant recipient age pure red cell aplasia inclusion criterion patients aged receive allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra define persistent red blood cell transfusion dependence posttransplant reticulocyte count despite full donor chimerism good leucocyte platelet recovery relapse progression underlie disease contraception method must prescribe duration clinical trial use effective contraceptive method treatment woman childbearing age continue abstinence heterosexual intercourse accept man study treatment period least last dose study treatment refrain donate sperm period health insurance coverage sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "exclusion criterion patients aged relapse underlie disease leucocyte chimerism pure red cell aplasia relate parvovirus b19 infection positive blood pcr known hiv hepatitis active infection active tuberculosis pregnancy hcg positive breastfeeding patient receive recombinant human erythropoietin patient receive proteasome inhibitor bortezomib example patient receive thrombopoietin receptor agonist artpo patient receive plasma plasmapheresis exchange transplant planned receive investigational drug within halflives investigational drug whichever long clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result hypersensitivity active substance history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer sucrose component study therapy amenable premedication steroid h2 blocker would prohibit treatment agent debilitating medical psychiatric illness tutorship curatorship understand informed consent optimal treatment followup",
    "INTERVENTION": "experimental treatment isatuximab treatment dose intravenous route first injection isatuximab perform randomization second injection may perform 2d reticulocyte third 2d reticulocyte patients assess randomization",
    "STATISTICS": "statistical analysis bilateral logrank test consider sample size randomized patient experimental group median transfusion independence h1 control group median transfusion independence h1 achieve power alpha risk considering patient include randomize patient include interim analysis perform observation event primary endpoint trial"
  },
  "EQUAALL01": {
    "TITLE": "full title evaluation longterm health status quality life adult survivor philadelphianegative acute lymphoblastic leukemia lymphoma treat intensive pediatric pediatricinspiredinspired protocol",
    "JUSTIFICATION": "scientific justification overall survival adult patient 1559y philadelphia negative acute lymphoblastic leukemia lymphoma dramatically improve use full pediatric pediatric inspired protocol graall2003 05ll03fralle2000 aim reduce risk relapse adopt intensive chemotherapeutical schedule approach lead global improvement overall survival 5yos whatever patient age responsible excess treatmentrelated mortality patient 5ytrm patient 45y pediatric longitudinal study point long term leukemia survivor increase risk develop specific adverse event like dysmetabolic syndrome obesity decrease fertility organ dysfunction osseous event impaired cognitive function study aim evaluate impact term longterm event qol adult patient receive intensified therapeutic approach recently implement adult cooperative group",
    "OBJECTIVE": "main objective primary endpoint evaluate prevalence late effect adult patient treat ago intensified pediatric inspire protocol graall2003 05ll03fralle2000 expose patient increase cumulative dos chemotherapy central nervous system irradiation allogeneic transplant total body irradiationbased regimen boost irradiation central nevous system primary endpoint thus define prevalence adverse event include metabolic trouble dysmetabolic syndrome dyslipidemia diabetes osseous event osteoporosis cardiac vascular trouble neurologic trouble lung dysfunction endocrinal trouble ophthalmological trouble fertility disorder secondary neoplasia secondary objective endpoint evaluate quality life patient correlate prevalence late effect qol status previous social situation previous medical condition treatment scheme include administration protocol phase delayed intensification maintenance centralnervous system irradiation allogeneic sct graftversus host disease occurrence elaborate riskadapted recommendation longterm followup adult patient treat reinforce therapeutic strategy secondary endpoint thus prevalence metabolic trouble dysmetabolic syndrome dyslipidemia diabetes prevalence osseous event osteoporosis prevalence cardiac vascular trouble prevalence neurologic trouble prevalence lung dysfunction prevalence endocrinal trouble quality life sf36 prevalence ophthalmological trouble prevalence fertility disorder prevalence secondary neoplasia",
    "DESIGN": "design study multicenter crosssectional interventional minimal risk constraint human research study",
    "INCLUSION CRITERIA": "population study participant adult patient age 1559y diagnosis treat ten ago ph1negative acute lymphoblastic leukemia lymphoma inclusion criterion patient philadelphianegative treat accord pediatriclike pediatricinspired protocol graall fralle without allogeneic transplant patients less diagnosis patient followup first complete remission patient give inform signed consent baseline examination",
    "EXCLUSION CRITERIA": "exclusion criterion patient experience relapse within past philadelphia positive patient",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis analysis handle left data truncation give patient survive able include study approximately patient include graall2003 among august considering patient alive last followup opportunity include patient treated accord protocol inclusion success approximately patient recruit allow assess prevalence trouble ci width assume prevalence assume prevalence detection respectively also allow reach statistical power least detecting"
  },
  "EFRAIM-II": {
    "TITLE": "full title empirical steroid antifungal immunocompromised patient acute respiratory failure undetermined etiology multicenter doubleblind randomize control trial",
    "JUSTIFICATION": "scientific justification acute respiratory failure lead reason icu admission immunocompromised patient failure identify acute respiratory failure etiology associate increased mechanical ventilation mortality rate confirm large efraim study publish undetermined acute respiratory failure etiology affect patient patient patient overall associate case fatality versus patient lung biopsy autopsy finding patient invasive fungal infection steroid sensitive affection organize pneumonia non infectious interstitial involvement drugrelated pulmonary toxicity lung infiltration underlying disease lymphoma carcinomatous lymphangitis systemic vasculitis connective tissue disease etc lead etiology study evaluate survival benefit empirical steroid antifungal immunocompromised patient acute respiratory failure undetermined etiology",
    "OBJECTIVE": "main objective primary endpoint main objective reduce mortality immunocompromised patient acute respiratory failure undetermined etiology day3 intervention would evaluate impact steroid isavuconazole icu discharge primary endpoint mortality secondary objective endpoint secondary study objective evaluate early empirical therapy affect icu hospital day28 mortality whether steroid increase proportion patient icu acquire microbiologically document bacterial infection within follow randomization proportion patient invasive fungal infection within follow randomization proportion patient hsv vzv cmv reactivation within follow randomization whether steroid complicate severe hypokalemia meq newly acquire decompensated diabetes severe newly acquire hypertension whether isavuconazole favor emergence infection aspergillus mucorale specie decreased sensitivity isavuconazole occurrence candida infection steroid affect psychiatric symptom posttraumatic stress disorder anxiety depression early intervention improve quality life secondary end point icu mortality hospital mortality mortality proportion patient icu acquire microbiologically document bacterial infection proportion patient invasive fungal infection within follow randomization proportion patient hsv vzv cmv reactivation within follow randomization occurrence severe hypokalemia meq decompensated diabetes severe newly acquire hypertension emergence aspergillus specie decreased sensitivity isavuconazole incidence candida infection incidence posttraumatic stress disorder iesr anxiety depression hads quality life sf36",
    "DESIGN": "design study multicenter doubleblind randomize controlled trial base factorial design",
    "INCLUSION CRITERIA": "population study participant immunecompromised patient acute respiratory failure undetermined etiology either intervention steroids antifungal associate improved day90 survival acute respiratory failure lead reason icu admission immunocompromised patient admission inclusion criterion age immunosuppressive drug solid organ transplant solid tumor hematological malignancy primary immune deficiency icu admission acute respiratory failure define respiratory distress tachypnea respiratory rate cyanosis labour breathing need 6l standard oxygen maintain spo2 high flow oxygen noninvasive invasive mechanical ventilation establish acute respiratory failure etiology hour hospital admission patient admit least hour hospital informed consent sign patient informed consent sign family members trustworthy person condition allow express consent write per situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent note patient pneumocystis pneumonia include give treatment require use neither antifungal drug corticosteroid",
    "EXCLUSION CRITERIA": "exclusion criterion patient improve enough discharge icu inclusion documented invasive fungal infection require antifungal therapy patient need receive prophylactic empirical antifungal treatment clinical care patient receive corticoid therapy palliative care comfort measure intubate resuscitate patient include pregnant breastfeeding social security coverage known hypersensitivity isavuconazole excipients cresemba specialty treatment ketoconazole ritonavir cyp3a4 inductor short qt syndrome patient family history short qt syndrome liver insufficiency stage moribund patient participation another interventional research acute respiratory failure person deprive liberty person subject psychiatric care patient enforced hospitalization adults legal protection unable give consent isolated hi",
    "INTERVENTION": "investigational medicinal product methylprednisolone give dose three recommend fibrosing pneumonitis deeply hypoxemic patient daily dose taper follow isavuconazole give dose every hour administration daily icu discharge event occur first patients one arm receive isavuconazole methylprednisolone whith establish interaction investigator must check smpc need information available comparator treatment placebo methylprednisolone placebo isavuconazole",
    "STATISTICS": "statistical analysis interim analysis perform recruitment patient day90 death whichever occur first"
  },
  "RECORDS": {
    "TITLE": "title rapid recognition corticosteroid resistant sensitive sepsis",
    "JUSTIFICATION": "background world health organization estimate yearly million people develop sepsis 11million die aprocchs phase3 placebocontrolled trial demonstrate absolute reduction sepsis mortality hydrocortisone fludrocortisone number factor may positively negatively impact corticosteroid cs benefit sepsis",
    "OBJECTIVE": "main objective primary endpoint compare effect hydrocortisone plus fludrocortisone versus placebo composite death persistent organ dysfunction define continued dependency mechanical ventilation new renal replacement therapy vasopressor assess intensive care unit adult different biological profile immune response corticosteroid bioactivity primary endpoint death persistent organ dysfunction define continued dependency mechanical ventilation renal replacement therapy vasopressor score sequential organ failure assessment score score secondary objective endpoint mortality healthrelated quality life daily organ function score sequential organ failure assessment score score daily secondary infection daily blood urinary level glucose sodium potassium daily gastroduodenal bleeding daily cognitive function muscle strength",
    "DESIGN": "study design multiarms parallel blind randomize control trial precede runin observational period observational phase runin period interventional phase",
    "INCLUSION CRITERIA": "inclusion criteria observational phase n1 interventional phase n1 patients admitted intensive care unit proven suspected infection main diagnosis community acquire pneumonia relate sepsis vasopressor dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer vasopressor maintain mean blood pressure least mmhg lactate level mmol acute respiratory distress syndrome ards ranieri acute onset within one apparent clinical insult progression respiratory syndrome bilateral opacity chest image explain pulmonary pathology pleural effusion atelectasis nodule etc evidence heart failure volume overload pao2 fio2 hg peep h2o patient world health organization sign informed write consent whevener able consent ascent representant whenever present time screen inclusion patients world health organization test one records specific biomarkers circi endocan gilz dualspecificity phosphatase monocyte distribution width lymphopenia transcriptomic srs2 endotype pcr covid19 pcr influenza pcr respiratory virus cutaneous vasoconstrictor response glucocorticoids affiliation social security system universal health coverage couverture maladie universelle couverture maladie universelle patients guardianship curatorship include patients case simple emergency legal definition include patients manage covid biological sample available",
    "EXCLUSION CRITERIA": "exclusion criteria observational phase n1 interventional phase pregnancy expected death withdrawal lifesustaining treatment within hour previously enrol study formal indication corticosteroid accord recent international guideline vaccination live virus within past hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients spc women childbearing potential use contraception nursing woman patient include stratum applicable apply cream infect ulcerated area",
    "INTERVENTION": "study intervention observational phase runin period additional biological sample restrospective part covid patient telephone followup interventional phase investigational product placebo administer patient basis records signatures investigational product include hydrocortisone hemisuccinate one intravenous injection every hour alpha fludrocortisone one tablet per via nasogastric tube treatment stop patient leave intensive care unit whichever occurs first without taper",
    "STATISTICS": "sample size enroll total patient adaptative trial sites expect enroll least 1or patient per enrol evaluable patient per arm study power detect absolute risk reduction correspond relative risk reduction"
  },
  "KAPKEY": {
    "TITLE": "full title phase2 multicentric study pembrolizumab classic endemic kaposis sarcoma",
    "JUSTIFICATION": "scientific justification classic endemic kaposis sarcoma lymphangioproliferations associate human herpes virus hhv8 treatment poorly codify chemotherapies give best transient response interferon response frequent drug often poorly tolerate elderly patient therefore new therapy need classic kaposi sarcoma represent ideal model evaluate new drug since patient receive concomitant immunosuppressive regimen antiviral therapy pembrolizumab antipd1 monoclonal antibody recently show improve survival several solid tumor kaposi sarcoma data available role pd1pdl1 axis significant pdl1 expression hhv8associated pleural effusion lymphoma kaposi sarcoma sample recently report experience classical endemic kaposi sarcoma support role pathway expression pdl1 subpopulation cell also nk cell peripheral blood cell patient expression pdl1 tumor cell kaposi sarcoma lesion study evaluate benefit safety profile pembrolizumab classic endemic kaposi sarcoma",
    "OBJECTIVE": "primary objective assessment criterion simons 2stage optimal design main objective assess whether pembrolizumab clinically inactive partial complete response probability truly active partial complete response probability classic endemic kaposis sarcoma use simons stage optimal design primary endpoint best overall response rate define occurrence complete response partial response follow actg criterion record start treatment beginning specific systemic therapy kaposi sarcoma occur extension phase event truly active conclusion simon 2step optimal design extension phase would perform evaluate element extension phase would perform far evaluate efficacy pembrolizumab setting additional patient include obtain accurate estimate treatment effect primary endpoint extension phase best overall response rate accord actg criterion record start treatment start kaposi sarcoma specific systemic therapy occur secondary objective assessment criterion secondary objective simons stage optimal design extension stage assess safety profile pembrolizumab classic endemic kaposis sarcoma characterize efficacy pembrolizumab relate pharmacodynamics assessment secondary endpoint efficacy endpoint different aspect clinical response evaluate best overall response rate accord pga criterion beginning specific systemic therapy kaposi sarcoma occur response rate accord actg pga criterion response rate number lesion best response define follow pga response rate size target lesion atbest response define follow pga response rate tumor infiltration target lesion andmonth best response define follow pga response rate lymphedema circumference scale absence painful ooze best response define follow pga time response define time first response record start treatment time progression define time start treatment progression patient response rate accord actg pga criterion extension stage duration response define time start response progression patient achieve partial complete response quality life follow qlc30 dlqi kaposi baseline cycle cycle cycle every eot early study termination safety endpoint safety assess term drug toxicity evaluate clinic laboratory parameter score accord common terminology criteria adverse events version study",
    "DESIGN": "experimental design uncontrolled openlabel multicentric phase2 study",
    "INCLUSION CRITERIA": "population involve adult classic endemic kaposis sarcoma inclusion criterion patient meet following criterion may include study simons 2stage optimal design extension stage classic endemic histologically confirm kaposi sarcoma progressive disease kaposi sarcoma lesion involve one limb segment involvement body surface kaposi sarcoma least lesion kaposi sarcoma least cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion least washout kaposi sarcoma specific therapy include chemotherapy immunotherapy provide write informed consent prior performance study specific procedure age sign informed consent performance status ecog performance scale demonstrate adequate organ function hematological absolute neutrophil count platelets hemoglobin dl renal calculated creatinine clearance use mdrd formula hepatic ast sgot alt sgpt 5xuln serum total bilirubin 5xuln direct bilirubin uln participant total bilirubin level 5xuln female subject childbearing potential negative serum pregnancy within hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "noninclusion criterion patient meet following criterion must include study simons 2stage optimal design extension stage know history organ transplantation receive systemic steroid therapy form immunosuppressive therapy within prior first dose trial treatment kaposi sarcoma symptomatic visceral involvement unless therapeutic option available previously receive treatment antipd1 antipd l1 antipdl2 antictla4 antibody antibody drug specifically target tcell costimulation immune checkpoint pathway uncontrolled infection hiv hbv hcv infection diagnosis immunodeficiency relate result chronic infection patients known hepatitis hepbsag control infection serum hepatitis virus dna pcr limit detection receive antiviral therapy hepatitis permit patients controlled infection must undergo periodic monitoring hbv dna per local standard must remain antiviral therapy least beyond last dose investigational study drug patients know hcv ab control infection undetectable hcv rna pcr either spontaneously response successful prior course antihcv therapy permit active infection require systemic therapy hypersensitivity pembrolizumab keytruda excipients prior anticancer monoclonal antibody mab within last recover grade1 selection adverse event due agent administer earlier prior chemotherapy target small molecule therapy radiation therapy within half life prior study recover grade1 selection adverse event due previously administer agent note participant grade2 neuropathy exception criterion may qualify study note subject receive major surgery must recover adequately toxicity complication intervention prior start therapy know additional malignancy progress require active treatment exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer active autoimmune disease require systemic treatment past use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type1 diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enroll active noninfectious pneumonitis know history noninfectious pneumonitis require steroid severe pulmonary disease hypoxia know psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial willing use adequate contraceptive method study visit throughout study period last dose study therapy receive live vaccine within prior first dose trial treatment participate trial currently participate participate study investigational agent within first dose treatment history current evidence condition therapy laboratory abnormality might confound result trial interfere subject participation full duration trial best interest subject participate opinion treating investigator patient guardianship curatorship",
    "INTERVENTION": "investigational medicinal product simons 2stage optimal design phase development phase2 treatment pembrolizumab route intraveinous infusion dose regimen per infusion every duration treatment cycle extension stage phase development phase2 treatment pembrolizumab route intraveinous infusion dose regimen per infusion every duration treatment cycle confirmed complete response define simons stage optimal design occur pembrolizumab treatment cycle last cycle complete response observe confirm least pembrolizumab stop comparator treatment na",
    "STATISTICS": "statistical analysis simons 2stage optimal design multicenter uncontrolled phase2 study base stage phase2 simons optimal design sample size computation base statistical hypothesis regard treatment effect main endpoint best overall response rate type1 error statistical power sample size compute assess whether drug inactive partial complete response probability truly active partial complete response probability based hypothesis compute patient would accrue stage necessary inclusion stop 9th inclusion wait primary endpoint trial stop conclusion inactivity response observe stage otherwise additional patient recruit total sample size patient least response indicate drug effective enough case observe response end stage stage directly begin withouit stop extension stage patient include extension stage consider main analysis expected complete best overall response rate complete response partial response would obtain ci interval complete response rate equal secondary analysis perform patient include extension stage plus patient include simons stage optimal design expect best overall response rate analysis reach ci interval complete response rate equal"
  },
  "UPFRONT-MUD": {
    "TITLE": "full title upfront matched unrelated donor transplantation pediatric patients idiopathic aplastic anemia phase2 feasibility study",
    "JUSTIFICATION": "scientific justification pediatric patient idiopathic aplastic anemia respond well adult immunosuppressive therapy ist longterm risk relapse ciclosporine dependence clonal evolution high uk investigator report estimate failurefree survival ist contrast successive child receive match unrelated donor hematopoietic stem cell transplantation excellent estimate failure free survival forty child previously fail ist excellent result upfront fully match unrelated donor hematopoietic stem cell transplantation become attractive firstline option uk cohort child idiopathic aplastic anemia thus receive matched unrelated donor hscts firstline therapy receive ist prior hematopoietic stem cell transplantation results excellent low graft versus host disease rate death idiopathic pneumonia cohort compare historical matched control transplant outcomes upfront unrelated cohort hematopoietic stem cell transplantation similar matched related donor hematopoietic stem cell transplantation superior ist unrelated hematopoietic stem cell transplantation postist failure since many investigator offer front match unrelated donor hematopoietic stem cell transplantation pediatric patient worldwide however result treat extreme caution design retrospective excellent front match unrelated donor hematopoietic stem cell transplantation may arise use alemtuzumab conditioning regimen alemtuzumab easily available worldwide formal quality oflife assessment moreover strategy highly dependent donor identification caucasian patient high likelihood match unrelated donor donor availability thus dont know many patient eventually receive hematopoietic stem cell transplantation risk infections complications cause unexpected donor delay cancellation prospective trial thus urgently need address feasibility procedure term timing delay offer matched unrelated donor hematopoietic stem cell transplantation condition regimen nothing know use regimen non alemtuzumabbased setting",
    "OBJECTIVE": "main objective primary endpoint main objective realize upfront hematopoietic stem cell transplantation within match unrelated donor identify primary endpoint upfront match unrelated donor hematopoietic stem cell transplantation effectively perform within identification match unrelated donor secondary objective endpoint secondary objective clinical biological outcome graft failure graft versus host disease progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment first consecutive neutrophils first consecutive platelet absolute number neutrophil platelet last platelet red blood cell transfusion acute graft versus host disease incidence date maximum grading first line treatment response steroid treatment course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading relapse incidence progression free survival incidence cmv ebv infection severe infection ctae grade34 nonrelapse mortality overall survival quality life questionnaire pedqql inclusion post transplantation chimerism immune reconstitution analyze nk regulatory cell level peripheral blood posttransplantation ferritin level",
    "DESIGN": "design study phase2 multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "population study participant pediatric patient age less idiopathic aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion inclusion criterion patients age 18years pediatric patient age less idiopathi aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion good probability hla10 matched unrelated donor available patient need least match unrelated donor identify within book bmdw bone marrow donors worldwide use easy match software include usual criterion allosct lansky karnofsky severe uncontrolled infection adequate organ function asat alat 5n total bilirubin 2n creatinine clearance high normal value age health insurance coverage beneficiaire ou ayant droit contraception method young girl men childbearing age must prescribe duration research parents read understand information note sign write informed consent patient agreement depend age seek typical presentation aplastic anemia posthepatitis nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius man absence permanent sterilization condom",
    "EXCLUSION CRITERIA": "exclusion criterion patients match related donor available uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis renal failure creatinine clearance high normal value age pregnant hcg positive breastfeeding heart failure accord nyha ii preexisting acute hemorrhagic cystitis urinary tract obstruction yellow fever vaccine within transplantation debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup depend age understanding contraindication treatment use research",
    "INTERVENTION": "transplant modalities conditioning regimen patient age less fludarabine cyclophosphamide antithymocyte globulin patient age fludarabine cyclophosphamide anti thymocyte globulin total body irradiation gray however allow realize tbi fludarabine local planning reason tbi antithymocyte globulin et fludarabine tbi fludarabine cyclophosphamide stem cell source bone marrow minimal target dose nucleated cells recipient ideal body weight graft less rich minimum target dose administer discretion physician graft versus host disease prophylaxis graft versus host disease prophylaxis consist association cyclosporine plus methotrexate iv cyclosporine post hematopoietic stem cell transplantation plus methotrexate iv give subsequently prevention ebv reactivation rituximab iv post hematopoietic stem cell transplantation infusion rituximab precede administration anti pyretic antihistaminic paracetamol diphenhydramine",
    "STATISTICS": "statistical analysis justification sample size use simon minimax twostage phase2 design demonstrate success primary outcome patient consider treatment valuable option less consider unacceptable interim analysis interim analysis perform inclusion trial terminate receive upfront match unrelated donor hematopoietic stem cell transplantation study end conclusion inefficacy otherwise inclusion pursue total patient conclude treatment efficacy least success identify among patient"
  },
  "HAPLORESCUE": {
    "TITLE": "full title haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide rescue patient graft failure phase2 study",
    "JUSTIFICATION": "scientific justification prognosis patient graft failure dismal transplantation sole option longterm survival currently consensus concern therapeutic option patient primary secondary within posttransplantation graft failure find new donor within acceptable delay challenge literature poor subject overall survival patient situation thus represent today challenging unmet medical need recently haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early hla mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil group retransplanted patient experience two consecutive graft failure successfully manage third haplosct son use ptcy retrospectively collect analyze data primary graft failure patient transplant center behalf french society stem cell transplantation cell therapy sfgmtc study population consist mainly patient primary secondary within posttransplantation graft failure undergo haplosct receive ptcy graft versushostdisease prophylaxis overall survival suggest approach might valid option particular poor clinical situation need validation phase2 multicenter national prospective cohort study",
    "OBJECTIVE": "main objective primary endpoint main objective rescue patient graft failure first allogeneic sct allosct use haplosct ptcy primary endpoint overall survival rate compare historical control secondary objective endpoint secondary objective graft failure gvhd progression free survival relapse nonrelapse mortality interval first allosct rescue haplosct quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment consecutive neutrophile consecutive platelet absolute number neutrophil platelet last platelet red blood cell transfusion use growth factor poor hematopoietic reconstitution acute gvhd incidence date maximum grading first line treatment response steroid treatment course case steroid refractory gvhd chronic gvhd incidence date grading relapse incidence progression free survival incidence cmv ebv infection severe infection ctae grade34 nonrelapse mortality incidence cardiac toxicity overall survival interval first allosct rescue haplosct quality life questionnaire eortc qlqc30 v3 inclusion posttransplantation chimerism immune reconstitution analyze nk regulatory cell level peripheral blood posttransplantation",
    "DESIGN": "design trial phase2 multicenter national prospective cohort study scope trial primary secondary within post transplantation graft failure rare devastate condition sct recent strategy haplo relate donor transplantation success transplantation tcell replete graft intensive immune suppression retrospective noncontrolled registry study recently suggest outcome haplosct use ptcy approach might superior actual standard care retransplantation unrelated donor moreover haplosct ptcy quick procedure cheap available almost patient study might thus favor strategy case primary secondary within post transplantation graft failure 1st sct",
    "INCLUSION CRITERIA": "population trial subject patients hematological disease suffer primary secondary within posttransplantation graft failure 1st allogeneic hematopoietic stem cell transplantation allosct inclusion criterion patients aged hematological disease suffering primary secondary within posttransplantation graft failure 1st allosct usual criterion allosct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine clearance identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detect patient mfi antibody direct towards distinct haplotype donor recipient health insurance coverage beneficiaire ou ayant droit understand informed consent optimal treatment followup contraception method must prescribe duration research women men childbearing age must use contraceptive method within last dose cyclophosphamide respectively sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "exclusion criterion patients aged uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis yellow fever vaccine within transplantation cancer last except basal cell carcinoma skin situ carcinoma cervix uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord nyha ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance urinary tract obstruction pregnant hcg positive breastfeeding debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship contraindications treatment use research",
    "INTERVENTION": "transplant modality medical product provide sponsor conditioning regimen fludarabine cyclophosphamide except patient receive total dose cyclophosphamide first bone marrow transplantation total body irradiation gray source stem cell source peripheral blood stem cell minimal target dose cd34 cells recipient gvhd prophylaxis cyclophosphamide ciclosporine residual mycophenolate mofetyl x2 prevention ebv reactivation rituximab post haplosct",
    "STATISTICS": "statistical analysis overall survival estimate use kaplan maiers estimator confidences intervals comparaison historical control perform use onesample logrank test propose sun et al terminal analysis perform followup last included patient"
  },
  "FIRST": {
    "TITLE": "full title upfront related donor transplantation patients myelodysplastic syndrome phase2 trial",
    "JUSTIFICATION": "scientific justification three recent prospective transplant transplant study conclude advantage overall survival transplantation patient high intermediate2 ipss risk significant krogers study prospective randomize trial assess pretransplant therapy mds patient yet information extract recent study french study patient donor receive hsct previously treat hypomethylating agent hma trend good survival patient achieve complete remission pre graft therapy hr high risk death unresponsiveness patient transform aml hr nakamuras study patient donor transplant previously treat hma multivariable cox model overall survival leukemiafree survival show excess risk patient treat hma moreover responder still high risk mortality compare patient receive pregraft therapy hr german study aim initiate azacytidine inclusion transplant patient cycle donor identified1 among register patient initiated 5aza lose pregraft therapy allocation donor nodonor arm different reason include death cycle 5aza patient donor arm transplant multivariable analysis show remission status influence overall survival previous clinical trial thus suggest substantial number patient plan transplantation transplant nowadays evidence hma benefit hsct clearly identify phase2 study aim assess feasibility upfront hsct patient high risk mds order increase probability transplant achieve subsequent remission good survival",
    "OBJECTIVE": "main objective primary endpoint primary objective demonstrate improved diseasefree survival patient undergo upfront transplantation related donor compare historical prospective cohort primary endpoint disease free survival transplantation secondary objective endpoint secondary objectives clinical biological outcome overall survival incidence transplantation donor identification incidence transformation aml relapse progression engraftment acute late rejection nonrelapse mortality acute gvhd chronic gvhd severe infection ctae grade34 cardiac event grade24 ctae secondary endpoints overall survival inclusion transplantation non relapse mortality transplantation cumulative incidence transformation acute myeloid leukemia inclusion acute gvhd grade post hsct chronic gvhd grade post hsct engraftment hematological recovery donor chimerism graft failure acute late rejection non engraftment post hsct severe infection ctae grade34 cardiac event grade24 ctae",
    "DESIGN": "design study study use uncontrolled phase2 openlabel design increase level incidence external comparison secondly perform demethylating agent use individual patient data prospective cohort robin ii 5azacytidine use aggregate data publish randomized clinical trial kroger",
    "INCLUSION CRITERIA": "population study participant adults patient mds diagnosis transplantation indicate related donor identify inclusion criterion inclusion criterion age hla match sibling donor familial haploidentical donor identify disease fulfill least one following criterion intermediate2 high risk accord classical ipss intermediate1 risk marrow fibrosis grade1 poor risk cytogenetics accord ipss classify high high risk accord ipss mds therapyrelated neoplasm usual criterion hsct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide lvf adequate organ function asat alat 5n total bilirubin 2n creatinine clearance accord cockroft formula case transplantation haploidentical donor absence donor specific antibody detect patient mfi antibody direct towards distinct haplotype donor recipient recommend ebmt guideline contraception method must prescribe woman childbearing age study cyclophosphamide use effective contraceptive method men participation study health insurance coverage write informed consent sign nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion exclusion criterion marrow blast time inclusion mds excess blast npm1 mutation recurrent genetic abnormality relate aml chemotherapy aml like intensive chemotherapy demethylating agent treat mds current stage disponibility unrelated donor mud absence genoidentical donor patient uncontrolled infection cancer last except basal cell carcinoma skin situ carcinoma cervix renal failure creatinine clearance accord cockroft formula contraindication treatment use research uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord nyha ii patient seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcvyellow fever vaccine alive vaccine within transplantation pregnancy hcg positive breastfeeding debilitating medical psychiatric illness would preclude give well understand inform consent optimal treatment followup protection law tutorship curatorship",
    "INTERVENTION": "",
    "STATISTICS": "statistical analysis twosided onesample logrank test calculate sample subject achieve power significance level detect proportion surviving new group proportion survive historic control group historical proportion estimate previous french cohort study publish leukemia disease free survival rate observe patient donor transplant upfront contrast ebmt study report disease free survival patient mds expect survive proportion period subjects accrue period followup continue period last subject add probability subject experience event study expected number event study assume survival time distribution group approximate reasonably well weibull distribution shape parameter increase level evidence external indirect comparison secondly perform demethylating agent use individual patient data prospective cohort robin ii 5azacytidine use aggregate data publish randomized clinical trial kroger"
  },
  "APARR": {
    "TITLE": "full title evaluation optimized allogeneic hematopoietic stem cell transplantation protocol posttransplant cyclophosphamide patient age acquire aplastic anemia refractory relapse immunosuppression",
    "JUSTIFICATION": "scientific justification hematopoietic stem cell transplantation major therapeutic option patient acquire aplastic anemia improved survival achieve patient young thanks good donor selection condition regimen graft versus host disease prophylaxis together improved supportive care however never case patient age overall survival hematopoietic stem cell transplantation never exceed use available sibling unrelated donor ref thus standard immunosuppressive therapy ist associate cisclosporine horse antithymocyte globuline together addition eltrombopag consider standard care adult patient aplastic anemia ref indeed outcome patient refractory firstline ist remain poor lack nontransplant treatment poor result transplantation age ref past decade significant decrease infectionrelated mortality population initial ist risk hemorrhage longterm fatigue still present moreover clonal evolution include paroxysmal nocturnal hemoglobinuria myelodysplastic syndrome mds acute myeloid leukemia still occur longterm grim prognosis mds acute myeloid leukemia ref overall survival adult patient acquire aplastic anemia refractory relapse ist outside hematopoietic stem cell transplantation thus ref recently new strategy prevent acute chronic graft versus host disease include tcell replete graft administration posttransplantation cyclophosphamide ptcy revolutionize field change extend option hematopoietic stem cell transplantation primary patient refractory relapse aplastic anemia lack hla match donor ref recently optimize baltimore protocol use ptcy strategy also appear improve engraftment reduce graft versus host disease classical setting sibling match unrelated hematopoietic stem cell transplantation outside aplastic anemia ref one first cause death hematopoietic stem cell transplantation patient age refractory relapse aplastic anemia graft versus host disease use optimize baltimore protocol type donor haplo also sibling match unrelated transplantation within field aplastic anemia rapidly appear promising ref using optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy haploidentical donor setting also case available matched sibling unrelated donor might prevent drastically graft versus host disease eventually practice change evaluating new transplant protocol new strategy main objective aparr",
    "OBJECTIVE": "main objective primary endpoint main objective demonstrate benefit term grfs graft versus host disease graft versus host disease primary secondary graft failurefree survival historical rate patient refractory relapse aplastic anemia undergo hematopoietic stem cell transplantation ref use optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy patient haploidentical donor setting primary endpoint grfs follow hcst primary composite endpoint measure time hematopoietic stem cell transplantation first following event primary secondary graft failure grade34 acute graft versus host disease severe chronic graft versus host disease death secondary objective endpoint secondary objective demonstrate benefit term clinical biological outcome primary secondary graft failure mortality overall survival quality life treatment relate morbidity notably severe infection cardiac toxicity chimerism immune reconstitution secondary endpoint engraftment consecutive neutrophile consecutive platelet donor chimerism total blood absolute number neutrophil platelet last platelet red blood cell transfusion acute graft versus host disease incidence grade24 chronic graft versus host disease incidence severe chronic graft versus host disease secondary graft failure severe infection ctcae grade34 incidence cardiac toxicity incidence cmv ebv infection mortality overall survival quality life questionnaire pretransplant chimerism immune reconstitution lymphocytes cd4 cd8 nk lymphocytes gammaglobulines",
    "DESIGN": "design study phase2 multicenter national prospective singlearm trial",
    "INCLUSION CRITERIA": "population study participant patients age refractory relapse aplastic anemia ist eligible hematopoietic stem cell transplantation inclusion criterion patients aged suffering acquire refractory severe idiopathic aplastic anemia least treatment antithymocyte globulin cyclosporine eltrombopag relapse allograft validate national multidisciplinary expertise meeting french reference centre aplastic anemia available genoidentical donor match donor haploidentical donor absence donor specific antibody detect patient mfi antibody distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 3n conjugate bilirubin 2n total bilirubin 2n available clearance creatinine health insurance coverage women childbearing potential men must use contraceptive method participation research last dose cyclophosphamide respectively sign write informed consent nb authorized contraceptive method woman childbearing potential absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant men absence permanent sterilization sexual abstinence condom individuals must meet inclusion criterion verify screen inclusion visit eligible participate study",
    "EXCLUSION CRITERIA": "exclusion criterion patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible except chromosome abnormality complex karyotype seropositivity hiv htlv12 active hepatitis associate hepatic cytolysis cancer last except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding yellow fever vaccine others live virus vaccine within transplantation research uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure accord nyha ii ventricular ejection fraction renal failure creatinine clearance contraindication mention smpc investigators brochure medicinal product plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance medicinal product excipients plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis accord investigators brochure smpc debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup legal protection tutorship curatorship state medical aid participation another interventional trial medicinal product cell therapy individuals meeting exclusion criterion verify screen inclusion visit ineligible participate study",
    "INTERVENTION": "transplants modality conditioning regimen thymoglobulin fludarabine pre transplant cyclophosphamide total body irradiation gray stem cell source bone marrow target nucleated cells recipient body weight granulocyte colony stimulate factor give subcutaneously start absolute neutrophil count great graft versus host disease prophylaxis cyclophosphamide tacrolimus per divide dos ivse mycophenolate mmf begin absence graft versus host disease mmf stop tacrolimus prevention ebv reactivation rituximab intravenously post hematopoietic stem cell transplantation except patient donor ebv serology ebv pcr negative infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine nb however permissible delay administration rituximab hour occur sunday great safety discretion investigator",
    "STATISTICS": "statistical analysis sample size calculation twosided onesample logrank test calculate sample subject achieve power significance level detect 2years grfs new group grfs historic control group patient follow analysis primary endpoint several interim analysis primary outcome measure plan every unless less enrolled patient base bayesian approach end trial accrual followup grfs estimate use kaplan meier method correspond confidence interval compare historical rate use one sample twosided logrank test additional terminal analysis use external patient observational cohort propensity score weighting ensure unbiased comparison enhance level evidence treatment effect"
  }
}